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Abstract 
ADP-ribosylation is an ancient posttranslational modification occurring throughout the 
kingdom of life. Poly-ADP-ribosylation mediated by members of the ARTD (PARP) family 
plays a pivotal role in the regulation of cellular processes including DNA repair, apoptosis, 
and signaling. Four different types of domains, e.g. certain macrodomains, have been reported 
to function as readers for poly-ADP-ribosylation and recruit further effector proteins. Beyond, 
most of these are also capable of binding to free ADP-ribose but none of them was shown to 
recognize mono-ADP-ribose attached to proteins. On the other hand several members of the 
ARTD (formerly PARP) family are unable to poly-ADP-ribosylate substrates but they transfer 
single units of ADP-ribose onto substrates. A representative and also the best-described 
member of this ARTD subfamily is ARTD10 (formerly PARP10).  
In this study two protein domains interacting with mono-ADP-ribosylated ARTD10 and 
substrates of ARTD10 were identified and analyzed. Initially, a co-localization between 
ARTD10 and ARTD8, another mono-ADP-ribosyltransferase of the ARTD family, was 
observed in cells. Since co-localization might suggest interactions between two proteins, the 
three macrodomains and the WWE domain of ARTD8 were examined for mediating this 
interaction. It was found that macrodomains 2 and 3 of the three macrodomains of ARTD8 
are capable of binding to mono-ADP-ribosylated ARTD10, the recognition being strictly 
dependent on the mono-ADP-ribosylation. Poly-ADP-ribosylated proteins like activated 
ARTD1 could not associate with these two domains, distinguishing them from other 
macrodomains that are described as poly-ADP-ribosylation reader modules. Solving the 
crystal structures of these macrodomains confirmed their capacity to bind free ADP-ribose. 
Furthermore, macrodomains 2 and 3 were demonstrated to recognize transiently expressed as 
well as endogenous ARTD10 but not its catalytically inactive mutant in cells. Additionally it 
was found that this recognition is not restricted to modified ARTD10 itself but the three tested 
substrates glycogen synthase kinase 3β (GSK3β), NF-κB essential modulator (NEMO) and 
the small G protein Ran-GTP could all be established as interaction partners of macrodomains 
of ARTD8 after mono-ADP-ribosylation in vitro and Ran-GTP also in cells.  
Thus this study contributes to the investigation of mono-ADP-ribosylation mediated by 
enzymes of the ARTD family as a so far poorly characterized posttranslational modification.   
First evidence of an intracellular mono-ADP-ribosylation activity by ARTD10 is provided by 
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this data. The discovery of two reader domains for mono-ADP-ribosylated ARTD10 
substrates provides a tool, which will assist by the characterization of intracellular ARTD10 
substrates and investigation of the biological effects caused by mono-ADP-ribosylation in the 
future. 
Insights from studies of ARTD1 (formerly PARP1), the founding member of the ARTD 
family, stress the importance of posttranslational modification and regulation by 
phosphorylation and acetylation for the enzymatic activity. For ARTD10 a phosphorylation 
site at threonine T101 by CyclinE/CDK2 has been reported in the literature so far. This 
phosphorylation stimulates the enzymatic activity. In this work it was found that GCN5 
acetylates ARTD10 and lysine K274 was mapped as the targeted site. This site is directly 
neighboring the glycine-rich region and located between this region and the RNA recognition 
motif of ARTD10. It remains to be investigated in the future, whether this acetylation site has 
an effect on the function of these two motifs in ARTD10. 
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Zusammenfassung 
 
ADP-Ribosilierung ist eine posttranslationale Proteinmodifikation, die in Organismen aller 
fünf Reiche des Lebens zu finden ist. Die Poly-ADP-Riboslierung von Proteinen wird von 
Mitgliedern der ARTD (bisher PARP) Familie durchgeführt und übt eine wichtige Rolle in 
der Regulation vieler zellulärer Prozesse, wie z.B. DNS Reparatur, Apoptose und 
Signaltransduktion, aus. Des Weiteren wurden bisher vier verschiedene Proteindomänen 
beschrieben, die Poly-ADP-Ribosilierung von Proteinen erkennen, daran binden und dadurch 
weitere Proteine zum Ort der Poly-ADP-Ribosilierung rekrutieren. Makrodomänen stellen ein 
Beispiel für diesen Domänen-Typ dar. Einige dieser Domänen können auch freie ADP-Ribose 
binden, aber es wurde bisher nicht demonstriert, dass eine Interaktion mit einer einzelnen 
ADP-Ribose, die an Proteine angeheftet ist, möglich ist. Allerdings gibt es einige Mitglieder 
der ARTD Familie, die einzelne Einheiten von ADP-Ribose, sogenannte Mono-ADP-Ribose, 
anstelle von Poly-ADP-Ribose auf ihre Substratproteine übertragen. ARTD10 (bisher 
PARP10) ist das am besten analysierte Mitglied dieser ARTD Unterfamilie, das sowohl sich 
selbst als auch Substratproteine mono-ADP-ribosilieren kann. 
 
In dieser Arbeit wurden zwei Proteindomänen identifiziert und analysiert, die mit mono-ADP-
ribosiliertem ARTD10 interagieren können. Darüber hinaus binden sie ebenfalls Substrate 
von ARTD10. Zu Beginn der Arbeit wurde eine Ko-Lokalisation zwischen ARTD10 und 
ARTD8 in der Zelle beobachtet. ARTD8 stellt ein weiteres mono-ADP-Ribose übertragendes 
Mitglied der ARTD Familie dar. Da eine Ko-Lokalisation zweier Proteine in bestimmten 
Fällen ein Anhaltspunkt für eine Interaktion sein kann, wurden die drei einzelnen 
Makrodomänen und die WWE Domäne von ARTD8 genauer untersucht, um herauszufinden, 
ob diese für die Ko-Lokalisation verantwortlich sind. Dabei konnte festgestellt werden, dass 
die Makrodomänen 2 und 3 von ARTD8 mono-ADP-ribosiliertes ARTD10 erkennen, d.h. 
binden, können. Die absolute Notwendigkeit des Vorhandenseins der mono-ADP-
Ribosilierung dafür wurde nachgewiesen. Dies stellt einen entscheidenden Unterschied 
zwischen den Makrodomänen von ARTD8 und denjenigen, die zuvor als Interaktoren von 
poly-ADP-ribosilierten Proteinen beschrieben wurden, dar. Die Analyse der Kristallstrukturen 
der Makrodomänen von ARTD8 bestätigte deren Fähigkeit, freie ADP-Ribose zu binden. 
Außerdem wurde nachgewiesen, dass Makrodomänen 2 und 3 sowohl transient exprimiertes 
ARTD10 als auch endogenes ARTD10 in Zellen erkennen. Die katalytisch inaktive Mutante 
von ARTD10 kann dies jedoch nicht. Zudem wurde in dieser Arbeit gezeigt, dass die 
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Makrodomänen 2 und 3 neben ARTD10 auch die drei getesteten Substrate Glycogen 
Synthetase Kinase 3β (GSK3β), den NF-κB essentiellen Modulator (NEMO) und das G-
Protein RanGTP in vitro binden, nachdem diese Proteine von ARTD10 mono-ADP-ribosiliert 
worden waren. Darüber hinaus wurde die Erkennung von Ran-GTP durch Makrodomäne 3 
auch in Zellen gezeigt. 
 
Folglich trägt diese Arbeit dazu bei, die durch Mitglieder der ARTD Familie vermittelte 
mono-ADP-Ribosilierung als bisher wenig erforschte posttranslationale Modifikation genauer 
zu untersuchen. So wird durch die Daten dieser Arbeit impliziert, dass ARTD10 tatsächlich 
auch in Zellen eine mono-ADP-ribosilierende Aktivität innehat. Folglich liefert die 
Identifikation und Analyse dieser Interaktionsdomänen eine Methode, um in der Zukunft 
intrazelluläre Substrate von ARTD10, sowie die durch die mono-ADP-Ribosilierung auf die 
Substrate ausgeübten biologischen Effekte genauer zu untersuchen. 
 
Untersuchungen von ARTD1 (früher PARP1), das am besten studierte Mitglied der ARTD 
Familie, haben gezeigt, dass posttranslationale Modifikationen und Regulierung der 
katalytischen Aktivität durch Phosphorilierung und Acetylierung wichtig sind. Bisher wurde 
von einer anderen Arbeitsgruppe eine Phosphorilierungsstelle an Threonin T101 in ARTD10 
gefunden. Diese wird durch den Cyclin E/CDK2 Komplex modifiziert und stimuliert die 
enzymatische Aktivität von ARTD10. In dieser Arbeit wurde eine Acetylierung von ARTD10 
nachgewiesen, die von der Histon Acetyltransferase GCN5 durchgeführt wird und Lysin 
K274 konnte als die modifzierte Aminosäure bestimmt werden. Diese Stelle liegt direkt neben 
der Glycin-reichen Region in ARTD10 und befindet sich zwischen dieser und einem RNS 
Erkennungsmotiv. In zukünftigen Untersuchungen muss herausgefunden werden, ob die 
Acetylierung dieser Aminosäure gegebenenfalls die Funktion dieser zweier Motive 
beeinflusst. 
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I Introduction 
I.1 Posttranslational modifications: Expanding the proteasome 
A posttranslational modification (PTM) is proteolytic cleavage of a protein or the covalent 
attachment of functional chemical groups to proteins after their translation (Walsh et al., 
2005). Besides alternative splicing on the transcriptional level, PTMs offer a major possibility 
of expanding the variety of the proteome. Among the most common and best-studied PTMs 
are phosphorylation, acetylation, ubiquitination, methylation, O-glycosylation, sumoylation 
and ADP-ribosylation (Walsh et al., 2005; Yang and Seto, 2008). They are mediated by 
specific enzymes and, depending on the PTM, different side chains of the amino acids are 
targeted. Likewise, a single amino acid may be aimed at by different PTMs. Lysines for 
example can be subjected to acetylation, methylation, neddylation, ubiquitination and further 
PTMs (Yang and Seto, 2008). The consequences of undergoing these modifications are as 
diverse as the modifications themselves, for instance conformational changes mediating 
modulation of the enzymatic activity, changing of the localization or providing or preventing 
binding sites for interaction partners (Walsh et al., 2005; Yang and Seto, 2008).  
Several PTMs shall be illustrated on the example of histones. Histones are well characterized 
substrates of multiple PTMs that are responsible for a fine-tuned regulation of transcription by 
recruiting non-histone proteins and changing chromatin structure (Figure 1) (Bannister and 
Kouzarides, 2011). The decipherment of the complex combination and also cross-talk of these 
PTMs on histones, which is also called the histone code, has been in the focus of epigenetic 
research for the last decades (Ruthenburg et al., 2007; Strahl and Allis, 2000). One 
modification, phosphorylation, is mediated by protein kinases and designated as the 
deposition of a phosphate group from adenosine triphosphosphate (ATP) to the hydroxyl 
group of serines, threonines or tyrosines. As an example, histone H3 is phosphorylated at 
tyrosine Y41 by the non-receptor tyrosine kinase janus kinase 2 (JAK2) (Dawson et al., 
2009). More general, histone phosphorylation of serines or threonines is found in mitosis and 
meiosis to facilitate chromatin compaction or in the DNA damage response (Banerjee and 
Chakravarti, 2011). For instance the H2A histone variant H2AX is phosphorylated at serine 
139 after DNA double strand breakage (Rogakou et al., 1998). Furthermore, histones are 
heavily acetylated, which is the addition of an acetyl group from the cofactor acetyl-
Coenzyme A (acetyl-CoA) to the -amino group of lysines (Bannister and Kouzarides, 2011). 
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Typically, histone acetylation especially at promoter regions is regarded as a mark for actively 
transcribed genes and also a prerequisite for this. So is histone H3 acetylated at lysine K14 
(H3K14) at promotor regions for example (Bannister and Kouzarides, 2011; MacDonald and 
Howe, 2009). Moreover, histone methylation on lysines and arginines is an important 
regulator of transcriptional activity. Lysine methyltransferases are highly specific enzymes 
that use S-adenosylmethionine as a donor for a methyl group that is transferred onto the -
amino groups of lysines (Bannister and Kouzarides, 2011). Thereby, mono-, di- and 
trimethylation on the same amino acid can be found, depending on the methyltransferase and 
making the code of histone methylation more complex (Barth and Imhof, 2010). Interestingly, 
methylation of H3K4, H3K36, and H3K79 are linked to actively transcribed genes whereas 
H3K9, H3K27, and H4K20 are transcriptional repressive marks (Bannister and Kouzarides, 
2011; Kouzarides, 2007).  
 
Figure 1: Cross-talk on histone modification  
PTMs of histones can positively or negatively influence other modifications. An arrowhead marks stimulating 
influences; a flat head denotes negative effects. K, R, P and S are abbreviations for the corresponding amino 
acids and numbers indicate their position on the histone. Me: methylation. Ac: acetylation. Ph: phosphorylation. 
Ub: ubiquitination (from: (Bannister and Kouzarides, 2011)). 
 
At the example of lysine methylation PTM cross-talk can be illustrated (Figure 1), meaning 
the presence of one modification influences another modification at the same or neighboring 
sites (Bannister and Kouzarides, 2011). For instance dimethylation of H3R2 is promoted by 
the protein arginine N-methyltransferase 6 (PRMT6). However, the presence of this 
modification restrains the methylation of H3K4 by the ASH2-MLL (absent, small or homeotic 
discs 2-mixed-lineage-leukemia)-complex and vice versa although not targeting the same 
amino acid (Guccione et al., 2007). 
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Importantly, besides the writers of PTMs, usually also reader modules of the PTMs are 
required. They serve as binding domains harbored by proteins that are recruited to these 
modifications (Bannister and Kouzarides, 2011). Among these recruited proteins there are 
transcription factors (Jacobson et al., 2000) and proteins that further modify chromatin 
(Huang et al., 2006). Acetylation can be read by bromodomains, often occurring in tandem or 
multiple domains within the same protein and exhibiting different affinities for diverse 
acetylated lysines (Barth and Imhof, 2010). As one example, the bromodomain of the 
transcription factor TBP-associated factor II 250 recognizes acetylated histone H4 (Jacobson 
et al., 2000). For methylated proteins, reader modules like chomo-, tudor-, malignant brain 
tumor (MBT) domains or plant homeo domain (PHD) domains were characterized 
(Kouzarides, 2007). The histone demethylase JMJ domain containing demethylase 2A 
(JMJD2A) for instance is recruited to methylated lysine K4 on histone H3 via its tudor 
domains (Huang et al., 2006). 
I.2 NAD+ and ADP-ribosylation 
The addition of ADP-ribose (ADPr) to a substrate protein (referred to as ADP-ribosylation) is 
a PTM that has already been known for several decades. The responsible enzymes for this 
modification are dependent on the co-factor nicotinamide adenine dinucleotide (NAD+) 
(Hottiger et al., 2010; Smith, 2001). Beyond being a co-factor for ADP-ribosylating enzymes, 
NAD+ fulfills diverse roles in the cellular metabolism and is required by several groups of 
enzymes. On the one hand there is the family of class III histone deacetylases (HDAC) called 
sirtuins (Denu, 2005) that cleave off acetyl groups from histones and other nuclear proteins as 
well as from proteins in the cytoplasm and mitochondria. This deacetylation reaction needs 
NAD+ as an acceptor for the removed acetyl group resulting in the formation of O-acetyl-
ADP-ribose (OAADPr) and the release of nicotinamide from NAD+ (Denu, 2005; Houtkooper 
et al., 2012). This family of enzymes has been implicated in cellular processes like glucose 
metabolism (Houtkooper et al., 2012), neurodegenerative diseases (Raghavan and Shah, 
2012) and aging (Finkel et al., 2009). Beyond sirtuins, ADP-ribosyl-cyclases play a role in 
cellular NAD+ consumption. These enzymes were originally discovered in marine animals as 
converters of NAD+ to cyclic ADPr and nicotinamide, e.g. in Aplysia californica (Hellmich 
and Strumwasser, 1991; Lee and Aarhus, 1991). The transmembrane protein CD38, occurring 
ubiquitously in all mammalian tissues, could be identified as its mammalian homolog 
(Howard et al., 1993; Lee, 2012). Since cyclic ADPr is known as a second messenger and 
Ca2+ mobilisator, these enzymes are involved in calcium signaling and thereby for example 
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suggested to be important in insulin secretion (Lee, 2012). Additional classical NAD+ 
consuming enzymes can be found in the field of oxidoreductases, utilizing NAD+ or NADH 
as proton-acceptor or proton-donor respectively for redoxreactions (Belenky et al., 2007; 
Goward and Nicholls, 1994).  
Further enzymes that utilize NAD+ as cofactor in the β-NAD+ form are present in the class of 
ADP-ribosyltransferases (ARTs). They attach either a single unit or several units of ADPr 
derived from their cofactor β-NAD+ onto target proteins whereas nicotinamide is released 
(Figure 2) (Althaus and Richter, 1987; Smith, 2001). 
 
Figure 2: ART mediated ADP-ribosylation reaction 
ADP-ribosyltransferases (ARTs) transfer the ADPr moiety from the co-factor β–NAD+ onto a specific amino 
acid (aa) of the acceptor protein. Depending on the ART enzymes, the acceptor amino acid differs. Nicotinamide 
is released during the reaction. 
 
I.3 Bacterial ADP-ribosyltransferases 
I.3.1 The H-Y-E class of ARTs 
At first, ARTs were described in the context of bacterial toxins that ADP-ribosylate host 
proteins. According to their structure and targets in the host cell, these toxins can be 
subdivided into several groups (Holbourn et al., 2006). One example is the diphtheria toxin 
that is secreted by corynebacterium diphtheriae. It transfers a single ADPr moiety onto 
aminoacyl transferase II (also known as elongation factor 2, eEF2) in host cells, leading to its 
inactivation and inhibition of protein biosynthesis (Honjo et al., 1968; Honjo et al., 1971). The 
diphtheria toxin is a proenzyme that requires cleavage for the activation of its enzymatic 
activity (Collier, 2001). The two resulting fragments re-associate after cleavage and are called 
A domain and B domain which is common for several bacterial toxins. Whereas the A domain 
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is responsible for the ART activity, the B domain consists of a transmembrane domain and a 
host cell receptor binding domain and thus promotes binding to cells and translocation of the 
catalytic A domain (Choe et al., 1992; Collier, 2001). 
As the structure of the toxin had been solved in complex with NAD+, it was obvious that the 
NAD+ binding cleft is different from the classical NAD+ binding motif of oxidoreductases, 
called Rossmann fold (Bell and Eisenberg, 1996; Bell et al., 1997). Generally, the binding 
cleft is composed of β-strands and an α-helix between strand 2 and 3. This is true for all 
identified ARTs so far (Bell et al., 1997; Otto et al., 2005; Yates et al., 2006). Another shared 
feature of ARTs is a flexible “active site loop” covering the NAD+ binding cleft in the 
inactive state of the enzyme (Domenighini and Rappuoli, 1996).  
 
Figure 3: Schematic representation of the interactions between amino acids of the H-Y-E and R-S-E 
motifs and NAD+  
A and B. The letters denoting the important amino acids of the H-Y-E motif (A) and R-S-E motif (B) are shown 
in red. Blue letters mark additional amino acids stacking with NAD+. Dashed lines indicate hydrogen bonds, 
which are essential for NAD+ binding (from: (Hottiger et al., 2010)).  
 
Further analysis of the catalytic center of the diphtheria toxin revealed conserved motifs that 
are shared with several other ARTs but not with all. These conserved motifs include 6 β-
strands and a characteristic histidine-tyrosine-glutamate (H-Y-E) motif that is implicated in 
NAD+ binding and catalytic activity (Figure 3A) (Domenighini and Rappuoli, 1996; Otto et 
al., 2005). In silico characterization indicated that the histidine is located in β-strand 1, the 
tyrosine in β-strand 3 and the glutamate in β-strand 5 (Otto et al., 2005). Interestingly, the 
glutamate, also called catalytic glutamate, is the only amino acid, which is conserved among 
all studied bacterial and also several mammalian ARTs. In concordance it was shown that 
A 
B 
INTRODUCTION 
6 
bacterial ARTs loose their catalytic activity if this glutamate is mutated (Carroll and Collier, 
1984, 1987; Otto et al., 2005). So the diphtheria toxin represents the founding member of the 
H-Y-E class of ARTs (Hottiger et al., 2010). Another member of this class is the exotoxin A 
from pseudomonas aeruginosa (Yates et al., 2006). The importance of this triad of amino 
acids will be addressed in more detail in chapter I.4. A related but distinct class of ARTs is 
referred to as R-S-E class of ARTs. 
I.3.2 The R-S-E class of ARTs 
Despite there is only little sequence conservation, the general 3-dimensional structure of the 
catalytic center of bacterial ARTs is conserved in terms of the composition of 6 β-strands. 
Still there are bacterial ARTs with different host target proteins and features. Especially the 
H-Y-E motif distinguishes diphtheria-like ARTs from ARTs that are similar to the cholera 
toxin (Hottiger et al., 2010). The cholera toxin mono-ADP-ribosylates the Gs subunit of the 
heterotrimeric stimulatory G-protein, supposed to result in the inhibition of its intrinsic 
GTPase activity, although that is being discussed controversially, and leading to its permanent 
activation. The activated Gs subunit is then in turn responsible for activation of the adenylate 
cyclase and the increase of cyclic adenosine monophosphate (cAMP) resulting in severe 
diarrhea of infected individuals (Cassel and Selinger, 1977; Kahn and Gilman, 1984a, b). 
Whereas the acceptor sites of ADP-ribosylation of the diphtheria toxin are modified histidines 
(diphtamide) (Oppenheimer and Bodley, 1981; Van Ness et al., 1980), it is known that 
cholera-like toxins modify arginines (Freissmuth and Gilman, 1989; Van Dop et al., 1984). A 
motif that is common in cholera-like toxins as well as in other arginine or sometimes also 
cysteine-specific ARTs like the pertussis toxin or the Escherichia coli heat-labile enterotoxin 
is the arginine-serine-glutamate (R-S-E) motif in the catalytic cleft (Figure 3B) (Domenighini 
and Rappuoli, 1996; Hsia et al., 1985). In most cases of arginine-specific ARTs, the 
conserved glutamate is followed by another glutamate expanding the R-S-E motif to an R-S-
EXE motif. As the H-Y-E motif for the diphtheria toxin-like ARTs, the R-S-E motif is 
essential for the catalytic activity of cholera toxin-like ARTs (Domenighini and Rappuoli, 
1996; Glowacki et al., 2002; Laing et al., 2011). However, although both motifs serve as 
NAD+ binding elements and catalyzer of ADP-ribosylation reactions, there are differences in 
the NAD+ binding characteristics and hydrogen bonding (Figure 3). Additionally, Otto et al. 
proposed, based on database analyses, that there are also further structural elements that 
discriminate the classes of H-Y-E ARTs and R-S-E ARTs (Hottiger et al., 2010; Otto et al., 
2005). 
INTRODUCTION 
7 
Altogether, several bacterial toxins exist that possess mono-ADP-ribosylation activity and that 
feature a structurally related catalytic center. However, the motifs important for catalysis as 
well as the host cell target proteins and the acceptor amino acids for the ADPr differ. Besides 
bacterial toxins, also mammalian ARTs could be identified. A group of mammalian arginine-
specific ARTs are the so called “ecto-ARTs” which are addressed in the next paragraph.  
I.3.3 Mammalian extracellular ARTs 
To date two major families of mammalian ARTs have been identified. The one is the PARP-
family enclosing PARP1, the best described mammalian ADP-ribosylating enzyme, which 
will be discussed in detail below. The other family is composed of five extracellular ARTs, in 
the following named “ecto-ARTs”. The name “ecto” is based on a common feature of these 
enzymes, namely that they are anchored via glycophosphatidylinositol in the plasma 
membrane with the catalytic domain being extracellular or they are secreted (Figure 4) 
(Welsby et al., 2012).  
 
Figure 4: ADP‐ribosylation by bacterial and mammalian ARTs  
The secreted cholera toxin binds to host cell receptors with help of the B subunit whereas the catalytically active 
A subunit is translocated into the host cell and mono-ADP-ribosylates Gα of heterotrimeric G proteins (left 
panel). The mammalian extracellular ecto-ARTs are depicted and the tissue or cell type of the highest expression 
is given (right panel). ART1-ART4 are glycophosphatidylinositol-anchored and ART5 is secreted. Membrane 
proteins (mp) or secreted proteins (sp) are ADP-ribosylated by ART1 and ART2. PARP-1 belongs to the family 
of intracellular ARTs and attaches polymers of ADPr to its substrates (from: (Koch-Nolte et al., 2006)). 
 
Whereas ART1 and ART3-5 are expressed in mice as well as in humans, there are 
divergences concerning ART2. In mice there exist two isoforms of Art2 due to gene 
duplication (Bortell et al., 1999; Glowacki et al., 2002; Prochazka et al., 1991). On the other 
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hand, ART2 expression in humans and chimpanzees is prevented because three in-frame stop 
codons are inserted into the gene (Haag et al., 1994). In accordance with the bacterial 
arginine-specific cholera-like toxins, ART1, mouse Art2 and 5 exhibit a classical R-S-EXE 
motif and are also supposed to be arginine-specific ARTs (Glowacki et al., 2002; Laing et al., 
2011). Since arginines are positively charged, the addition of ADPr carrying two negative 
charges by its phosphates significantly changes the charge and chemical properties of the 
substrate (Laing et al., 2011). In contrast, in human or mouse ART3 these amino acids are 
replaced by R-L-ERI or S-L-DSV respectively and in human and mouse ART4 by R-S-KKE 
or G-S-RKS. Therefore, it is supposed that they might be inactive (Glowacki et al., 2002) or 
cysteine-specific (Grahnert et al., 2002). 
The first identified member of the ecto ARTs is ART1. It was originally discovered in rabbit 
skeletal muscle (Zolkiewska et al., 1992) but reveals conservation between human and mouse 
ART1 (Okazaki and Moss, 1998). ART1 also occurs on heart muscle cells, lymphocytes and 
neutrophils. Several substrates have been characterized so far, e.g. the extracellular domain of 
integrin 7 on mouse skeletal muscle cells thereby altering integrin 7’s affinity for its ligand 
laminin (Zhao et al., 2005; Zolkiewska and Moss, 1997). Moreover, ART1 modifies co-
receptors on mouse T-cells resulting in T-cell receptor signaling inhibition (Liu et al., 1999) 
and it has been shown to mono-ADP-ribosylate antimicrobial factors like -defensin-1 (Paone 
et al., 2002).  
One emerging question is if the physiological concentrations of NAD+ in the extracellular 
milieu are sufficient to act as a co-factor for ecto-ARTs (Zolkiewska, 2005). Under normal 
circumstances it is thought that these concentrations are too low. However, NAD+ release 
from intracellular sources after tissue damage, inflammatory responses and mechanical force 
on muscle cells or neurons has been reported. This supply is considered to regulate and maybe 
suffice for ecto-ART enzymatic activity (Zolkiewska, 2005). 
The murine Art2 (RT6) is predominantly found on T-cells (Welsby et al., 2012). Like ART1, 
Art2 ADP-ribosylates T-cell receptor subunits at their extracellular domains after NAD+ 
release during inflammation. It also modifies the purinergic receptor P2X ligand-gated ion 
channel 7 (P2X7) (Adriouch et al., 2007; Seman et al., 2003), leading to its activation, which 
in turn triggers a calcium flux and finally results in apoptosis. This form of apoptosis is also 
termed NAD+-induced T-cell death (Seman et al., 2003). The mechanism how ADP-
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ribosylation activates P2X7 is still matter of debate (Adriouch et al., 2007; Seman et al., 
2003).  
Mouse Art5 is expressed in testis, heart and skeletal muscle (Glowacki et al., 2001). However 
the functions of ART5 as well as ecto-ART3 and 4 have not been extensively studied so far, 
except that ART5 can glycohydrolase NAD+ (Glowacki et al., 2001). Despite the limited 
information, the tissue specific expression and the defined functions of ART1 and Art2 allow 
hypothesizing that ecto-ARTs are generally involved in immune responses (Hong et al., 2007; 
Welsby et al., 2012).  
I.4 The ARTD (PARP)-family 
Besides ecto-ARTs, the poly-ADP-ribose-polymerase (PARP)-family constitutes the other 
class of mammalian ARTs. In contrast to the bacterial toxins and ecto-ARTs, enzymes of the 
PARP family occur intracellularly and several members are capable of synthesizing ADPr 
polymers (Schreiber et al., 2006). Generally they share a catalytic domain with ADP-
ribosyltransferase activity, which is located near the C-terminus of the proteins, except for 
PARP4. Beyond the catalytic domain, the domain architecture of the single family members is 
diverse (Figure 5). More details on the different domains will be given in the description of 
the individual PARPs (Gibson and Kraus, 2012; Luo and Kraus, 2012; Schreiber et al., 2006).  
Since the founding member of the PARP-family, PARP1, exhibits ADPr polymer forming 
activity the family was called “PARP”. Likewise PARP2-PARP6 possess this activity and are 
in the following also referred to as “bona fide” enzymes because of that. However, the 
denotation “PARP” was regarded as partially misguiding because mono-ADP-
ribosyltransferases exist within the PARP family. Furthermore the bona fide PARPs are not 
polymerases in the biochemical sense but rather ADPr transferases being able to repetitively 
transfer ADPr moieties onto substrates, resulting in the formation of chains of poly-ADP-
ribose (PAR) (Hottiger et al., 2010). That is why recently effort has been made by Hottiger et 
al. to develop a new nomenclature for this family in order to give consideration to the diverse 
nature of ADP-ribosylation properties of the family members (Hottiger et al., 2010). 
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Figure 5: Overview of the ARTD family 
A schematic representation of the domain architecture of the 17 members of the ARTD family is illustrated. The 
old (old n.) and new (new n.) nomenclature as well as the variants of the H-Y-E motifs in the active center are 
indicated on the right. Additionally, it is indicated whether the enzymes are active (Y), predicted to be active (Y 
(P)) or inactive (N). The BRCA1 carboxyterminal domain (BRCT ) was originally found in the C-terminal part 
of the protein breast cancer 1 early onset (BRCA1) that facilitates interactions with DNA repair proteins. WGR 
stands for a motif with the central amino acids W-G-R. PRD stands for the PARP regulatory domain and is 
suggested to control poly-ADP-ribose (PAR) branching. The vault protein inter-alpha-trypsin (VIT) domain and 
the Willebrand type A (vWA) domain in ARTD4 are probably implicated in protein-protein interaction, vWA 
suggested to require metal ions. The ankyrin repeat domains (ANK) and the sterile alpha motif (SAM) occur in 
ARTD5 and ARTD6 and are also suggested to be involved in protein-protein interactions. Also zinc fingers 
mediate interaction between proteins, proteins and RNA or proteins and DNA. CBD: Centrosome binding 
domain. HPS: Histidine-proline-serine rich region. Macro: macrodomain. NES: nuclear export signal. RRM: 
RNA recognition motif. WWE: Domain containing a tryptophane- tryptophane- glutamate (W-W-E) motif. ZF/ 
THP: Zincfinger/ TiPARP homolgous domain. MVP-BD: Major-vault particle binding domain. Glycine-rich: 
Glycine-rich region. UIM: ubiquitin interaction motif. (Information combined from (Hottiger et al., 2010; Kleine 
et al., 2008; Luo and Kraus, 2012; Schreiber et al., 2006)). 
 
After crystallization of catalytic domains of several members of the PARP family (Karlberg et 
al., 2010; Ruf et al., 1996; Ruf et al., 1998) as well as in silico analyses (Otto et al., 2005), a 
structural relationship between the PARP catalytic domains and the diphtheria toxin-like ART 
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catalytic domains became obvious. The previously described H-Y-E motif is also conserved 
in PARP1-6 and only slightly modified in the other family members and distinguishes them 
from cholera toxin-like ARTs and ecto-ARTs exhibiting the catalytic R-S-E motif (Figure 6) 
(Hottiger et al., 2010; Otto et al., 2005; Ruf et al., 1996). Therefore the PARP family has now 
been termed ADP-ribosyltransferase diphtheria toxin-like (ARTD) family (Hottiger et al., 
2010).  
 
 
Figure 6: Comparison of the key structural features and details of the active sites ARTs 
The R-S-E ARTs (bacterial exotoxins and mammalian ecto ARTs), H-Y-E ARTs (bacterial toxins and bona fide 
ARTDs/ PARPs), and H-Y-E variant ARTs (bacterial transferases and more reccently identified “mono ARTD/ 
PARP” enzymes) are contrasted. The structures are derived from the active sites of chicken ARTD1 (PARP1, 
protein data bank entry 1a26, 3pax), human ARTD10 (PARP10, 3hkv), Diphteria toxin (1tox), tRNA 
phosphotransferase (1wfx), C3 exotoxin (1ojz) and rat ART2 (1og3). The respective 6 β-strands are illustrated in 
rainbow colors with the N-terminal β-strand 1 colored in blue and β-strand 6 in red. The flexible loop between -
strand 4 and 5 is depicted in purple (rearranged from (Hottiger et al., 2010)) 
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An overview of the different members of the ARTD family including their names according 
to the former and the new nomenclature is given in Figure 5. Although this new nomenclature 
is used throughout this work, there are figures derived from older publications that still utilize 
the old nomenclature. 
The structure of the catalytic center and NAD+ binding fold of all ARTD family members 
consists of 6 antiparallel -strands, an -helix between -strand 2 and 3 and a flexible loop 
between -strand 4 and 5, which is in principle characteristic for all ART enzymes (Hottiger 
et al., 2010; Otto et al., 2005). However, the length of the flexible loop varies from enzyme to 
enzyme as it is illustrated by the purple loops in Figure 6 (Hottiger et al., 2010). Although the 
H-Y-E motif is not completely conserved throughout all ARTDs, the tyrosine (Y) in -strand 
3 is shared by all members and the histidine (H) in -strand by 15 of the 17 ARTDs (Otto et 
al., 2005). The glutamate in -strand 5, directly following the flexible loop between -strand 
4 and 5 and being important for catalytic activity in bacterial toxins, only occurs in ARTD1-6 
and is replaced by leucins, isoleucins, valins, threonines or tyrosines in ARTD7-17 as 
indicated in Figure 5 (Hottiger et al., 2010; Otto et al., 2005). This amino acid exchange has a 
drastic effect on the catalytic activity and is supposed to make the difference between mono-
ADP-ribosyltransferases and PAR forming enzymes (Kleine et al., 2008).  
I.4.1 The catalytic mechanism: Poly-ADP-ribosylation vs. mono-ADP-ribosylation 
The best studied member is ARTD1. It is capable of synthesizing long polymers of more than 
200 units of branched and unbranched ADPr covalently onto substrate proteins or itself 
(Figure 7) (D'Amours et al., 1999; Gibson and Kraus, 2012). During unbranched chain 
elongation, the next ADPr unit is always attached to the adenine-proximal ribose. Branching 
denotes the linkage of a free ADPr unit to the adenine-distal ribose and it is suggested to 
happen at every 20-50th ADPr moiety (D'Amours et al., 1999; Gibson and Kraus, 2012). 
Since a single unit of ADPr comprises two phosphate groups carrying negative charges, these 
PAR chains are highly negatively charged polymers (D'Amours et al., 1999). Additionally it 
is postulated that these long chains adapt a helical secondary structure exhibiting similarities 
to DNA and RNA structure. That is why PAR chains are sometimes described as “third type 
of nucleic” (D'Amours et al., 1999). The polymerization reaction itself can be subdivided into 
different steps. First an initiation step is required that includes mono-ADP-ribosylation of the 
protein itself or the substrate providing a start point for the second step, the PAR chain 
elongation reaction. The branching reaction constitutes a third step. Chemically the linkage 
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between the ADPr units is an O-glycosidic C1’’-C2’ bond independent whether the PAR 
structure is linear or branched (Hassa et al., 2006; Miwa et al., 1981; Ruf et al., 1998). 
 
Figure 7: NAD+, ADPr and formation of PAR  
The chemical structures of NAD+, ADPr and a PAR chain consisting of two ADPr units formed by ARTD1 are 
demonstrated. The C atoms where the elongation or branching reactions take place are indicated. In this scheme, 
the acceptor of ADPr on the modified protein is the carboxyl group of a glutamate or aspartate. However, also 
lysines are regarded as potential acceptor amino acids (see text for details) (from: (Luo and Kraus, 2012)). 
 
At the molecular level the acceptor amino acid of the substrate protein performs a 
nucleophilic attack on the C1 atom of the nicotinamide-proximal ribose of NAD+ as depicted 
in Figure 8A. Still, this applies to the initiation reaction whereas during the PAR chain 
elongation a ribose hydroxyl group fulfills the nucleophilic part. During this attack, 
nicotinamide represents the leaving group and an oxocarbenium ion-like transition state is 
formed (Kleine et al., 2008; Parikh and Schramm, 2004; Ruf et al., 1998). This transition state 
is supported by the catalytic glutamate of the ARTD enzyme (Ruf et al., 1998), which 
supports the oxocarbenium ion-like transition state and can elevate the nucleophilicity of the 
acceptor amino acids if it is positioned close enough to the catalytic center (Figure 8A) 
(Kleine et al., 2008; Parikh and Schramm, 2004; Ruf et al., 1998). In the case of ARTD1 it is 
supposed that glutamates or aspartates serve as acceptor amino acids (Desmarais et al., 1991; 
Hassa et al., 2006; Kleine et al., 2008; Tao et al., 2009). However, this is discussed 
controversially and even though a lot of effort has been made throughout the last decades, the 
substrate modification or automodification sites of ARTD1 are still matter of an ongoing 
debate. The modification sites of the other poly-ADP-ribosylating enzymes of the ARTD 
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family have not been identified (Hassa et al., 2006). On the contrary it has been reported 
recently that lysines rather than glutamates constitute the acceptor amino acids within the 
automodification domain of ARTD1, leaving open whether different amino acids can be 
modified outside the automodification domain (Altmeyer et al., 2009).  
 
 
Figure 8: Substrate-assisted catalysis by ARTD10  
A. Catalytic mechanism of ARTD1. The acceptor amino acid of the substrate performs a nucleophilic attack on 
the nicotinamide-proximal ribose. The subsequent transition state is supported by the catalytic glutamate of 
ARTD1. B. Substrate-assisted catalysis by ARTD10. The nucleophilic attack is conducted by a hydroxyl group 
of the nicotinamide-proximal ribose and the oxocarbenium ion transition state is stabilized once by the substrate 
glutamate (adapted from: (Kleine et al., 2008)). 
 
The catalytic glutamate is lacking in ARTD7-17. Furthermore, no PAR synthesizing activity 
could be shown for either tested enzymes of these but putative or validated mono-ADP-
ribosylation capacity (Kleine et al., 2008). It is thus suggested by Kleine et al. that a substrate 
derived glutamate replaces the catalytic glutamate in promoting the oxocarbenium ion-like 
transition state in a mechanism called “substrate assisted catalysis”. After the first round of 
ADP-ribosylation, the oxocarbenium ion transition state cannot be stabilized anymore since 
A B 
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the catalytic glutamate is missing and the substrate glutamate is now bound to the ADPr. Thus 
no chain elongation can occur (Figure 8B) (Kleine et al., 2008).  
Together, the ARTD family can be divided into two groups based on their catalytic activity: 
the PAR forming enzymes and the ARTs being marked by the lack of the catalytic glutamate. 
Additionally there is a subgroup of ARTDs (ARTD9 and ARTD13), which are not only 
lacking the glutamate but also the histidine of the H-Y-E triad. Since the histidine is involved 
in NAD+ binding (Ruf et al., 1996; Ruf et al., 1998) it is suggested that they are catalytically 
inactive (Figure 5) (Kleine et al., 2008). That has already been demonstrated for ARTD9 
(Aguiar et al., 2005). In the following, some members of the ARTD family will be described 
in more detail. 
I.4.2 ARTD1 (PARP1) 
According to genomic approaches and database comparisons ARTD1 was identified as the 
founding member of the ARTD family and subsequently it is the best studied enzyme and a 
variety of functions has been assigned to ARTD1. It was first most likely described in 1963 as 
a DNA-dependent nuclear enzyme (Chambon et al., 1963). Since 1963, it has been in the 
focus of diverse research areas including DNA repair, tumorigenesis, cellular stress, 
transcription, chromatin structure and DNA methylation (Hassa et al., 2006; Krishnakumar 
and Kraus, 2010; Luo and Kraus, 2012). It has a size of 116 kDa and includes an N-terminal 
DNA binding domain consisting of three unusual zinc fingers (Figure 5). Two of the three 
zinc fingers were recently crystallized together with a single stranded DNA end (Ali et al., 
2012). The authors concluded from these crystal structures that zinc finger 1(ZnF1) and zinc 
finger 2 (ZnF2) cooperate in binding to DNA single strand breaks by interacting with the 
minor or major groove of DNA, respectively. Thereby they facilitate the recruitment of 
ARTD1 to sites of DNA damage. But it was observed that the conformation of ZnF1 and 
ZnF2 on a DNA strand makes it rather unlikely that the zinc fingers are derived from the same 
polypeptide. Instead it is suggested that ARTD1 homodimerizes in order to recognize single 
strand DNA breaks (Ali et al., 2012). Furthermore, due to its nuclear localization signal 
(NLS) ARTD1 is a nuclear protein and bears an automodification domain (AMD) 
(Krishnakumar and Kraus, 2010) containing acceptor amino acids for poly-ADP-ribosylation 
(PARylation). It was proposed by Mendoza-Alvarez et al. that ARTD1 possesses four auto-
modification sites (Mendoza-Alvarez and Alvarez-Gonzalez, 1999), whereas Altmeyer et al. 
identified more than four sites (Altmeyer et al., 2009), and Desmarais et al. suggested 28 sites 
(Desmarais et al., 1991). Despite some of these data were generated up to 20 years ago, the 
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numbers of auto-modification sites are still discussed as mentioned above. The AMD harbors 
a breast cancer 1 early onset (BRCA1) carboxyterminal domain (BRCT) postulated to be 
responsible for protein-protein interactions (Krishnakumar and Kraus, 2010; Schreiber et al., 
2006). A tryptophane-glycine-arginine motif (WGR) has been reported to be essential for the 
catalytic PARylation activity that is conducted by the catalytic PARP-domain located at the 
C-terminus (Altmeyer et al., 2009; Krishnakumar and Kraus, 2010; Schreiber et al., 2006). 
 
Figure 9: Response of ARTD1, ARTD2 and ARTD3 to DNA damage  
DNA damage can be caused by different factors like irradiation, oxidative damage or drugs. During repair by 
e.g. DNA glycosylases and the DNA-(apurinic or apyrimidinic site) lyase (APE 1) or without functional 
homologous repair, single strand breaks (SSB) or double strand breaks (DSB) occur and are sensed by ARTD1 
(1) (and also ARTD2 and ARTD3) leading to formation of PAR chains (2). In the case of heavy DNA damage 
and strong ARTD1 activation, the massive consumption of the co-factor NAD+ ends up in energy depletion and 
cell death (6). After mild DNA damage the synthesis of PAR chains recruit chromatin remodeling enzymes (3) 
and DNA repair enzymes (4). BER: base excision repair. SSBR: single strand break repair. NHEJ: non-
homologous end joining. HR: homologous recombination (from: (De Vos et al., 2012)).  
 
In normal and unstressed cells ARTD1 is inactive and resides in the nucleus or is loosely 
associated with chromatin and is activated upon DNA damage (Ali et al., 2012; D'Amours et 
al., 1999; Pion et al., 2005). The consequence of the activation is the rapid formation of long 
PAR chains, which are attached to ARTD1 itself, to histones and additional proteins including 
some involved in single-strand break repair (SSBR) or double-strand break repair (DSBR) 
(De Vos et al., 2012; Pleschke et al., 2000). Although the question of indispensability of 
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ARTD1 in DNA repair and the direct effect of PARylation on the individual enzymes are not 
understood in detail, PARylation often serves to recruit chromatin remodelers or DNA repair 
factors to sites of DNA damage. This is illustrated by the scheme shown in Figure 9 
(D'Amours et al., 1999; De Vos et al., 2012; Kim et al., 2005; Krishnakumar and Kraus, 2010; 
Pleschke et al., 2000).  
One example is XRCC-1, a component of the base excision repair (BER) pathway, which is 
recruited to single strand breaks by automodified ARTD1 (El-Khamisy et al., 2003; Pleschke 
et al., 2000). Additionally it must be considered that two negative charges are attached to a 
protein by each unit of ADPr that is transferred. So it is supposed that the addition of long 
negatively charged PAR polymers to ARTD1 attached to DNA strand breaks leads to the 
release of ARTD1 from DNA and a decondensation and increased accessibility of chromatin 
structure. This in turn is considered to facilitate DNA repair (D'Amours et al., 1999).  
ARTD1 can be regarded as a switch between cell death and survival after DNA damage, 
dependent on the severity. Thus besides DNA repair, ARTD1 is also involved in cell death by 
apoptosis as well as by necrosis (Kim et al., 2005). Apoptosis is regarded as a programmed 
cell death mediated by a cascade of caspase enzymes and characterized by ordered DNA 
fragmentation into 200 bp segments, and the securing of cell components into apoptotic 
bodies phagocytosed by neighbouring cells. Consequently no cellular components are 
released into the surrounding tissue (Edinger and Thompson, 2004). On the other hand 
necrosis is a form of cell death designated by vacuole formation in the cytoplasm and 
ruptering of the plasma membrane resulting in cell bursting and inflammation. Necrosis is 
amongst others triggered by loss of cellular energy mediated by NAD+ and adenine 
triphosphate (ATP) depletion (Edinger and Thompson, 2004). As a consequence of massive 
DNA damage, hyperactivation of ARTD1 can take place and shortage of NAD+ can occur, 
resulting in a massive ATP consumption for re-synthesis of NAD+ and this ATP consumption 
leads to necrosis. In response to less severe DNA damage, DNA repair is facilitated as 
described above and in Figure 9 (De Vos et al., 2012; Kim et al., 2005). Moreover it has been 
shown that ARTD1 activation promotes the translocation of apoptosis inducing factor (AIF) 
from mitochondria into the nucleus resulting in AIF-induced DNA fragmentation and 
chromatin condensation and leading to cell death by apoptosis (Kim et al., 2005). The exact 
mechanism how the AIF release is triggered is still matter of debate (Kim et al., 2005; Wang 
et al., 2011; Yu et al., 2002). In order to separate the cell death induced by ARTD1 from cell 
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death types like caspase-dependent apoptosis, the former is referred to as partanathos (David 
et al., 2009). 
Due to ARTD1’s role in DNA repair, it has emerged as a target for cancer treatment by 
developing specific ARTD1 inhibitors. Since ARTD1 is involved in recruitment of factors for 
the SSBR, inhibition of ARTD1 would lead to defects in SSBR and consequently single 
strans breaks (SSBs) would be turned into double strand breaks (DSBs) during DNA 
replication. Usually this is compensated by DSB repair (Bryant et al., 2005; Krishnakumar 
and Kraus, 2010). One of these inhibitors is Olaparib, which has gained importance in 
treatment of mammary carcinoma with inherited BRCA1 or BRCA2 defects. BRCA1 and 2 
are essential components of the homologous recombination repair machinery for DSBs. 
Deficiency of this repair mechanism results in collapsing of replication forks and ultimately in 
cell death. Consequently a model is proposed that the combination of ARTD1 inhibition, 
leading to DSBs and defects in DSBR in BRCA1/2 deficient mammary carcinoma cells, 
would culminate in cell death of the tumor cells. This strategy is termed “synthetic lethality” 
and has been confirmed in several studies and clinical trials for Olaparib (Bryant et al., 2005; 
Farmer et al., 2005; Krishnakumar and Kraus, 2010).  
However, ARTD1 is not only activated upon DNA damage. It can also be stimulated by 
binding to protein interaction partners or specific DNA structures like supercoils and 
subsequently PARylate histones (Kraus and Lis, 2003). Furthermore, ARTD1 has been 
reported to be implicated in transcription (Kraus and Lis, 2003). One example for ARTD1’s 
role in transcriptional regulation is its involvement in the NF-B pathway where it acts as a 
co-activator of NF-B. It interacts with two subunits of NF-B, p50 and p65, and with 
components of the mediator complex that consists of transcriptional co-activators (Hassa et 
al., 2003; Hassa et al., 2005; Hassa and Hottiger, 2002). Thereby the transcription of a subset 
of NF-B target genes is promoted by a mechanism that requires further investigation (Hassa 
et al., 2005) but does not depend on its catalytic activity (Hassa et al., 2003; Hassa et al., 
2001). On the other hand there is evidence for inhibition of binding of transcription factors 
after PARylation by ARTD1 at other promoters (Kraus and Lis, 2003).   
Together, ARTD1 is the enzyme that generates the majority of PAR in cells and is highly 
involved in important cellular processes including DNA repair, apoptosis and transcriptional 
regulation (Hassa et al., 2005; Pleschke et al., 2000; Yu et al., 2002). Taking this into 
consideration, it is surprising that Artd1-/- knockout mice are viable and fertile. They are prone 
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to genotoxic stress and severe combined immunodeficiency mice for example have a higher 
tumor incidence but overall the phenotype is rather mild (Krishnakumar and Kraus, 2010). 
However, the Artd1-/- and Artd2-/- double knockout is lethal, suggesting that ARTD1 and 
ARTD2 have at least in part redundant functions (Ménissier de Murcia et al., 2003). 
I.4.3 ARTD2 and ARTD3 
As the lethality of Artd1-/- and Artd2-/- double knockout mice already suggests, ARTD2 has 
been reported to have similar activities to ARTD1. ARTD1 and ARTD2 share 43% sequence 
identity in their catalytic domain. ARTD2 also possesses the catalytic glutamate enabling 
PAR synthesis and is located in the nucleus. Additionally its enzymatic activity is also 
stimulated by DNA damage and it is involved in DNA repair although its DNA binding 
domain is different from ARTD1 (Amé et al., 1999).  
It forms heterodimers with ARTD1 and shares interaction partners. Furthermore it has been 
shown to be important for genome integrity (Schreiber et al., 2002). On the other hand it also 
fulfills functions independent of the DNA damage response. One example is its negative 
regulation of the SIRT1 promoter, which in turn leads to a reduced number of mitochondria in 
skeletal muscle and liver. Consequently, also activities in regulation of transcription were 
demonstrated for ARTD2 (Bai et al., 2011). 
ARTD3, another bona fide ARTD member, is also involved in DNA repair mechanisms. At 
the current state of knowledge it exclusively participates in double strand break repair, 
functioning together with ARTD1 (Boehler et al., 2011; Rulten et al., 2011). 
I.4.4 ARTD5/6 (Tankyrases) 
ARTD5 and ARTD6 (formerly tankyrase 1 and tankyrase 2) are also PAR-synthesizing 
members of the ARTD family. They both share a high degree of homology despite ARTD6 
lacking the N-terminal histidine-proline-serine repeat domain of ARTD5. Both contain 24 
ankyrin repeats, which are implicated in protein-protein interactions (Schreiber et al., 2006; 
Smith et al., 1998). Originally ARTD5 was identified as a telomere associated protein where 
it PARylates the negative modulator of telomere length, telomeric repeat binding factor 1 
(TRF1). TRF1 is speculated to dissociate from telomeres upon PARylation and allows 
telomere elongation in telomerase-expressing cells (Smith and de Lange, 2000; Smith et al., 
1998). ARTD5 was also found to be important for the proper formation of bipolar mitotic 
spindles (Chang et al., 2005). ARTD6 seems to be partly redundant to ARTD5, already 
implicated by the strong homology, but less important for the control of telomere length. 
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Consequently ARTD6 is considered to have some ARTD5-independent functions (Schreiber 
et al., 2006). More recently, Huang et al. identified ARTD5 and ARTD6 as regulators of the 
WNT signaling pathway by PARylating axin, which is a limiting part of the WNT destruction 
complex (Huang et al., 2009). Among others, this destruction complex is composed of β-
catenin, axin as a scaffolding protein, adenomatous polyposis coli protein and the kinases 
glycogen synthetase kinase 3β (GSK3β) and casein kinase 1 (CK1). Without WNT pathway 
activation, these kinases phosphorylate the WNT transcription factor β-catenin, which 
promotes its ubiquitination and degradation, thereby controlling the abundance of β-catenin 
(Willert and Jones, 2006). It was demonstrated that ARTD5/6 interact with axin via the 
ankyrin repeats and PARylate axin (Huang et al., 2009), resulting in the recruitment of the E3 
ubiquitin ligase RING finger protein 146 (RNF146), ubiquitination of axin and its 
proteosomal degradation. Subsequently, the β-catenin destruction complex lacks its 
scaffolding factor axin and is not functional anymore. That in turn stabilizes β-catenin that 
can fulfill its role as transcription factor. Importantly, the recruitment of RNF146 is mediated 
by a WWE domain, which will be described in detail in I.6.3. Mutation of components of the 
WNT signaling pathway is a cause for several tumors (Callow et al., 2011; Huang et al., 2009; 
Zhang et al., 2011).  
Summarizing, the ARTD family members ARTD5 and ARTD6 are localized both, in the 
nucleus and in the cytoplasm and fulfill functions distinct from ARTD1 and ARTD2.  
I.4.5 ARTD10 
Originally ARTD10 was identified as an interaction partner of the proto-oncogene c-MYC 
(Yu et al., 2005). Interestingly, the ARTD10 gene is also localized to the same chromosome as 
c-MYC (8q24) and was demonstrated to translocate together with c-MYC in Burkitt’s 
lymphoma cell lines. In addition, the ARTD10 gene overlaps with the plectin 1 gene and they 
share the last two exons of ARTD10, encoding for the catalytic domain. However, these exons 
seem to be non-coding for plectin 1 (Lesniewicz et al., 2005; Yu et al., 2005). Furthermore 
ARTD10 is expressed in all tissues studied by Yu et al. but the level is highest in 
hematopoietic tissues. This can also be observed at the protein level (Yu et al., 2005). The 
ARTD10 protein consists of 1025 amino acids and has a molecular weight of 110 kDa. 
Although Yu et al. initially described ARTD10 as an enzyme that auto-ADP-ribosylates and 
catalyzes oligo- or poly-ADP-ribosylation but it was later identified and confirmed as the first 
mono-ADP-ribosyltransferase (mART) of the ARTD family (Kleine et al., 2008; Yu et al., 
2005). Additionally, it is the exemplary enzyme for the model of substrate-assisted catalysis 
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of ARTD7-ARTD17 described above. Accordingly, the catalytic glutamate in the active 
center of ARTD10 is replaced by an isoleucine and the enzyme mono-ADP-ribosylates acid 
residues on target proteins (Kleine et al., 2008). Furthermore, Kleine et al. demonstrated a 
robust automodification capability of ARTD10 in enzymatic in vitro assays, which is 
efficiently inhibited by the addition of general ARTD inhibitors like benzamide. The targeted 
site(s) of automodification are only partially known. A glutamate at position E882 could be 
identified as target site but the authors emphasized that additional sites must exist (Kleine et 
al., 2008).  
 
Figure 10: Domain architecture of ARTD10 
The different domains of ARTD10 are depicted as deducted and information is combined from database 
predictions, Yu et al. and Kleine et al. (Kleine et al., 2012; Kleine et al., 2008; Yu et al., 2005). The indicated 
residues refer to the amino acids of human ARTD10. The core catalytic center, the region procuring ARTD10’s 
interaction with c-MYC (Yu et al., 2005), a glycine rich region (lilac), a region harboring an unconventional 
NLS (orange) and a glutamate rich region (green) are designated. RRM: RNA recognition motif; NLS: nuclear 
localization signal; NES: nuclear export sequence; UIM: ubiquitin interaction motif. 
 
 
Based on database homology searches the domain architecture of ARTD10 was analyzed. It is 
unique among the ARTD family since ARTD10 is the only enzyme of the family combining 
two ubiquitin interaction motifs (UIMs) with a RNA recognition motif (RRM) and the 
catalytic ARTD domain (Figure 10) (Kleine et al., 2008; Yu et al., 2005). RRMs themselves 
are rather abundant protein domains in eukaryotes, which are often found in tandem. They 
mediate high affinity RNA binding but also protein-protein interactions. Depending on the 
RRM they can either recognize RNA, other RRMs or proteins domains or both (Maris et al., 
2005). Moreover proteins containing RRMs have been implicated in RNA translation, 
processing, RNA stability or in protein nuclear import (Cassola et al., 2010). Still the function 
of ARTD10’s RRM has been poorly investigated so far. A glycine-rich domain, found by 
database homology searches, is also located near the N-terminus. It comprises amino acids 
(aa) 281–399 (Yu et al., 2005). UIMs are -helical motifs that bind to ubiquitin, a 76 aa 
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protein that can be posttranslationally attached to proteins as a monomer or as polymers 
(Haglund and Dikic, 2005). Depending on how the ubiquitins are polymerized, this 
modification serves as signal for proteosomal degradation (K-48 linked ubiquitin) or 
endocytosis, DNA repair and signaling, e.g. NF-B signaling (K-63 linked ubiquitin). On the 
other hand, mono-ubiquitination has been shown to regulate protein interactions, localization 
and activity. Furthermore there is evidence that UIM containing proteins are mono-
ubiquitinated and that for modification the UIM is a prerequisite (Haglund and Dikic, 2005; 
Hoeller et al., 2007). The function(s) of ARTD10’s UIMs are largely unknown. Beyond, 
ARTD10 possesses a nuclear export sequence (NES) within a glutamate-rich region, which is 
functional because ARTD10 accumulates in the nucleus upon mutation of the NES or 
inhibition of chromosome region maintenance 1 protein homolog (CRM1)-dependent nuclear 
export by leptomycin B (Kleine et al., 2012; Yu et al., 2005). The nuclear import is organized 
by a non-classical nuclear localization signal (NLS) within the region of aa 408-649. 
However, the NLS does not promote a complete nuclear localization of the protein but rather 
mediates an even distribution. Thus ARTD10 shuttles between the nucleus and the cytoplasm 
(Kleine et al., 2012). 
The functions of ARTD10 as mART have remained poorly understood. It has been identified 
as an interaction partner of c-MYC, which is a well-studied oncogene that is capable to 
transform cells together with activated Ras. Although c-MYC apppears not to be an in vitro 
substrate of ARTD10 (Yu et al., 2005), ARTD10 co-expression interferes with the c-
MYC/Ha-Ras-dependent transformation of rat embryo fibroblasts. However, for this effect 
the catalytic activity of ARTD10 was shown to be not required but the NES and thus its 
ability to shuttle into the cytoplasm. A more detailed mechanism of how ARTD10 interferes 
with c-MYC/ Ha-Ras transformation remains to be investigated (Yu et al., 2005). Consistent 
with this observations, overexpression of ARTD10 inhibits cell proliferation in HeLa cells 
(Kleine et al., 2008). But this is not a general effect because ARTD10 overexpression does 
not have any obvious influence on HEK293 or U2OS cell proliferation (Yu et al., 2005). On 
the other hand Chou et al. showed that knockdown of ARTD10 in HeLa cells leads to a delay 
in the G1-S-phase transition of the cell cycle and also increases cell death. Consequently, 
Chou et al. concluded that at least HeLa cells are sensitive to changes in ARTD10 levels. In 
the course of their study, Chou et al. furthermore detected a phosphorylation of nucleolar 
ARTD10 at threonine 101 (T101) by Cyclin E/Cycline-dependent kinase 2 (CDK2) in 
proliferating cells. The phosphorylation occurs in late G1/S-phase according to the cell cycle 
INTRODUCTION 
23 
dependent expression and activation of the Cyclin E/CDK2 complex at the G1/S-phase 
transition. It has been reported that this phosphorylation stimulates the automodification 
activity of ARTD10 approximately 8 times (Chou et al., 2006). In general only few ADP-
ribosylated substrates of ARTD10 have been identified by in vitro enzymatic assays, e.g. 
ARTD10 itself, core histones and especially histone H2A (Yu et al., 2005). Lately ARTD10 
was described to accumulate in dynamic cytoplasmic and nuclear foci, which contain poly-
ubiquitin and partially co-localize with the poly-ubiquitin receptor p62/Sequestosome 1 
(SQSTM1) as a function of its ubiquitin-associated domain. p62/SQSTM1 is implicated in 
autophagy (Johansen and Lamark, 2011; Kleine et al., 2012). 
Additionally it has been reported recently that knockdown of ARTD10 in primary human 
hepatocytes causes a decrease in apolipoprotein B secretion. Apolipoprotein B is a carrier and 
supporter of synthesis of triacyl-glycerol-rich lipoproteins (Shen et al., 2012).    
I.4.6 ARTD8  
Due to database analyses, ARTD8 is proposed to belong to the subfamily of mARTs of the 
ARTD family since the catalytic glutamate is substituted by an isoleucine (Kleine et al., 
2008). Being composed of 1817 amino acids and having a molecular weight of 203 kDa, it is 
the largest enzyme of the ARTD family. As all family members it is characterized by the 
conserved C-terminal catalytic domain. Additionally it possesses a WWE domain neighboring 
the catalytic domain as well as three macrodomains (Goenka and Boothby, 2006; Otto et al., 
2005). WWE domains are usually implicated in mediating protein interactions and occur in 
proteins linked to ADP-ribosylation or ubiquitination where it can be found as single domain 
or in tandem (Wang et al., 2012). The functions of WWE and also of the macrodomains will 
be addressed in detail in chapter I.6. 
Originally ARTD8 was described as a coactivator of Signal Transducer and Activator of 
Transcription 6 (STAT6) and was referred to as CoaSt6 (Goenka and Boothby, 2006; Goenka 
et al., 2007). Cytoplasmic STAT6 is phosphorylated and activated by Interleukin-4 (IL-4) 
through JAK kinases, dimerizes and translocates into the nucleus to activate target gene 
transcription. This IL-4 cytokine pathway plays important roles in lymphocytes and usually 
promotes cell survival (Goenka and Kaplan, 2011). The activation potential of STAT6 has 
been shown to be enhanced by ARTD8. The macrodomains alone are sufficient for a partial 
activation but the combination of macrodomains with the WWE and the catalytic domain are 
more potent co-activators and the catalytic activity is mandatory. Additionally, the 
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macrodomains interact with Stat6. Although STAT6 itself is not an ARTD8 substrate, this 
applies for a STAT6 associated transcriptional cofactor, p100. Nevertheless, these studies do 
not reveal the detailed function of ARTD8 and its automodification or consequences of the 
p100 ADP-ribosylation (Goenka and Boothby, 2006; Goenka et al., 2007). Additionally 
ARTD8 was shown to reduce apoptosis rates in B-cells but not in T-cells after IL-4 treatment 
(Cho et al., 2009). This is mediated by IL-4 dependent and ARTD8 supported repression of 
the caspase-3 activation. Accordingly, ARTD8 is an essential co-factor for the IL4-dependent 
expression of the anti-apoptotic survival factors serine/threonine-protein kinase 1 (pim-1) and 
induced myeloid leukemia cell differentiation protein 1 (Mcl-1). ARTD8 promotes B-cell 
survival at different points but is selective for the beforehand mentioned survival factors and 
is not a general co-activator of B-cell survival. Since overexpression of pim-1 and Mcl-1 are 
oncogenic in B-cell lymphomagenesis, Cho et al. propose an involvement of ARTD8 in 
cancer development (Cho et al., 2009). 
Another implication of ARTD8 in tumors is its structural similarity to ARTD9. ARTD9 was 
found to be overexpressed in aggressive diffuse large B-cell lymphomas with poor outcome 
where it supports B-cell migration (Aguiar et al., 2000). Although ARTD9 is shorter, it 
possesses a similar combination of domains as ARTD8, namely the PARP catalytic domain 
and two macrodomains (Figure 5) (Schreiber et al., 2006) and the genes of both proteins are 
localized on chromosome band 3q21 in direct neighborhood. However, in contrast to ARTD8, 
ARTD9 lacks enzymatic activity (Aguiar et al., 2005).  
Furthermore it has been reported that ARTD8 influences the stability of phosphoglucose 
isomerase (PGI) in a fibrosarcoma cell line (Yanagawa et al., 2007). PGI promotes the 
interconversion of glucose-6-phosphate and fructose-6-phosphate. On the other hand PGI can 
be secreted and exhibit cytokine-like functions and was also identified as the autocrine 
motility factor (AMF) that is secreted by tumor cells. After secretion it binds in an autocrine 
way to the gp78/AMF receptor, initiating a signaling cascade and resulting in cell motility and 
cancer cell metastasis. If ARTD8 is knocked down, ubiquitination of AMF, which targets it 
for lysosomal degradation, was shown to be enhanced. Consequently ARTD8 stabilizes AMF 
by reducing directly or indirectly its ubiquitination. However, the detailed mechanism has not 
been investigated so far (Yanagawa et al., 2007). 
Together ARTD8 is described as a coactivator of STAT6-dependent transcription in B-cells 
and supports cell survival (Cho et al., 2009; Goenka et al., 2007). These findings, its similarity 
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to ARTD9 (Schreiber et al., 2006), and the study about its stabilization of AMF (Yanagawa et 
al., 2007), indicate a link of ARTD8 to tumorigenesis (Cho et al., 2009). However all these 
studies do not provide a clear mechanism how ARTD8 mediates its effects. It is not 
completely clear which role the macrodomains, the WWE domain or the catalytic activity and 
potential ADP-ribosylated substrates of ARTD8 play. 
I.5 Removing ADP-ribosylation 
Phosphorylation, acetylation and methylation are reversible and like most PTMs can be 
removed by specific enzymes in tightly regulated manners (Bannister and Kouzarides, 2011; 
Kouzarides, 2007). This seems also true for the ADP-ribosylation of proteins mediated by the 
ARTD family, although the evidence is not complete. The “erasers” of PAR synthesized by 
the ADPr polymer forming members of the ARTD family are better characterized compared 
to mono-ADP-ribosylhydrolases. The two discovered counteractors of PAR forming enzymes 
and especially of ARTD1 as main contributor of PAR synthesis in cells are the poly-ADP-
ribose glycohydrolase (PARG) (Krishnakumar and Kraus, 2010; Slade et al., 2011) and the 
ADP-ribosylhydrolase 3 (ARH3) (Mueller-Dieckmann et al., 2006). 
I.5.1 PARG 
PARG is an enzyme that hydrolyzes glycosidic ribose-ribose bonds. It was originally 
discovered by Miwa and Sigimura in calf thymus nuclear extracts exhibiting PAR cleaving 
activity (Miwa and Sugimura, 1971). At that time and in the following years there was 
confusion about how many PARG enzymes exist because purifications yielded several PARG 
proteins of varying size. Today it is known that PARG is encoded by a single gene but is 
expressed as different isoforms and depending on the isoform, protein size and subcellular 
localization differ (Schreiber et al., 2006). The first two isoforms are the 110 kDa nuclear 
PARG and a considerably smaller 65 kDa PARG is localized to mitochondria. Two additional 
cytoplasmic isoforms with apparent molecular sizes of 103 kDa and 99 kDa are known 
(Haince et al., 2006; Meyer-Ficca et al., 2004; Schreiber et al., 2006).  
With regard to its enzymatic abilities PARG generally hydrolyzes the C1’’-C2’ O-glycosidic 
bond between ADPr subunits of PAR chains. The reaction velocity of the PAR degradation 
process is very quick and it is assumed that it starts directly after PAR synthesis. Hence 
PARylation of proteins is a transient modification with a short half-life, which can be as short 
as 1 min after DNA damage (D'Amours et al., 1999). Furthermore, in the first decades after its 
discovery PARG was suggested to have exo- and to a lesser extend also endoglycosidase 
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activity and consequently being able to degrade PAR chains from the terminal end as well as 
to split bonds within the PAR polymer (Brochu et al., 1994; Ikejima and Gill, 1988; Schreiber 
et al., 2006). However, although the PAR formation, especially mediated by ARTD1, has 
been investigated intensively only little information about the enzymatic mechanisms of its 
antagonist PARG was availabe (Schreiber et al., 2006) until recently two groups published 
more elaborated structural analyses. Three catalytically important acidic amino acids were 
identified in PARG’s catalytic center, an aspartate and two glutamates, and a PARG signature 
sequence (GGG-X6-8-QEE) has been postulated (Patel et al., 2005; Slade et al., 2011). 
In a study published in 2011, PARG orthologues were identified in fungi and bacteria and 
used for characterization (Slade et al., 2011). All were demonstrated to be able to hydrolyze 
the typical PAR ribose-ribose bond but are unable to remove the initial ADPr connected to the 
substrate. As a striking novelty, it was observed by solving crystal structures of a bacterial 
Thermomonospora curvata PARG that the active center is a typical macrodomain fold with an 
additional N-terminal loop containing the PARG signature and being unique for PARG 
enzymes. Consistently crystal structures also revealed that ADPr is bound by PARG similar to 
macrodomains (see I.6.2). The additional loop most likely explains the enzymatic difference 
between PARG, which is able to hydrolyze PAR, and macrodomains which have not been 
reported to cleave ribose-ribose bonds. Indeed the binding characteristics of bacterial PARG 
to ADPr imply that PAR chain degradation can only occur from the terminal ADPr due to its 
tunnel-like shape where the ADPr is bound. Slade et al. postulate space limitations for further 
ADPr units. Mutational studies of the residues involved showed that this proposed mechanism 
could also apply for human PARG. Consequently Slade et al. suggest that the PARG enzyme 
only bears exoglycohydrolase activity, which would stand in contrast to the argumentations of 
the studies mentioned previously. Further work is required to resolve this issue (Slade et al., 
2011). 
The biological role of PARG is best investigated in respect of its interplay with ARTD1. With 
regard to the fact that the main source of PAR generation, ARTD1, is located in the nucleus it 
is striking that two cytoplasmic isoforms exist (Schreiber et al., 2006). However, on the one 
hand there are also ADPr polymer forming ARTDs in the cytoplasm, e.g. ARTD4-6. On the 
other hand also cytoplasmic PARG isoforms were demonstrated to shuttle in and out of the 
nucleus (Haince et al., 2006). Nuclear as well as cytoplasmic isoforms are known to be 
recruited to PARylated, laser-generated DNA damage sites by two mechanisms. First they 
interact with PAR chains, most likely synthesized by ARTD1. Secondly they are recruited via 
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associating with the DNA replication and repair factor proliferating cell nuclear antigen 
(PCNA) (Mortusewicz et al., 2011). Generally the balance of PAR synthesis and degradation 
is regarded to be pivotal because a complete PARG knockout results in embryonic lethality of 
mice (Koh et al., 2004). 
I.5.2 ARH 3 
The family of ARHs currently comprises three known members, ARH1-3. ARH1 was 
identified as an ADPr hydrolase cleaving stereospecifically the α-glycosidic bond between an 
arginine on the substrate protein and ADPr (Moss et al., 1985; Moss et al., 1986). This seems 
to be important for maintenance of proper cell proliferation since a knockout of ARH1 results 
in accelerated tumor formation in mice (Glowacki et al., 2002; Kato et al., 2011). The 
concrete targets of this intracellular ARH remain to be unrevealed. As one possibility, ARH1 
could be designated to protect a cell against actions of bacterial toxins, including cholera toxin 
(Kato et al., 2007), that ADP-ribosylate arginine residues. In contrast, ARH3 exhibits 
different substrate specificities from ARH1 since it is unable to cleave arginine-ADPr bonds 
but breaks down PAR into monomers of ADPr. Concordantly, the amino acid sequence 
similarity between ARH1 and ARH3 (both 39 kDa) is only 22% although belonging to the 
same protein family (Oka et al., 2006). Although both facilitate the cleavage of PAR polymers 
into ADPr, it has been reported that the architecture of the catalytic center of ARH3 is distinct 
from the one of PARG since the binding of ADPr depend on two magnesium ions in the 
catalytic cleft as revealed by docking studies (Mueller-Dieckmann et al., 2006). 
Additionally it was shown that ARH3 can degrade PAR chains located in mitochondria (Niere 
et al., 2012). The corresponding experiments were conducted by PAR generation in response 
to overexpression of the ARTD1 catalytic domain fused to a mitochondrial localization signal. 
So it remains to be investigated if ARH3 possesses a physiological role in controlling 
mitochondrial PAR status (Niere et al., 2012). Beyond the findings described above, no 
further published insights are available regarding the function of ARH3 and also ARH2. 
I.6 Reading ADP-ribosylation 
Beyond effects of PTMs on function of substrates there is frequently also a need for proteins 
or protein domains that can interpret the PTM. As bromodomains bind acetylated histones and 
chromo- or tudordomains recognize methylated histones (Bannister and Kouzarides, 2011; 
Kouzarides, 2007), four distinct domain types were characterized that can detect PARylation. 
These are described in this chapter.  
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I.6.1 A short linear motif constitutes the first ADPr recognizer 
A first hint for existing ADPr binding motifs was found by Malanga et al. in 1998 as they 
discovered a non-covalent binding of the tumor suppressor protein p53 to PAR chains by 
three different regions within the protein thus impairing the DNA-binding abilities of p53 
(Malanga et al., 1998). In later reports a peptide of approximately 20 amino acids containing a 
cluster of basic and hydrophobic amino acids was identified to mediate these interactions 
(Pleschke et al., 2000). This original consensus motif could be specified by in silico screening 
and more proteins harboring this PAR binding signature were found: [HKR]1-X2-X3-
[AIQVY]4-[KR]5-[KR]6-[AILV]7-[FILPV]8 (Gagné et al., 2008). Although there are only few 
conserved amino acids, this motif occurs in defined groups of proteins beyond p53. In a 
screen, PAR binding could be observed for example for core histones, p21, proteins involved 
in DNA-damage response like XRCC1, DNA ligase III, p52 of NF-B, DNA-dependent 
protein kinase, DNA replication factors and also histone acetyltransferases like p300 and 
p300/Creb binding protein-associated factor (P/CAF) (Gagné et al., 2008; Pleschke et al., 
2000). Interestingly, this PAR binding motif is not capable to interact with ADPr or known 
derivatives or PAR alone (Kalisch et al., 2012). Summarizing this motif is present in groups 
of proteins that are linked to the cell cycle, DNA repair, chromatin and chromatin stability, all 
of which have been shown to involve PAR synthesis conducted by enzymes of the ARTD 
family before (Gagné et al., 2008). 
I.6.2 Macrodomains are ADPr binding modules 
Macrodomains are protein domains that occur in a variety of species throughout the kingdom 
of life. Macrodomain containing proteins have been identified in eukaryotes (Gottschalk et al., 
2009; Timinszky et al., 2009), viruses (Kuri et al., 2011; Tan et al., 2009), archaea (Allen et 
al., 2003; Karras et al., 2005) so far and there also exist predicted macrodomain containing 
proteins in bacteria (Letunic et al., 2009). For humans there are currently ten proteins with 
macrodomains denoted in Swiss-Prot and the prosite database as depicted in Table 1 
(Consortium, 2012; Hulo et al., 2006). Strikingly, each of these proteins possesses a single 
macrodomain except ARTD7-9 of the ARTD family, harboring two or three domains (Gibson 
and Kraus, 2012). 
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Table 1: Human macrodomain containing proteins 
Ten human proteins possess a macrodomain (left column). Numbers of macrodomains of the proteins are given 
(right column) as well as the amino acids (in brackets). Information is derived from Swiss-Prot and the prosite 
database (Consortium, 2012; Hulo et al., 2006). 
Protein Macrodomains
Core histone macroH2A1 Macro(184-370) 
Core histone macroH2A2 Macro(184-370) 
ARTD9/PARP9 Macro1(107-296), Macro2(306-487) 
ARTD8/PARP14 Macro1(791-978), Macro2(1003-1190), 
Macro3(1216-1387) 
ARTD7/PARP15 Macro1(56-245), Macro2(271-442) 
MacroD1 Macro(141-322) 
MacroD2 Macro(59-240) 
CHD1L/ ALC1  
(Chromodomain-helicase-DNA binding protein l-like) 
Macro(704-897) 
C6orf130 Macro(2-152) 
GDAP2  
(ganglioside-induced differentiation-associated protein 2) 
Macro(43-223) 
 
Generally they are described as one of four robust PAR binding modules (Dani et al., 2009; 
Karras et al., 2005; Kustatscher et al., 2005). An overview about these modules is given in 
Figure 11. For details on the WWE or PAR binding zinc finger (PBZ) domains see below. 
The first studies were conducted with the bacterial macrodomain of AF1521 protein, derived 
from Archaeoglobus fulgidus. Its crystal structure was solved in 2003 (Allen et al., 2003) and 
subsequently Karras et al. revealed in isothermal calorimetry titration binding assays a high 
affinity of this macrodomain for ADPr in the nanomolar range (Karras et al., 2005). The 
affinities were much lower for similar compounds to ADPr, like ADP, ATP and AMP, 
whereas the binding to adenosine, NAD+ or GDP was hardly detectable (Karras et al., 2005).  
The first eukaryotic characterized macrodomain and founding member of this domain type 
was detected in the histone variant macroH2A (Pehrson and Fried, 1992). It is one of the best 
investigated macrodomains in mammals. The histone domain of MacroH2A shows a 
sequence identity to histone H2A of 64% (Chakravarthy et al., 2005). MacroH2A is enriched 
in heterochromatin, especially on the inactivated X chromosome (Chadwick et al., 2001; 
Nusinow et al., 2007). However, besides the X-chromosome it can also be found in 
centrosome regions (Rasmussen et al., 2000). Currently three variants of macroH2A are 
known: macroH2A1.1, macroH2A1.2 and macroH2A2. Whereas macroH2A1.1 and 
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macroH2A1.2 are splice variants of one gene located on chromosome 5, macroH2A2 is 
transcribed from a different gene on chromosome 10 (Costanzi and Pehrson, 2001; 
Rasmussen et al., 2000).  
 
Figure 11: Overview of the binding abilities of PAR interacting modules  
A. Two ADPr units attached to a substrate protein are shown. The (n-1) ADPr is illustrated in pink, whereas the 
terminal ADPr is shown in blue. The colored boxes designate the part of the PAR chain, which is recognized by 
the indicated PAR readers. Consequently the WWE domain requires an iso-ADPr containing the unique C1’-C2’ 
O-glycosidic bond of a PAR chain. PBZ domains are also capable of interacting with the glycosidic bond as well 
as with the adenine of the terminal ADPr. Macrodomains recognize the terminal ADPr, which fits in their central 
binding cleft. B. Details of the four binding modules are given. * The consensus sequence is denoted as 
([HKR]1-X2-X3-[AIQVY]4-[KR]5-[KR]6-[AILV]7-[FILPV]8) (from (Gibson and Kraus, 2012)). 
 
Despite sequence similarities of these macroH2A variants, their macrodomains have different 
abilities. Timinszky et al. observed that the macrodomain of the histone variant macroH2A1.1 
but not macroH2A1.2 binds free ADPr, PAR and localizes to sites of ARTD1 activity in cells. 
Similar results to the recruitment of macroH2A1.1 to sites of PARylation were obtained for 
the macrodomain containing proteins MacroD1, amplified in liver cancer 1 (ALC1) and 
MacroD2 by Timinszky et al. Also a macrodomain of ARTD9 interacted with PAR. 
(Timinszky et al., 2009). 
In a study by Dani et al. the authors used the ability of the macrodomain of AF1521 to bind to 
free ADPr in order to isolate ADP-ribosylated proteins from cells (Dani et al., 2009). They 
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fished among others the β-subunit of G proteins, vimentin and ARTD1 with the macrodomain 
and identified the proteins by mass spectrometry (Dani et al., 2009). However, the 
macrodomain of AF1521 is also capable of binding to PAR (Karras et al., 2005) and the study 
left open, whether the identified proteins were poly- or mono-ADP-ribosylated.  
Since macrodomains from different species and proteins share the capability of ADPr binding, 
it is assumable that there exists a certain degree of either sequence or structural homology. 
Although the sequence alignment of different macrodomains from diverse species reveals 
considerable heterogeneity (Figure 12), there are some very conserved regions, which were 
defined using structural alignments (Karras et al., 2005). Especially the amino acids that have 
been implicated in ADPr binding and form a hydrophobic pocket are conserved as crystal 
structures indicate (Karras et al., 2005; Peterson et al., 2011; Slade et al., 2011). This 
hydrophic binding cleft of macrodomains is composed of a canonical --sheet. For 
AF1521 it was demonstrated that the ADP-distal ribose of ADPr is particularly important for 
binding to the macrodomain. However, also the adenine base and the diphosphate of the 
ADPr make contacts with the amino acids of the hydrophobic pockets (Karras et al., 2005; 
Timinszky et al., 2009). In accordance with the high affinity for ADPr and the binding center 
being a hydrophobic pocket making several contacts with the ADPr sitting within the cleft, it 
is suggested that macrodomains recognize the terminal ADPr rather than binding along the 
PAR chain (Chen et al., 2011; Till and Ladurner, 2009; Timinszky et al., 2009). Of particular 
importance is a glycine residue (Figure 12) in the canonical fold, which abolishes ADPr 
binding after mutation to a glutamate (Dani et al., 2009). 
 
Figure 12: Alignment of three different human macrodomains 
The macrodomain of MacroD1, the macrodomain of the histone variant macroH2A1 and Macro2 of ARTD8 
were aligned, generated by the Clustal W software (Larkin et al., 2007). The corresponding amino acids of the 
proteins are indicated and a conserved glycine residue is marked in red. According to Larkin et. al, the asterisk 
(*) indicates fully conserved residues, the colon (:) marks amino acids with highly similar characteristics and the 
period (.) stands for amino acids with weakly similar characteristics.  
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I.6.2.1. Function of macrodomains 
Macrodomains were identified as ADPr binding modules several years ago, but the functions 
of macrodomain containing proteins are only poorly defined. For macroH2A it was 
demonstrated that after induction of DNA damage and thus ARTD1 activation, full-length 
macroH2A1.1 accumulates at the point of activation and leads to local rearrangements of 
chromatin. Consequently the macrodomain part is responsible for the transient recruitment of 
this histone variant to DNA damage sites. The detailed consequences remain to be unraveled 
(Timinszky et al., 2009). 
Additionally there are reports on another chromatin-related protein possessing a macrodomain 
and being capable of PAR binding: The chromatin remodeling enzyme ALC1, exhibiting an 
intrinsic helicase activity and being directly involved in DNA repair. Ahel et al. described that 
intrinsic ALC1 nucleosome-reposition activity as well as ALC1’s interaction with DNA 
damage repair enzymes is stimulated by PARylation by ARTD1. Furthermore ALC1 is 
rapidly recruited to PARylated DNA damage sites dependent on the PAR binding of its 
macrodomain (Ahel et al., 2009; Gottschalk et al., 2009).  
Another idea regarding the function of macrodomains was proposed by Chen et al.. They 
observed that macrodomain proteins can occur as fusion proteins with sirtuin proteins in 
pathogenic bacteria and fungi and sometimes are present in the same operon as sirtuin-like 
proteins in bacteria (Chen et al., 2011). The family of sirtuins has NAD+-dependent protein 
and histone deacetylation capacity. During this reaction, OAADPr, a molecule that is 
postulated to be involved in signaling processes, is released (Denu, 2005; Grubisha et al., 
2006; Jackson and Denu, 2002). Chen et al. demonstrated that some macrodomains are able to 
hydrolyze OAADPr, whereby ADPr and acetate are produced. Examples are the human 
MacroD1 and MacroD2 as well as macrodomain proteins from bacteria (Chen et al., 2011). 
The consequence of this enzymatic activity however remains unclear.  
Another described enzymatic function of macrodomains is the slow hydrolyzing activity 
towards ADP-ribose-1”-phosphate in vitro, a byproduct that is produced during tRNA 
splicing. The resulting products are ADPr and inorganic phosphate. This could be observed 
for AF1521 (Karras et al., 2005) as well as for a few viral macrodomains as described below 
(Saikatendu et al., 2005).  
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I.6.2.2. Viral macrodomains 
Beyond eukaryotic and archaeic macrodomains, there is an emerging focus on viral 
macrodomains. So far, these domains have been found in different types of viruses including 
chronaviruses, toroviruses, the hepatitis E virus and alphaviruses (Egloff et al., 2006; Malet et 
al., 2009; Malet et al., 2006; Saikatendu et al., 2005). Main of the proteins with 
macrodomains are involved in viral replication (Neuvonen and Ahola, 2009). 
Several of the viral macrodomains were demonstrated to have dephosphorylating activity 
towards ADP-ribose-1”-phosphate (Putics et al., 2005; Saikatendu et al., 2005). The so-called 
“X-domain” of the SARS coronavirus represents one of these domains (Saikatendu et al., 
2005). However, meanwhile it is discussed that the ADP-ribose-1”-phosphate 
dephosphorylation activity is not the main function of viral macrodomains since the velocity 
of the reaction is slow (Egloff et al., 2006). Indeed it has been shown for multiple but not all 
viral macrodomains that they are also potent PAR binders (Egloff et al., 2006; Malet et al., 
2009; Neuvonen and Ahola, 2009).  
A direct link between infection and function of macrodomains of these viruses remains mostly 
elusive. One proposal made by Kalisch et al. is the interference in or usage of host cell 
pathways by viral macrodomain containing proteins by interacting with PAR (Kalisch et al., 
2012). Furthermore, there is a report on the SARS-unique domain, the domain that is proposed 
to be important for the exceeding infectiousness of the virus. After crystallization of this 
domain, structure analysis revealed that it is composed of two further macrodomains, 
additionally to the SARS X-domain (Tan et al., 2009). In contrast to the X-domain they do not 
reveal any affinity for ADPr but for guanine-rich nucleic-acid structures, the so-called G-
quadroduplexes. The authors speculated that these macrodomains could consequently be 
involved in host cell mRNA binding (Tan et al., 2009).  
I.6.3 The WWE domain 
The WWE domain is known as a protein-protein interaction domain and named after three 
conserved residues (W-W-E) in its center. Strikingly, it appears in two classes of enzymes, the 
ARTD family (Schreiber et al., 2006) and E3 ubiquitin ligases. Thus a connection between 
ADP-ribosylation and ubiquitination was suggested by several groups (Callow et al., 2011; 
Wang et al., 2012; Zhang et al., 2011). Recent studies have indeed identified the RING-
domain E3 ligase RNF146 (also called Iduna) as an interactor of PARylated axin, a 
component of the β-catenin destruction complex in the WNT pathway, via its WWE domain. 
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As described above, the PARylation is generated by ARTD5 and 6 (Callow et al., 2011; 
Zhang et al., 2011). There have been several other PARylated interaction partners of RNF146 
identified, including ARTD1, DNA ligase III and several DNA damage response proteins like 
XRCC1. Furthermore, substrate binding via PAR chains was demonstrated to be a general 
stimulator for ubiquitination activity of RNF146 (Kang et al., 2011). The stability of SH3 
domain-binding protein 2 (3BP2), an adaptor protein of a signaling complex containing Src 
family kinases, is also regulated in a similar manner. 3BP2 is another substrate for ARTD5 
and upon PARylation, RNF146 is recruited via its WWE domain, ubiquitinates 3BP2 and thus 
marks it for proteosomal degradation. Mutation of the ARTD5 binding sequence in 3BP2 
abolishes the PAR dependent degradation of 3BP2 and is linked to the cherubism disease 
(Guettler et al., 2011; Levaot et al., 2011).  
Further analysis of the PAR binding properties of the RNF146-WWE domain revealed that it 
is not able to bind to free ADPr like macrodomains do. However, it efficiently interacts with 
iso-ADPr, the smallest unit of the PAR chain including the O-glycosidic C1’’-C2’ bond 
between the two riboses that is generated during PAR synthesis. Consequently, this glycosidic 
bond is essential for efficient binding (Wang et al., 2012). Co-crystallization of RNF146 and 
iso-ADPr displayed four residues essential for binding. These residues are conserved in 
several WWE domains, e.g. in the one of ARTD11, and accordingly these WWE domains 
also interact with PAR. On the other hand the WWE domains of the DDHD domain-
containing protein 2 (DDHD2) and ARTD8 lack two of these residues and consistently they 
do not interact with PAR. So several but not all WWE domains have been reported to be 
another robust PAR binding module and Wang et al. suggest that the WWE domain is unable 
to recognize mono-ADPr (Wang et al., 2012). 
I.6.4 The PBZ domain 
As a fourth PAR reader module, a novel zinc finger type (PAR-binding zinc fingers, PBZ) 
was demonstrated to recognize PAR. So far only few proteins possessing this PBZ have been 
defined and all are eukaryotic, which is why Ahel et al. proposed a co-evolution between 
PAR writers of the ARTD family and PAR readers (Ahel et al., 2008). All analyzed PBZ 
domains were demonstrated to bind PAR in vitro and in vivo, but in contrast to macrodomains 
they have only low affinities for free ADPr (Ahel et al., 2008; Eustermann et al., 2010; Isogai 
et al., 2010).  
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Further insight into the PAR binding capacity was derived from crystal structures of aprataxin 
and PNK-like factor (APLF) harboring two PBZ domains and checkpoint with forkhead and 
RING finger domains protein (CHFR) containing a single PBZ domain (Isogai et al., 2010; Li 
et al., 2010; Oberoi et al., 2010). Binding assays revealed interaction with ADPr and a 
considerably stronger interaction with 2’-O--D-ribofuranosyladenosine, which is a derivate 
that contains the PAR typical αC1’’-C2’ O-glycosidic bond. Thus it is suggested that a 
structural change in the ADPr molecule is necessary to mediate tighter binding, which is 
achieved if ribose rings of molecules are linked via the PAR glycosidic bond (Eustermann et 
al., 2010). Consistently the binding site of this domain is rather surface exposed instead of a 
deep binding pocket, enabling interactions with the backbone of PAR chains and the 
glycosidic bonds as well as base stacking with the adenine of the terminal ADPr, and not only 
a capping of the PAR chain like it is proposed for macrodomains (Ahel et al., 2008; Isogai et 
al., 2010; Li et al., 2010; Oberoi et al., 2010).  
The cellular function of PBZ domains was analyzed in more detail for APLF and CHFR (Ahel 
et al., 2008; Kashima et al., 2012; Li et al., 2010). CHFR possess one PBZ domain and is an 
E3 ubiquitin ligase involved in control of entry in mitosis and participates in stopping the 
progression into mitosis in case of mitotic stress. Although the distinct mechanism how 
CHFR regulates the entry into mitosis and which role its ubiquitin ligase activity plays is not 
clear, PAR binding via its PBZ domain was shown to be involved (Ahel et al., 2008). 
Additionally ARTD1 activity is necessary and in turn, CHFR is a substrate of ARTD1 in vitro 
(Ahel et al., 2008). In addition, Kashima et al. proposed a role for CHFR in ARTD1 
degradation in response to mitotic stress. They demonstrated that during mitotic stress 
ARTD1 automodifies and CHFR can subsequently bind ARTD1 via its PBZ domain, which 
facilitates the polyubiquitination of ARTD1 by CHFR. This PTM then promotes the 
proteosomal degradation of ARTD1, in turn leading to cell cycle arrest at the early mitotic 
checkpoint by a so far unknown mechanism (Kashima et al., 2012). Whereas CHFR possesses 
a single PBZ domain, the DNA break repair associated nuclease APLF contains two PBZ 
domains and is involved in ARTD1-dependent DNA damage repair processes (Eustermann et 
al., 2010; Li et al., 2010; Mehrotra et al., 2011; Rulten et al., 2011). Both domains on its own 
are capable of in vitro ADPr binding to a certain extent but offer a much higher affinity for 
PAR. Of note, the tandem PBZ domains interact with PAR with a 1000 fold higher affinity 
than the single domains (Li et al., 2010). Interestingly, Mehrotra et al. have reported recently 
that APLF acts as a histone chaperone during DNA repair and is required for recruitment of 
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macroH2A to PARylated sites of DNA damage. Thus proteins containing two different PAR-
binding domains co-localize at sites of DNA damage (Mehrotra et al., 2011). Consequently, 
mechanistically PBZ domains and WWE domains are both PAR recognition modules that 
depend on the O-glycosidic bond (Eustermann et al., 2010; Gibson and Kraus, 2012; Wang et 
al., 2012). Together four PAR interacting domains have been described and only two of the 
four, i.e. macrodomains and PBZ domains, have been reported to be generally capable of 
binding to a single ADPr unit (Karras et al., 2005; Kustatscher et al., 2005; Li et al., 2010). 
Additionally, neither of these has been shown to bind to a single ADPr unit attached to a 
protein implying a need for the identification of domains being able to read mono-ADP-
ribosylation.  
I.7 Ran 
Ran is a GTPase and a member of the small G-protein family, which is involved in the 
nucleo-cytoplasmic transport of proteins during interphase (Güttler and Görlich, 2011) and in 
the coordination of mitosis (Clarke and Zhang, 2008).  
In eukaryotic cells the chromosomes are kept in the nucleus, which is isolated from the 
cytoplasm by a double membrane called nuclear envelope. In order to facilitate the entry of 
nuclear proteins after their protein biosynthesis in the cytoplasm as well as an exchange of 
proteins between cytoplasm and the nucleus, the nuclear double membrane is interspersed 
with the nuclear pore complexes (NPCs) consisting of nucleoporins (Strambio-De-Castillia et 
al., 2010). These NPCs allow passive diffusion of proteins smaller than 40 kDa from the 
cytoplasm into the nucleus and vice versa. However, proteins of a larger size need an active 
transport through the NPCs (Terry et al., 2007). The transport of the majority of proteins is 
mediated by a family of transport factors, the karyopherin-importin- family also including 
exportins, that bind their cargo proteins directly or via an adaptor protein and interact with 
nucleoporins in the nuclear-cytoplasmic shuttling process. In order to be recognized, cargo 
proteins must exhibit an NLS or an NES (Pemberton and Paschal, 2005; Terry et al., 2007). 
The assembly and disassembly of several of these import and export complexes is regulated 
by a Ran-GTP gradient. The Ran-GTP form is enriched in the nucleus and forms a ternary 
complex with exportins and cargo proteins to facilitate export from the nucleus (Figure 13) 
(Clarke and Zhang, 2008; Monecke et al., 2009).  
One typical exportin interacting with RAN is CRM1. Interaction between Ran-GTP and 
CRM1 as well as between CRM1 and its cargo protein harbouring a leucine-rich NES is 
INTRODUCTION 
37 
described to induce a conformational change in CRM1 that promotes the formation of a 
CRM1-Ran-GTP-cargo complex (Monecke et al., 2009). After translocation of this ternary 
complex into the cytoplasm, the Ran GTPase-activating protein-1 (RanGAP1) and the Ran-
binding protein-1 or -2 (RanBP1 or RanBP2, respectively) promote the hydrolysis of GTP to 
GDP which in turn leads to a conformational change of Ran and the release of the CRM1 and 
the cargo. Ran-GDP is reimported by the nuclear transport factor-2 into the nucleus (Clarke 
and Zhang, 2008). There, the chromatin bound nucleotide exchange factor RanGEF (also 
called RCC1) facilitates the GTP loading of Ran and enables it to evoke dissociation of cargo 
proteins from importin- complexes. Consequently, Ran is involved in nuclear import as well 
as in export processes (Clarke and Zhang, 2008; Pemberton and Paschal, 2005). 
 
  
Figure 13: Ran is involved in nucleo-cytoplasmic transport  
In the nucleus, Ran occurs predominantly in the GTP-bound form. It builds a complex together with exportins 
like CRM1 and enables the binding of their cargo proteins harboring a nuclear export signal (NES). As a 
complex they shuttle through nuclear pores into the cytoplasm. In the cytoplasm Ran’s intrinsic GTPase activity 
is stimulated by RanGAP1 and RanBP1 or RanBP2. The hydrolysis of GTP to GDP causes a conformational 
change in Ran resulting in the separation of the export complex. Then it is actively re-imported into the nucleus 
by nuclear transport factor-2 (NTF-2). Subsequently Ran is loaded with GTP by RCC1, thereby generating a 
Ran-GTP gradient being high in the nucleus and low in the cytoplasm. In its GTP-bound from Ran also causes 
the release of imported cargo proteins from importin-β (from: (Clarke and Zhang, 2008)). 
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Moreover, Ran participates in the regulation of cell division, which has mainly been 
investigated in egg extracts of X. laevis. Generally, Ran in its GTP-bound form has been 
reported to promote the generation of microtubules at the centrosome and thereby spindle 
assembly. It is suggested that RCC1/RanGEF is also linked to chromatin at mitotic 
chromosomes and acts as nucleotide exchange factor (Caudron et al., 2005; Kalab and Heald, 
2008). This results in the idea for development of a Ran-GTP gradient that has its maximum 
around chromosomes in X. laevis egg extracts and allows Ran-GTP derived activities in close 
proximity to chromosomes. The importin-/importin- dimer sequesters spindle assembly 
factors in the nucleus during interphase and thus prevents their activity. At the onset of 
mitosis, these complexes are located near chromosomes (Clarke and Zhang, 2008). 
Comparable to the nuclear import, Ran-GTP is implicated in the dissociation of such factors 
from importins in mitosis. One target of Ran-GTP is the Targeting Protein for Xklp2 (TPX2). 
TPX2 drives the re-localization of a motor protein to the ends of microtubules and stimulates 
Aurora A kinase. Also initial studies in human cells revealed the importance of Ran-GTP for 
proper spindle organization. Although the absence of Ran-GTP does not lead to a stop of 
mitosis in human somatic cells, it causes a delay (Clarke and Zhang, 2008) and the 
overexpression of a Ran-GTP mutant that cannot hydrolyze GTP results in mitotic defects like 
multipolar spindles (Moore et al., 2002).  
I.8 Acetylation  
Acetylation denotes the addition of an acetyl group to a substrate protein, typically modified 
at the -amine group of lysines, with the required acetyl group being derived from the co-
factor acetyl-CoA (Lee and Workman, 2007). It is mediated by lysine acetyltransferases 
(KATs) which are also often called histone acetyltransferases (HATs) due to historical 
reasons, because acetylation of histone tails was first discovered as a mechanism of epigenetic 
surveillance of transcription (Norris et al., 2009). Generally, HATs are assorted to three 
groups, the GCN5 N-acetyltransferases (GNATs), the MYST acetyltransferases and a class of 
HATs that do not feature a common consensus HAT domain like the proteins of the GNATs 
and MYST groups do (Lee and Workman, 2007). Examples for the family of GNATs are the 
general control of amino acid synthesis protein 5 (GCN5) and p300/Creb binding protein 
associated factor (P/CAF). The acetyltransferases mortality factor (Morf), Ybf2, Sas2 and the 
60 kDa Tat-interactive protein (Tip60) are assigned to the MYST family. On the other hand, 
the HATs CREB binding protein (CBP) and p300 cannot be grouped in one of these two 
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families (Kimura et al., 2005; Lee and Workman, 2007). Furthermore, HATs usually act as 
the catalytic enzyme in large complexes consisting of multiple subunits. These subunits are 
responsible for recruitment of the enzyme to its targets, modulation of activity and substrate 
specificity, mediated by a variety of different interaction domains like bromodomains, 
chromodomains, WD40 repeats and PHD fingers (Lee and Workman, 2007; Workman, 2006). 
Since histones are the best-studied substrates of acetylation, most of these discovered domains 
are known as readers of the histone code. So these domains have been reported to recruit 
HAT-complexes to chromatin, depending on the modifications already present on histones 
(Lee and Workman, 2007; Yang and Seto, 2008). Still, they can also recognize modifications 
on non-histone proteins. As an example, the bromodomain of CBP does not only interact with 
acetylated lysines on histones but also with the acetylated lysine K382 on p53 (Mujtaba et al., 
2004). Acetylation can be removed from proteins by histone deacetylases (HDAC), being 
subgrouped into HDACs of class I and II and the NAD+-dependent sirtuins, constituiting class 
III of HDACs (Denu, 2005). 
Functionally, histone acetylation contributes to the regulation of transcription by organizing 
chromatin (Workman, 2006). Overall, it has been regarded for a long time as a PTM 
facilitating transcription by rearranging histones and providing access to chromatin for 
transcription factors (Barth and Imhof, 2010). Yet more recently evidence has arisen that also 
histone deacetylation, mediated by HDACs, can facilitate active transcription. Consequently, 
the black and white picture of histone acetylation facilitating transcription and histone 
deacetylation mediating transcription repression is not completely accurate anymore (Lee and 
Workman, 2007; Shahbazian and Grunstein, 2007). Moreover, acetylation of non-histone 
proteins has diverse effects and has been less well studied. In the case of the adenosine 
monophosphate-activated kinase (AMPK) for example, acetylation reduces the interaction 
with an AMPK-activating kinase (Lin et al., 2012). In the following, the two lysine 
acetyltransferases GCN5 and P/CAF and their complexes as well as targets and functions are 
described in more detail.  
I.8.1 GNATs, GCN5 and P/CAF 
GCN5 and P/CAF are both HATs that belong to the large superfamily of GNATs, which 
comprises acetyltransferases throughout the kingdom of life. GCN5 is the metazoan homolog 
to the yeast “general control nonderepressible 5” (yGcn5) belonging to the first identified 
yeast Spt-Ada-Gcn5-acetyltransferase (SAGA) complex (Nagy and Tora, 2007; Spedale et al., 
2012). Both homologs possess the C-terminal acetyltransferase domain and a bromodomain. 
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Whereas non-vertebrates only have a single GCN5 gene, vertebrates underwent a GCN5 gene 
duplication that after evolutionary deviation resulted in the P/CAF encoding gene (Spedale et 
al., 2012). This is the reason why GCN5 and P/CAF share a high substrate and sequence 
identity of 73% and can be found in the same type of complexes (Nagy and Tora, 2007). 
Generally, in metazoans there are two different supercomplexes containing either GCN5 of 
P/CAF as aceyltransferase, suggesting a partial functional overlap but also distinct roles 
because there is a 17% sequence diversity in the two acetyltransferase units (Nagy and Tora, 
2007; Spedale et al., 2012). One of the complexes is known as the SPT3-TAF9-Ada-GCN5-
acetyltransferase (STAGA) complex being built up of at least 19 subunits and having a 
molecular weight of approximately 2 MDa. It can also be found in the model organism 
drosophila melanogaster and is the homolog of the SAGA complex in yeast (Nagy and Tora, 
2007). Beyond the acetyltransferases it comprises several transcription factors and Ada 
proteins, being adaptor proteins and implicated in modulating the HAT activity, but also the 
ubiquitin carboxyl-terminal hydrolase 8 (UBP8) (Martinez et al., 1998; Nagy and Tora, 2007; 
Ogryzko et al., 1998). The other one is the 700-800 kDa Ada2a-containing complex (ATAC), 
which has been reported to only occur in multicellular eukaryotes (Spedale et al., 2012). It is 
composed of 10 ATAC-specific subunits but also shares several proteins with the STAGA 
complex. Unique to this complex is ATAC2, a protein that also contains a HAT domain, 
being suggested as a second catalytic activity in this complex (Nagy and Tora, 2007; Orpinell 
et al., 2010; Spedale et al., 2012).  
As for HATs in general, the function and activity of these large complexes is best investigated 
for their chromatin regulation capacity. In a genome-wide binding study it was revealed that 
the STAGA complex is mainly but not exclusively found at promoters of specific actively 
transcribed genes whereas the ATAC complex is additionally recruited to specific enhancer 
regions. The authors suggest that despite the partial redundancy in complex, both complexes 
exhibit different regulatory functions (Krebs et al., 2011; Larschan and Winston, 2001). A 
further co-activator of transcription, the HAT p300, has been reported to be often localized 
together with the STAGA or ATAC complexes at promoters although it does not belong to 
either of these complexes. This results in two independent HAT activities contributing to 
transcription. Such a co-enrichment of STAGA and p300 also occurs at the few enhancer 
regions where STAGA is found. However, Krebs et al. demonstrated that ATAC does not 
necessarily need the presence of p300 at enhancers (Figure 14) (Krebs et al., 2011).  
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In agreement with that, several studies imply a co-activator function of these complexes for 
specific gene loci. So it is suggested that GCN5 or P/CAF containing complexes may play a 
role in transcriptional regulation activity of c-MYC by being recruited to c-MYC target genes 
via a complex member and acetylate histones which in turn facilitates active transcription 
(Bouchard et al., 2001). 
 
Figure 14: STAGA and ATAC complexes are localized to specific gene loci in human cells  
Human ATAC complexes are localized at enhancer regions as well as at promoters. Whereas at promoters also 
the HAT and co-activator p300 is enriched, there are enhancer regions of genes where a p300-independent 
activation by the ATAC complex takes place. The human STAGA (here called SAGA) complex is mainly found 
at promoter regions of actively transcribed genes, together with p300. There are also enhancer regions where 
STAGA complexes could be identified, although to a lesser extent than ATAC complexes. In contrast to 
enhancer regions containing the ATAC complex, here p300 is always abundant (from: (Krebs et al., 2011)). 
 
Additionally the GCN5-STAGA complex is involved in transcription of the IFN promoter 
by acetylating nucleosomes, which enables chromatin remodeling (Agalioti et al., 2000). Still, 
in the literature it is not always distinguished if the responsible HAT in these complexes is 
GCN5 or P/CAF. That is usually explained by a highly similar structure of these two 
acetyltransferases and the fact that both are found in STAGA as well as in ATAC complexes. 
One example for a STAGA complex depending on GCN5 is its transcription co-activator 
function of target genes for nuclear hormone or vitamin receptors (Yanagisawa et al., 2002). 
Beyond histones there have been further non-histone targets of GCN5 or P/CAF identified. 
However the most non-histone targets still are associated with chromatin and transcription, 
namely being chromatin remodelers, transcription factors or transcriptional co-activators 
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(Nagy and Tora, 2007). Nonetheless this does mostly but not always promote transcription by 
enhancing nuclear localization of transcription factors but can also be inhibiting because the 
acetylation can also facilitate the nuclear export or loosening of DNA binding of transcription 
factors (Nagy and Tora, 2007). Furthermore it is suggested that non-chromatin associated 
targets exist for GCN5 or P/CAF complexes. As one example, GCN5 or P/CAF directly 
acetylate c-MYC at lysines K323 and K417 and thereby increase protein stability (Patel et al., 
2004). Additionally, a GCN5 or P/CAF-containing ATAC complex facilitates cell cycle-
dependent acetylation of the Cyclin A component of the Cyclin A/CDK2 complex, which 
finally results in the initiation of mitosis (Orpinell et al., 2010).  
Together, the metazoan acetyltransferases GCN5 and P/CAF are usually located to the two 
distinct multi-subunit complexes ATAC or STAGA in a mutually exclusive manner (Nagy 
and Tora, 2007). The predominantly studied roles of ATAC and STAGA are global and also 
gene-specific acetylation of histones and chromatin associated proteins being in most cases in 
co-activating. However, there also exist non-histone and non-chromatin targets. 
I.9 Aim of work 
ADP-ribosylation is known as an ancient PTM. The field of ADP-ribosylation divides into 
mono-ADP-ribosylation and poly-ADP-ribosylation. Mono-ADP-ribosylation by bacterial 
toxins as well as by extracellular ARTs has been described to modulate protein functions 
(Glowacki et al., 2002; Honjo et al., 1971). On the other hand poly-ADP-ribosylation by 
enzymes of the ARTD family has been implicated in the regulation of complex cellular 
mechanisms like DNA repair, apoptosis, and regulation of signaling pathways (Krishnakumar 
and Kraus, 2010). Therefore an emerging focus was laid on the identification of readers of 
PARylation. Four different types of modules were found to function as reasers of PAR but no 
distinct module for binding to mono-ADP-ribosylated substrates has been reported (Kalisch et 
al., 2012). Additionally, previously several members of the ARTD family were described to 
transfer only single moieties of ADPr onto substrate proteins, thus being mono-ADP-
ribosyltransferases. ARTD10 constitutes the founding member of this subclass. Its catalytic 
mechanism was analyzed in detail and also in vitro substrates like core histone were defined 
(Kleine et al., 2008). However, the enzymatic characterization and the analysis of its catalytic 
mechanism is currently restricted to in vitro data and it is unclear whether this modification 
actually happens in cells and how mono-ADP-ribosylation is read. There are no antibodies 
against mono-ADP-ribosylated proteins available and other methods like the application of 
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mass spectrometry in order to identify mono-ADP-ribosylated proteins by ARTD10 in cells 
are not successful due to the instability of the ester bond between substrate and ADPr under 
mass spectrometry conditions. Therefore, the aim of the first part of this work was to identify 
and characterize a reader module for mono-ADP-ribosylation of ARTD10 and its substrates. 
The identification should be extended by using this reader module to monitor intracellular 
mono-ADP-ribosylation capacity of ARTD10. 
Although the catalytic mechanism of ARTD10 has been examined, the only information about 
its regulation was obtained by the description of phosphorylation by CyclinE/CDK2 
modulating its enzymatic activity (Chou et al., 2006), a finding that could not be reproduced 
by our group. Still there are typically more complex mechanisms for the regulation of 
enzymes, often mediated by a combination of PTMs (Seet et al., 2006). Therefore the second 
part of this work intended to shed light on potential PTMs of ARTD10. It focussed on the 
identification of acetylation sites within ARTD10. 
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II Results and Discussion 
II.1 The recognition of ARTD10 substrates by Artd8 macrodomains 
II.1.1 Macrodomains of Artd8 interact with automodified ARTD10 in vitro 
Previous studies of our group proposed that several members of the ARTD family catalyze 
mono-ADP-ribosylation instead of PARylation and demonstrated it for ARTD10 in vitro 
(Kleine et al., 2008). However, there are no reports describing readers of mono-ADP-
ribosylated proteins. The identification of readers for intracellular mono-ADP-ribosylation 
would be of interest in general and for the further investigation of intracellular mono-ADP-
ribosylation by ARTD10 as the founding member of ARTD mARTs. The observation of the 
following experiment, originally intended to monitor the subcellular localization of ARTD10, 
gave a first indication of possible readers. HeLa cells were transiently co-transfected with 
plasmids encoding enhanced green fluorescent protein (EGFP)-tagged human ARTD10 and 
Flag-tagged murine Artd8 (here and in the following referring to the protein) (Figure 15A). 
After fixation the cells were stained with Flag-tag-specific antibodies and secondary 
antibodies conjugated with Alexa Fluor 555 and the distribution of Flag-Artd8 and EGFP-
ARTD10 was analyzed by immunofluorescence imaging. A co-localization of Flag-tagged 
Artd8 and EGFP-tagged ARTD10 was observed (Figure 15B). Because co-localization might 
indicate an interaction between the corresponding proteins and because Artd8 harbors four 
putative PAR binding modules, three macrodomains and a WWE domain (Figure 15A), it was 
tested whether either of these can bind to mono-ADP-ribosylated ARTD10. Therefore full 
length ARTD10 was tandem affinity purified (TAP) from Flp-In T-REx HEK293 cells, which 
stably express C-terminally TAP-tagged ARTD10 upon doxycycline treatment. Purified 
ARTD10 was then subjected to an enzymatic ADP-ribosylation assay reaction during which it 
mono-ADP-ribosylates itself (referred to as automodification) as well as potential substrate 
proteins if these are added to the enzymatic assay. Because the cofactor β-NAD+ is mandatory 
for mono-ADP-ribosylation, in vitro ADP-ribosylation assays without β-NAD+ served as a 
negative control throughout the following experiments (Kleine et al., 2008). In a subsequent 
in vitro glutathione-S-transferase (GST)-pulldown assay an interaction between ARTD10 and 
the domains of Artd8 was tested and the bound proteins analyzed by sodium dodecyl sulfate 
(SDS)-PAGE, Western blotting and immunodetection with specific antibodies. An ARTD10-
specific signal was obtained for the automodified but not for the unmodified ARTD10 after a 
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pulldown with GST-tagged macrodomains1-3 of Artd8 (referred to as Macro1-3) but not with 
the single macrodomain1 (Macro1) or the WWE domain (Figure 15C). For all in vitro 
experiments blots were stained with Ponceau S Red to demonstrate the input of the applied 
proteins. This showed that the signal for ARTD10, obtained in the pulldown with GST-
Macro1-3, was not due to lower amounts of GST-Macro1 or GST-WWE in the pulldown 
assays (Figure 15C, lower panel). This result pointed at an interaction of automodified 
ARTD10 with Macro1-3.  
         
 
Figure 15: Macrodomains of Artd8 interact with ARTD10 
A. Scheme of the domain architecture of Artd8. The indicated amino acid numbers correspond to the murine 
Artd8 whereas the numbers in brackets refer to human ARTD8. RRM: RNA recognition motif; WWE: protein 
interaction motif designated by a conserved trytophane-tryptophane-glutamate motif; Catalytic domain: mono-
ADP-ribosylation domain.  
B. HeLa cells were transiently co-transfected with plasmids encoding EGFP-tagged ARTD10 and FLAG-tagged 
Artd8. 24 h after transfection cells were fixed with 3.8% para-formaldehyde and stained with Flag-specific 
antibodies (C2) and Alexa Fluor 555-labeled secondary antibodies. Staining and protein localization of Flag-
Artd8 and EGFP-ARTD10 was analyzed by confocal microscopy using the Zeiss LSM510 microscope. Scale 
bar: 20 µM. This experiment was performed by H. Kleine and is adapted from Forst et al., manuscript submitted. 
C. 0.5 µg of TAP-ARTD10 were subjected to an enzymatic ADP-ribosylation assay with or without addition of 
500 µM β-NAD+. Subsequently the reaction was incubated with 5 µg bacterially expressed GST-tagged Macro1, 
Macro1-3 or WWE of Artd8 bound to glutathione sepharose. Bound proteins were analyzed by SDS-PAGE and 
Western blotting with ARTD10-specific monoclonal antibodies (5H11) (upper panel). 50% (v/v) of an ADP-
ribosylation assay with or without β-NAD+ addition was analyzed as input control. Ponceau S Red staining of the 
blot membrane was conducted for control (lower panel). 
 
The data shown here was confirmed by at least two biologically independent experiments. 
A 
E 
RESULTS AND DISCUSSION 
46 
Next it was assessed which macrodomain was responsible for the interaction and in vitro 
GST-pulldown assays with the single GST-tagged macrodomains of Artd8 and ARTD10, 
previously subjected to an ADP-ribosylation assay with or without β-NAD+, were conducted,. 
The experimental set-up of this assay was as in the experiment described before and also 
maintained for the following experiments. In addition to GST-Macro1-3, also GST-
macrodomain3 (Macro3) and to a lesser extend GST-macrodomain2 (Macro2) were capable 
to bind the modified ARTD10 (Figure 16A). Furthermore the interaction was proportional to 
the concentration of β-NAD+ that was applied to the ADP-ribosylation assays (Figure 16B). 
Because higher concentrations of β-NAD+ in ADP-ribosylation assays usually result in higher 
levels of automodification (Kleine et al., 2008), it can be concluded that the interaction 
depended on the degree of mono-ADP-ribosylation of ARTD10. Binding to GST alone or 
glutathione-sepharose was not observed (Figure 16B). However, GST is a rather large tag of 
approximately 25 kDa. In order to exclude tag-specific effects, pulldown assays were also 
performed with hexahistidine (His)-tagged macrodomains. Therefore, ADP-ribosylation 
assays with ARTD10 were conducted as described before and subsequently incubated with 
His-tagged macrodomains coupled to TALON™ metal affinity resin. His-Macro1-3 revealed 
the strongest interaction with mono-ADP-ribosylated ARTD10, indicated by the most intense 
signal for ARTD10, but also His-tagged Macro3 and to a much lesser extend His-Macro2 
bound modified ARTD10 (Figure 16C). The results were comparable to the GST-pulldown 
experiments. Additionally, the N-terminal fragment GST-ARTD10(1-255), which is not 
substrate of ARTD10 (Kleine et al., 2008), was enclosed in the ADP-ribosylation assay and 
the subsequent pulldown assay. This protein did not bind to any of the macrodomains (Figure 
16C, middle panel).  
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Figure 16: Macro2 and Macro3 are responsible for the interaction 
A. TAP-ARTD10 (0.5 µg) was incubated in an ADP-ribosylation assay in the presence or absence of 500 µM β-
NAD+. Next the reaction was added to a pulldown assay with GST-tagged and bacterially expressed 
macrodomains of Artd8 or GST alone that were coupled to glutathione sepharose. For evaluation SDS-PAGE 
and Western blot analysis was performed with ARTD10-specific monoclonal antibodies (5H11). 
B. The experiment was performed as in panel A with the exception that different concentrations of β-NAD+ were 
used in the ADP-ribosylation assay as denoted and the pulldown was performed with the indicated GST-
proteins. 
C. 0.5 µg TAP-ARTD10 were automodified in the presence or absence of 500 µM β-NAD+ in ADP-ribosylation 
assays and 5 µg of GST-ARTD10 (1-255) were included. For control, ADP-ribosylation assays in the presence 
of 500 µM β-NAD+ and GST-ARTD10(1-255) but in the absence of TAP-ARTD10 were performed. Then  His-
pulldown assays with 5 µg of bacterically expressed His-tagged Artd8 macrodomains coupled to TALON™ 
metal affinity resin and the ADP-ribosylation reactions were performed and analyzed using SDS-PAGE and 
Western blotting with polyclonal ARTD10-specific (E09) and monoclonal GST-specific antibodies. 
For panels A-C: 50% (v/v) of ADP-ribosylation assays was analyzed directly by SDS-PAGE and Western 
blotting for input control. Ponceau S Red staining of the Western blot membranes prior to the incubation with the 
primary ARTD10-specific antibodies is shown for control (lower panels).  
 
The displayed data is representative for at least two independent experiments. 
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Since these first experiments pointed at a mono-ADP-ribosylation mediated interaction 
between ARTD10 and Macro2 and Macro3, this was further investigated by using different 
mutants and inhibitors. The principle of the following assays was similar to the previous 
experiments, in which ARTD10 was first ADP-ribosylated and then incubated together with 
tagged macrodomains coupled to glutathionesepharose or TALON™ metal affinity resin. 
First the necessity of catalytic activity for the interaction with macrodomains was tested by 
repeating the pulldown assay with tandem affinity purified ARTD10-G888W. As previously 
shown by our group, this point mutation completely abolishes the catalytic activity but can 
still be recognized by ARTD10-specific antibodies (Kleine et al., 2008). No interaction 
between this catalytic inactive ARTD10-G888W and His-Macro1-3 was detectable in the in 
vitro His-pulldown assay, while binding of the wild type protein was observed (Figure 17A). 
Ponceau S Red staining confirmed the application of equal amounts of His-Macro1-3 in the 
pulldown assay (Figure 17A, lower panel). Secondly, benzamide, a broad inhibitor of ARTD 
activity (Kleine et al., 2008) was included in the ADP-ribosylation assay prior to a His-
pulldown assay. With increasing concentrations of benzamide, decreasing auto-ADP-
ribosylation was expected. Consistent with the previous data, an inverse correlation was 
observed between the concentration of benzamide and ARTD10 binding to His-Macro1-3 
(Figure 17B). Thus the reduced catalytic activity led to weaker interactions with His-Macro1-
3. Of note, benzamide could not be removed from the enzymatic assay before it was subjected 
to the pulldown. So the possibility that benzamide was bound to macrodomains and competed 
with mono-ADP-ribosylated ARTD10 for binding cannot be excluded. Thirdly, increasing 
concentrations of free ADPr were applied to the pulldown assays because ADPr is capable of 
interacting with the binding cleft of macrodomains (Karras et al., 2005; Timinszky et al., 
2009). ADPr was a weak competitor of binding (Figure 17C). This implies that ADPr 
occupied the binding cleft of Macro1-3 and competed with mono-ADP-ribosylated ARTD10 
for binding. The six weaker bands migrating at approximately 70 kDa are explained by 
unspecific cross-reactions of the ARTD10 polyclonal antibodies (E09) with the His-tagged 
macrodomains (Figure 17B, C).  
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Figure 17: The specific interaction between Artd8 macrodomains and ARTD10 depends on mono-ADP-
ribosylation in vitro  
A. 0.5 µg TAP-ARTD10 or TAP-ARTD10-G888W were automodified in enzymatic ADP-ribosylation assays in 
the presence or absence of 500 µM β-NAD+. The interaction between ARTD10 proteins and His-tagged Macro1-
3 immobilized on TALON™ metal affinity resin was analyzed via SDS-PAGE and Western blot analysis with 
ARTD10-specific polyclonal antibodies (E09) (upper panel).  
B. 0.5 µg TAP-ARTD10 were subjected to enzymatic ADP-ribosylation assays with or without 500 µM β-
NAD+. Additionally, the indicated concentrations of the ARTD inhibitor benzamide were added. The entire 
reactions were subjected to a pulldown assay with His-tagged Macro1-3 linked to TALON™ metal affinity resin. 
Bound ARTD10 was analyzed as in panel A.  
C. ADP-ribosylation of TAP-ARTD10 was performed as in panel A. Subsequently, the reaction was incubated 
together with His-tagged Macro1-3 coupled to TALON™ metal affinity resin and the indicated concentrations of 
ADP-Ribose. The experiment was analyzed as in panel A.  
D. Enzymatic ADP-ribosylation assay were conducted as in panel A. Then ARTD10 was subjected to a 
pulldown assay with His-tagged Macro2 or Macro2-G1055E immobilized on TALON™ metal affinity resin. 
The experiment was evaluated as in panel A. 
For all experiments, an input control containing 50% (v/v) of an ADP-ribosylation assay with TAP-ARTD10 +/- 
500 µM β-NAD+ was analyzed. Ponceau S Red staining of the blot membranes is shown as control in the lower 
panels of A-D. All experiments were at least performed three times and a representative experiment is shown. 
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Lastly, glycine G1055 of Macro2 was mutated to a glutamate (Macro2-G1055E). The 
substitution of this conserved amino acid has been shown to abrogate ADPr binding in other 
macrodomains (Dani et al., 2009). As expected considering the previous three experiments, 
no ARTD10-specific signal was detectable on Western blots after pulldown with His-Macro2-
G1055. So His-Macro2-G1055E displayed no binding to modified or unmodified ARTD10 
(Figure 17D).  
Thus taken together this set of in vitro data supported the hypothesis that auto-mono-ADP-
ribosylation of ARTD10 was a pre-requisite for its interaction with macrodomains of Artd8. 
 
Several groups have reported on the capacity of macrodomains to associate with PAR chains 
as well as with free ADPr but not on binding to mono-ADP-ribosylated proteins. For instance 
the macrodomain of the histone variant macroH2A1.1 was demonstrated to bind free ADPr as 
well as to be recruited to ARTD1-mediated PARylation upon DNA damage in cells 
(Timinszky et al., 2009). Similar results were obtained for the macrodomain of the chromatin 
remodeler ALC1, which is also targeted to PARylated DNA damage sites by its macrodomain 
(Ahel et al., 2009; Gottschalk et al., 2009). Hence it was addressed whether the observed 
interaction between automodified ARTD10 and Macro2 and Macro3 was specific for Artd8 
macrodomains or a general but so far undiscovered feature of macrodomains. Therefore, the 
macrodomain of the histone variant macroH2A1.1(aa 162-369) that was demonstrated to be a 
robust PAR binder before and the binding-deficient mutant macroH2A1.1(162-369)-
G224E/F348A were included in the experiment (Timinszky et al., 2009). Neither unmodified 
nor automodified ARTD10 interacted with GST-macroH2A1.1(aa 162-369) (Figure 18A). 
The amounts of all applied GST-proteins were comparable, except for GST-Macro1-3 where 
even a bit lower amounts were pulled down, which strengthens the result (Figure 18A, lower 
panel). Contrariwise it should be tested whether macrodomains of Artd8 can recognize 
PARylated proteins. Therefore ARTD1 was His-purified from insect cells (kindly provided by 
M. Hottiger, University of Zurich) and subjected to an ADP-ribosylation assay as described 
for ARTD10 before. The GST-pulldown assay with GST-tagged macrodomains of Artd8 was 
conducted and potential interactions with ARTD1 instead of ARTD10 were measured. 
Beyond the macrodomains of Artd8, again GST-tagged macroH2A1.1 (162-369) was 
included as a positive control or its binding-deficient mutant as a negative control (Figure 
18B).  
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Figure 18: Specificity of Artd8 macrodomains 
A. 0.5 µg TAP-ARTD10 were applied to enzymatic ADP-ribosylation assays with or without 500 µM of the co-
factor β-NAD+. Next the reactions were incubated with GST-tagged Macro2 or Macro3 of Artd8 or GST-tagged 
macroH2A1.1(162-369) or macroH2A1.1(162-369)-G224E/F348A, all immobilized on glutathione sepharose. 
Bound proteins were analyzed via SDS-PAGE and Western blot with ARTD10-specific monoclonal antibodies 
(5H11).  
B. 0.3 µg of baculo-derived His-tagged ARTD1 was incubated with or without 500 µM β-NAD+. Afterwards, a 
pulldown with GST-tagged macrodomains of Artd8 or GST-tagged macroH2A1.1(162-369) or 
macroH2A1.1(162-369)-G224E/F348A and glutathione sepharose was performed. The reaction was evaluated 
by SDS-PAGE and Western blot analysis with ARTD1-specific polyclonal antibodies. 
An input control containing 50% (v/v) of the ADP-ribosylation assays is shown in panels A and B. The Western 
blot membranes were stained with Ponceau S Red to monitor the amounts of input proteins (lower panels).  
 
Experiments were performed at least three times with similar set-ups and outcomes.  
 
The automodification of ARTD1 in the presence of β–NAD+ was demonstrated by the diffuse 
bands in the input control, which occurred due to the heterogeneous nature of PAR chains 
attached to ARTD1 (Figure 18B, lane 2). As expected and described in the literature 
(Timinszky et al., 2009), automodified ARTD1 revealed a robust binding to GST-
macroH2A1.1(162-369) but not to the mutant GST-macroH2A1.1(162-369)-G224E/F348A, 
indicated by the ARTD1-specific signals in Western blot analysis. Of note the single 
macrodomains of Artd8 displayed no detectable association (Figure 18B). 
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Figure 19: Comparison of macrodomains of murine and human ARTD8. 
A. Sequence alignment of the three macrodomains of murine and human ARTD8, which was generated by the 
Clustal W software (Larkin et al., 2007). According to Larkin et. al, the asterisk (*) indicates fully conserved 
residues, the colon (:) marks amino acids with highly similar characteristics and the period (.) stands for amino 
acids with weakly similar characteristics. The sequence of the macrodomains is marked in yellow, whereas the 
linker regions are unlabeled. 
B. 0.5 µg TAP-ARTD10 were used in the presence or absence of 500 µM β-NAD+ in ADP-ribosylation assays. 
Then these were added to in vitro pulldown assays with single or combinations of bacterially expressed His-
tagged macrodomains of human ARTD8, which were coupled to TALON™ metal affinity resin. Interactions 
were analyzed via SDS-PAGE and Western blot with an ARTD10-specific polyclonal antiserum (E09). The blot 
membrane was stained with Ponceau S Red for control (lower panel). The input constitutes 50% (v/v) of ADP-
ribosylation assays performed with our without 500 µM β-NAD+ that were directly applied to SDS-PAGE and 
Western blot without incubating them in pulldown assays. 
 The result was confirmed by a second experiment with the same experimental set-up. 
 
All experiments shown thus far were performed with macrodomains of murine Artd8 due to 
the fact that the first co-localization events were observed with murine Artd8 and because of 
the unavailability of a full length clone of human ARTD8. However, there is a high degree of 
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sequence similarity between murine and human ARTD8 macrodomains as alignments 
revealed (Figure 19A). Therefore it was hypothesized that macrodomains of both species 
would exhibit comparable binding affinities to mono-ADP-ribosylated ARTD10. In order to 
test this, the in vitro His-pulldown assays were repeated with automodified or unmodified 
ARTD10 and macrodomains of human ARTD8 (hMacro, plasmids encoding human 
macrodomains were kindly provided by H. Schüler, Karolinska Institute Stockholm) (Figure 
19B). Importantly, an ARTD10-specific signal was detected after pulldown assays of 
modified ARTD10 with His-tagged hMacro2 and hMacro3 as well as with the combination of 
His-tagged hMacro1-3 and hMacro2+3 but not with hMacro1. Comparable amounts of His-
tagged hMacrodomains were applied (Figure 19B, lower panel) and the bands representing 
proteins of a molecular weight of approximately 60 kDa were most likely unspecific cross-
reactions of the ARTD10 antibody with impurities of the His-protein purifications. Thus also 
His-hMacro2 and His-hMacro3 of human ARTD8 interacted with modified but not with 
unmodified ARTD10 in a comparable manner to Macro2 and Macro3 of murine Artd8. In 
summary macrodomains of both human and murine ARTD8 exhibited similar binding 
properties for ARTD10 and consequently all subsequent in vitro and in cell assays except the 
crystallization experiments were performed with murine Artd8. 
To further analyze the architecture and binding characteristics of the single macrodomains, we 
collaborated with Herwig Schüler’s group at the Karolinska Institute in Stockholm who 
solved and analyzed the crystal structures of the single macrodomains of ARTD8 (Figure 20). 
The superposition of all three macrodomains of ARTD8 and also of macrodomain 2 of 
ARTD7 for comparison demonstrated a structural conservation, especially for the ADPr 
binding cleft (Figure 20A).  
The principal organization of the binding cleft containing a central β–sheet and being flanked 
by α–helices (Figure 20A) is a common feature of macrodomains. However, there exist 
differences in the number of strands of the β–sheet. Af1521 harbors a seven-stranded β-sheet 
like ARTD8 macrodomains but the cleft of two other macrodomain containing proteins, 
MacroD1 and C6orf130, comprises a six-stranded β-sheet (Chen et al., 2011; Karras et al., 
2005; Peterson et al., 2011). The consequence of this structural difference remains to be 
investigated. 
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Figure 20: Crystal structures of ARTD8 macrodomains (adapted from Forst et al., manuscript submitted) 
A. A superposition of the crystal structures from hMacro1 (blue), hMacro2 (green), hMacro3 (salmon) of 
ARTD8 and macrodomain2 of human ARTD7 (grey) is illustrated. 
B. Isothermal titration calorimetry (ITC) data of macrodomains of human ARTD8. The binding affinities of the 
single domains for free ADPr are given. 
C.-E. Single macrodomain crystal structures are shown in complex with ADPr. Residues important for contacts 
to ADPr are indicated. Roman numbers mark the different loops of the binding cleft of macrodomains.  
The data is part of Forst et al., manuscript submitted. The crystallization was performed in collaboration with 
and by Herwig Schüler and Tobias Karlberg (Structural Genomics Consortium and Department of Medical 
Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden). The ITC data were obtained by 
Andreas Ladurner and Bianca Nijmeijer (Institute of Physiological Chemistry, University of München, 
Germany). 
 
Interestingly, Macro1 did not interact with automodified ARTD10 in our analyses, although 
its overall structure is comparable to Macro2 and Macro3 (Figure 20A). However, we also 
collaborated with Andreas Ladurner and Bianca Nijemeijer (Institute of Physiological 
Chemistry, University of München, Germany) who performed isothermal titration calorimetry 
(ITC) experiments. This is a method suitable for analysis of binding affinities that are 
represented by dissociation constants (Kd values). The affinities of the single macrodomain 
constructs for ADPr, which were used for the crystallization, were determined. The Kd values 
showed that hMacro1 exhibits a lower affinity for ADPr in comparison to hMacro2 and 
hMacro3 (Figure 20B). This was in support of our findings in the pulldown assays. Moreover, 
C 
A B 
D E 
1Macrodomain Kd (µM), ITC 
hMacro1 192±7 
hMacro2 6.0±0.1 
hMacro3 1.9±0.1 
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a more detailed analysis of the contacts formed between the ADPr-binding cleft of ARTD8 
macrodomains and ADPr revealed a difference (Figure 20C-E):  
MacroH2A is reported to possesses an aspartate chain in loop V which can form a hydrogen 
bond with the nitrogen N6 of the adenine base, a bonding that was shown to be required for 
ADPr binding of macroH2A1.1 (Kustatscher et al., 2005). The corresponding residue, D1235, 
is conserved in Macro3 (Figure 20E) and exchanged against a glutamine in Macro2 (Figure 
20D, Q1024) that is still able to form the hydrogen bond. A corresponding amino acid and 
consequently the hydrogen bond is lacking in Macro1 (Figure 20C). This might lead to a 
weaker binding of ADPr and at least partially explains why we did not observe comparable 
interaction of Macro1 with automodified ARTD10. Still this does not necessarily mean that 
Macro1 is not capable of binding to mono-ADP-ribosylation at all. For example the 
underlying sequence of the protein backbone may specify Macro1 binding. 
In summary, all these in vitro data indicate features of Artd8 macrodomains that distinguish 
them from macrodomains previously described in the literature. Whereas several investigated 
macrodomains exhibit PAR-binding properties (Ahel et al., 2009; Egloff et al., 2006; 
Gottschalk et al., 2009; Karras et al., 2005; Timinszky et al., 2009), the single macrodomains 
of Artd8 do not (Figure 18). In contrast our data suggest that Macro2 and Macro3 of Artd8 are 
rather specific for mono-ADP-ribosylated ARTD10 in vitro (Figure 16, Figure 17 and Figure 
18) but at this point it remained to be investigated whether this also accounts for other mono-
ADP-ribosylated proteins. Of note, the magnitude of binding to the combination of Macro1-3 
was often higher than the binding to single Macro2 or Macro3 domains (Figure 16A and C, 
Figure 19B) suggesting either a cooperative binding effect of Macro1-3 or the presence of 
more than one automodification site on ARTD10. In this regard it is important to mention that 
the automodification sites on ARTD10 have not been identified completely so far due to a 
lack of relevant tools. However, in the previously published study of Kleine et al. a 
substitution of the glutamate at position 882 (E882) by alanine in ARTD10 lead to reduced 
auto-ADP-ribosylation of this ARTD10 mutant but did not completely abolish ADP-
ribosylation. The catalytic activity itself was not impaired by that mutation. This suggested 
that E882 is only one of potentially several acceptor site for auto-ADP-ribosylation (Kleine et 
al., 2008). Additionally, more than one automodification site has been mapped for other 
members of the ARTD family (Altmeyer et al., 2009; Tao et al., 2009). Combining these 
observations it can be speculated that ARTD10 contains more than one automodification site 
as well. Thus the enhanced interaction between Macro1-3 and modified ARTD10 could be 
RESULTS AND DISCUSSION 
56 
explained by Macro2 and Macro3 interacting with two different ADPr moieties attached to a 
single ARTD10 protein, and thereby mediating cooperative binding. In support of this 
interpretation is the finding that the two PBZ domains of the APLF protein cooperate in PAR 
binding (Li et al., 2010). These two PBZ domains bind PAR independently of each other with 
affinities differing approximately 10 fold (Kd 5.2 x 10-7 M vs. Kd 8.3 x 10-6 M). However the 
combination of these domains in one polypeptide reveals a 1000 fold increased PAR binding 
affinity (Li et al., 2010). The authors speculate that the 22 aa linker region between the two 
domains is reorganized upon PAR binding and contributes to the interaction or causes 
conformational changes in the two PBZ domains as it was shown for other zinc fingers with 
linker regions of a certain length (Laity et al., 2000; Li et al., 2010). The linker region 
between Macro2 and Macro3 is composed of 24 aa (Figure 19A). Hence the option of the 
linker causing changes in the macrodomains upon substrate binding and adding to the binding 
of a polypeptide containing both macrodomains cannot be excluded. However, the observed 
effect for Macro1-3 is much smaller than for the tandem PBZ domains and it must be 
considered that PBZ domains bind along PAR chains, which exhibit multiple binding sites 
that are required for the discussed hypothesis of linker contributions. Reorganization of the 
linker region upon binding of Macro2 and Macro3 to ADPr would also postulate the existence 
of more than one mono-ADP-ribose on ARTD10, thus more than one automodification site. 
Consequently the determination of the amount of automodification sites is indispensable to 
answer the question why Macro1-3 exhibits increased binding compared to the single 
macrodomains. Afterwards, mutagenesis and shortening of the linker region, provided that the 
folding of Macro2 and Macro3 is unaltered, could be performed to investigate putative linker 
binding assistances. This could be measured by ADPr binding in ITC experiments. Besides, 
the linker region may also be relevant for the flexibility and the positioning of the 
macrodomains. 
Moreover, Macro1 of Artd8 did not show significant interaction with neither mono-ADP-
ribosylated ARTD10 nor poly-ADP-ribosylated ARTD1 under conditions used (Figure 15, 
Figure 16, Figure 18 Figure 19). The fact that the crystal structure of hMacro1 in complex 
with ADPr could be solved implied that an interaction is in principle possible. However, small 
but potentially crucial structural differences exist when ADPr binding is analyzed (Figure 
20C). These might lead to lower binding affinities, which were observed in the pulldowns and 
ITC experiment (Figure 20B). As a result it can be concluded that the three macrodomains of 
RESULTS AND DISCUSSION 
57 
Artd8 are not redundant although similar in the overall structure (Figure 20A) but may fulfill 
distinct tasks.  
The data presented in this part of this work could be expanded by pulldown assays with 
further putative or confirmed mART members of the ARTD family. That would provide a 
hint whether macrodomains of Artd8 recognize specifically ARTD10 substrates or are more 
general readers of mono-ADP-ribosylation. One possible candidate would be ARTD15, which 
was recently confirmed to possess mART activity (Di Paola et al., 2012).  
II.1.2 Macrodomains of Artd8 associate with active ARTD10 in cells 
The previous experiments characterized an interaction between Macro2 and Macro3 of Artd8 
and mono-ADP-ribosylated ARTD10 in vitro and suggested its dependency on mono-ADP-
ribosylation. We were now interested to investigate this interaction in cells because all 
previously published studies left open to formally demonstrate mono-ADP-ribosylation 
mediated by ARTD10 in cells. Thus we performed co-localization studies in Flp-In T-REx 
HeLa cell lines stably expressing ARTD10 or ARTD10-G888W upon doxycycline treatment. 
These cells were transfected with plasmids encoding the EGFP-tagged macrodomains and 
ARTD10 biosynthesis was induced for 24 h. Afterwards cells were fixed and stained with 
ARTD10-specific monoclonal antibodies and Alexa Fluor 555-conjugated secondary 
antibodies. The localization of ARTD10 and EGFP-tagged macrodomains was evaluated by 
confocal microscopy. The distribution of the EGFP-tagged macrodomains was generally even 
throughout the cell without ARTD10 expression (Figure 21A and B, left panels). A 
predominant cytoplasmic distribution with accumulation in several foci per cell was revealed 
by immunofluorescence staining of ARTD10, whose biosynthesis was triggered by 
doxycycline treatment (Figure 21A, right panels). Simultaneously EGFP-Macro2, EGFP-
Macro3 and especially EGFP-Macro1-3 accumulated in these foci upon doxycycline 
treatment as well and co-localized with ARTD10 as demonstrated by the yellow dots in 
merged images (Figure 21A, right panels and magnifications). However there was no co-
localization observed for ARTD10 and EGFP alone, EGFP-Macro1 or the ADPr-binding 
deficient mutant EGFP-Macro2-G1055E (Figure 21A, right panels). Moreover, association 
was undetectable for the catalytic inactive mutant ARTD10-G888W with any of the EGFP-
tagged macrodomain constructs either, although the inactive mutant accumulated in 
prominent dots as well (Figure 21B). 
RESULTS AND DISCUSSION 
58 
 
Figure 21: Macrodomains of Artd8 co-localize with active ARTD10 in a stable HeLa cell line  
For figure legend see next page. 
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A. Flp-In T-REx HeLa cells stably expressing ARTD10 protein upon doxycycline treatment (established by N. 
Herzog) were transfected with plasmids encoding EGFP-tagged macrodomains of Artd8 or EGFP only as control 
using the calcium phosphate method. ARTD10 biosynthesis was induced by treatment with 1 µg/ml doxycycline 
for 24 h or cells were left untreated. Then cells were fixed with 3.7% para-formaldehyde and strained with 
ARTD10-specific monoclonal antibodies (5H11) and with the fluorophor Alexa Fluor 555-labeled secondary α-
rat antibodies. The cellular distribution of ARTD10 and the different EGFP-tagged proteins was analyzed by 
confocal microscopy using the Zeiss LSM510 microscope. On the left panels cells without doxycycline addition 
are shown. The right panels comprise confocal microscopy images from cells after ARTD10 induction whereas 
merge images illustrate an overlay of the EGFP and Alexa Fluor 555 channels. On the right magnifications of the 
indicated merge images are shown. White arrows point at co-localization events. Scale bar: 20 µM. 
B. The experiment was carried out as in panel A with the exception that Flp-In T-REx HeLa cells stably 
expressing the catalytic inactive mutant ARTD10-G888W upon doxycycline treatment were used.  
 
The displayed experiments were performed three times with similar results. 
 
In order to analyze whether the observed co-localization occurred directly at the onset of 
ARTD10 biosynthesis or was an effect of later events, time course experiments were 
performed in these Flp-In T-REx HeLa cells. These were transiently transfected with plasmids 
encoding EGFP-Macro1-3 and the expression of ARTD10 or the catalytically inactive mutant 
ARTD10-G888W was induced for 0 h, 2 h, 4 h, 6 h, 8 h and 24 h, and cells were fixed, 
stained and analyzed as before (Figure 22 and Figure 23). ARTD10-specific 
immunofluorescence signals were detectable after 4 h of doxycycline treatment and small foci 
were visible. Whereas EGFP-Macro1-3 did not reveal any foci formation at the 0 h and 2 h 
time points, it co-localized with ARTD10 in these foci by 4 h and at later time points (Figure 
22). Comparable to wild type ARTD10, a signal for the catalytically inactive ARTD10-
G888W was visible after 4 h doxycycline treatment (Figure 23). Despite the distinctive foci 
formation of ARTD10-G888W, no co-localization with EGFP-Macro1-3 was observable at 
any time point (Figure 23).  
Here it should be pointed out that the striking foci accumulation could always be observed for 
ARTD10 in immunofluorescence imaging. At the moment, the nature of these foci is not 
completely clear but ubiquitin as well as the poly-ubiquitin receptor p62/SQSTM1 partially 
associate with these structures (Kleine et al., 2012). Among other functions, p62 is involved 
in the regulation of autophagy by sequestering ubiquitinated proteins into aggregates before 
these are degraded by the autophagy machinery (Johansen and Lamark, 2011; Moscat and 
Diaz-Meco, 2011). Nevertheless the accumulation of ARTD10 in dot-like structures is not 
dependent on the presence of p62 since it can also be observed in p62 -/- knockout mouse 
embryo fibroblasts (Kleine et al., 2012). Here the foci formation served as tool to visualize 
co-localization that would not be possible if the monitored proteins were completely equally 
distributed throughout the cell.  
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Figure 22: Time curve of ARTD10 expression and co-localization with Macro1-3 
Flp-In T-REx HeLaARTD10 cells were transiently transfected with plasmids encoding EGFP-tagged Macro1-3 
using the FugeneHD transfection method. 24 h after transfection the ARTD10 biosynthesis was induced by 
addition of 1µg/ml doxycycline for indicated periods of time. Cells were fixed with 3.8% para-formaldehyde and 
stained with ARTD10-specific monoclonal antibodies (5H11) and α-rat secondary antibodies coupled to the 
fluorescent dye Alexa Fluor 555. Nuclei were stained with Hoechst 33258. Localization of EGFP-tagged 
Macro1-3 and ARTD10 was assessed by confocal microscopy (microscope: Zeiss LSM710). White arrows point 
at co-localization events. Scale bar: 20 µM. 
 
Two further experiments, one using an identical set-up and one applying fewer time points confirmed the results 
of this experiment. 
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Figure 23: Time curve of ARTD10-G888W expression and co-localization with Macro1-3 
The experiment was conducted as described for the one shown in Figure 22 with the exception that it was carried 
out with stable Flp-In T-REx HeLa ARTD10-G888W cells.  
Two further experiments, one using an identical set-up and one applying fewer time points confirmed the results 
of this experiment.  
 
Formally it cannot be excluded that other unknown components of these foci contributed to 
the recruitment of EGFP- tagged Macro2, Macro3 and Macro1-3. Still with regard to the fact 
that the presence of p62 is not mandatory for foci formation and the only difference between 
Figure 21A and B or Figure 22 and Figure 23 is the catalytic activity, it is tempting to 
speculate that the observed co-localization was dependent on the catalytic activity of 
ARTD10.  
RESULTS AND DISCUSSION 
62 
Of note is the difference in shape and appearance of the Flp-In T-REx HeLa cells in the 
immunofluorescence experiments (Figure 21, Figure 22, and Figure 23). This is most likely 
due to the application of two different transfection methods. Figure 21 shows cells transiently 
transfected with plasmids encoding the EGFP-tagged constructs using the calcium phosphate 
transfection method (Chen and Okayama, 1988). On the other hand, the cells used for 
immunofluorescence staining of Figure 22 and Figure 23 were transfected using the non-
liposomal transfection reagent FugeneHD. These cells appeared rounded up, which is usually 
indicative of stress. Thus the FugeneHD transfection method seems to cause a higher 
transfection stress in these HeLa cells than the calcium phosphate method as it was observed 
frequently. Despite the obvious differences between the two transfection protocols, the results 
obtained were similar.  
In summary wild type ARTD10 but not the catalytically inactive mutant ARTD10-G888W 
co-localized with Macro2, Macro3 and Macro1-3 in Flp-In T-REx HeLa cells with strongest 
association with Macro1-3. Thus the catalytic activity of ARTD10 was required. Furthermore 
it can be concluded that the co-localization was seen as soon as ARTD10 could be visualized. 
Taking into consideration that co-localization is often indicative for an interaction between 
proteins, these experiments pointed at a possible interaction between macrodomains of Artd8 
and ARTD10 in cells and are also the first hints of ARTD10 being actually active in cells.  
In order to follow up on this we used the co-immunoprecipitation method as another 
technique to measure interaction of proteins in cells. Therefore HEK293 cells were transiently 
co-transfected with plasmids encoding EGFP alone or the EGFP-tagged macrodomains of 
Artd8 and haemagglutinin (HA)-tagged ARTD10 or HA-tagged ARTD10-G888W. The co-
immunoprecipitations were performed with EGFP-tag specific antibodies of low stringency 
cell lysates and co-precipitation of wild type or the inactive mutant of HA-ARTD10 was 
measured by SDS-PAGE and Western blotting with ARTD10-specific antibodies. HA-
ARTD10 was co-immunoprecipitated by EGFP-Macro2 and EGFP-Macro1-3 (Figure 24, 
lanes 2 and 4) but not by the EGFP-tag alone, EGFP-Macro1 or the ADPr-binding deficient 
mutant EGFP-Macro2-G1055E (Figure 24, lanes 1, 5 and 6). As expected from our previous 
results, HA-ARTD10 was not co-immunoprecipiated by EGFP-Macro1 (Figure 24, lane 1). 
However and to a certain extent unexpectedly, EGFP-Macro3 was also unable to interact with 
HA-ARTD10 (Figure 24, lane 3). It is illustrated by different band intensities that the amounts 
of precipitated EGFP-macrodomains were not completely even as for example less EGFP-
Macro1-3 was precipitated (Figure 24, upper panel). Despite lower EGFP-Macro1-3 protein 
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levels an interaction with HA-ARTD10 was visible. So the absence of signals for co-
precipitated HA-ARTD10 in the EGFP-Macro2G1055E lane for example was not due to 
fewer levels of precipitated EGFP-Macro2-G1055E in comparison to EGFP-Macro2 but due 
to binding deficiency. On the other hand HA-ARTD10-G888W as a negative control 
displayed no interaction with any of the single macrodomains or EGFP (Figure 24, lanes 7-9, 
11-12).  
 
Figure 24: ARTD10 co-immunprecipitates with macrodomains of Artd8 
HEK293 cells were transiently co-transfected with plasmids encoding HA-ARTD10 or HA-ARTD10-G888W 
and plasmids for the EGFP-tagged macrodomains by calcium phosphate transfection. Cells were lysed and 
immunoprecipitations with tag-specific antibodies (α-GFP, 9F9) were conducted 48 h after transfection. 
Immunoprecipitated proteins were analyzed via SDS-PAGE and Western blotting with GFP-specific (9F9) and 
ARTD10-specific antibodies (5H11, upper panel) as indicated. Incubation of Western blot membranes of total 
cell lysates (TCL) with ARTD10-specific antibodies (5H11) served as control for ARTD10 protein expression 
(lower panel). Incubation of TCL-Western blot membranes with GAPDH-specific antibodies was used to 
monitor loading of the TCL. The amount of TCL was 5% (v/v) of the lysates used for immunoprecipitation.  
 
This experiment was repeated more than three times providing the same results. 
 
A weak HA-ARTD10-G888W-specific Western blot signal was derived from samples where 
EGFP-Macro1-3 and HA-ARTD10-G888W were co-transfected and EGFP-Macro1-3 was 
precipitated (Figure 24, lane 10). This was unexpected since no co-localization between this 
inactive mutant and EGFP-Macro1-3 could be monitored in immunofluorescence imaging. 
However it has to be taken into account that the co-localization experiment was conducted in 
HeLa cells whereas the co-immunoprecipitation was performed with HEK293 cell lysates. It 
might be possible that HEK293 cells contain higher levels of endogenous ARTD10 that could 
have ADP-ribosylated also HA-ARTD10-G888W, resulting in a weak interaction with EGFP-
Macro1-3. This would be supported by the notion that the signal derived for precipitated HA-
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ARTD10-G888W was substantially weaker than the one for wild type HA-ARTD10 (compare 
Figure 24, lanes 4 and 10). This hypothesis will need to be further evaluated by for example 
the knockdown of endogenous ARTD10 by shRNA constructs and simultaneously co-
transfecting shRNA resistant ARTD10 and ARTD10-G888W constructs and repeating the co-
immunoprecipitations. Together the findings obtained by the co-immunoprecipitation 
experiments are compatible with the co-localizations. 
The enzymes PARG and ARH3 are well described to hydrolyze PAR chains attached to 
proteins but leaving the last ADPr linked to the protein (Mueller-Dieckmann et al., 2006; Oka 
et al., 2006; Slade et al., 2011). No enzyme has been reported thus far to cleave the bond 
between the last ADPr and the putative acidic acceptor amino acid of the substrate (Kleine et 
al., 2008; Slade et al., 2011). However, Rosenthal et al. discovered that the macrodomain of 
the protein MacroD2 has the capacity to hydrolyze mono-ADP-ribosylation attached to 
ARTD10 (Rosenthal et al., manuscript submitted). MacroD2 was originally shown to 
hydrolyze OAADPr (Chen et al., 2011). It occurs in several isoforms derived from alternative 
splicing. Since Rosenthal et al. either used the isolated macrodomain of MacroD2 or the 
isoform 1 (iso 1) of MacroD2, this isoform was also included in the co-immunoprecipitation 
experiments of this work to further evaluate the hypothesis of a mono-ADP-ribosylation-
dependent interaction between macrodomains of Artd8 and ARTD10 in cells. HA-tagged 
ARTD10 or the catalytic inactive mutant was transiently co-expressed with EGFP-tagged 
Macro1-3 or EGFP alone and HA-tagged MacroD2 iso 1 or an empty vector control into 
HEK293 cells. Remarkably the co-expression of MacroD2 significantly reduced the 
interaction between wild type HA-ARTD10 and EGFP-Macro1-3 whereas all the controls 
were as expected (Figure 25A, lane 2). Evidence that equal amounts of EGFP-Macro1-3 were 
precipitated is provided by the GFP-specific signal (Figure 25A, upper panel) and comparable 
amounts of input protein are demonstrated by the ARTD10-specific bands in the total cell 
lysates (TCL) (Figure 25A, lower panel). Notably in the TCL only the first part of the HA-
MacroD2 band was stained with the HA-specific antibodies. However, that was most likely 
due to uneven Western blotting in that part of the blot (Figure 25A, TCL lanes 2 and 4) since 
the shape of the typical double band was still recognizable and the first part of the band was 
successfully stained. 
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Figure 25: MacroD2 co-expression reduces interaction between ARTD10 and Macro1-3 
A. Plasmids encoding HA-tagged ARTD10 or ARTD10-G888W were transiently co-transfected with plasmids 
encoding EGFP-tagged Macro1-3 or EGFP and HA-tagged isoform 1 of MacroD2 as indicated above into 
HEK293 cells. Cells were lysed, co-immunoprecpitations with tag specific antibodies (α-GFP, 9F9) were 
performed and precipitated proteins were analyzed by SDS-PAGE and Western Blotting with ARTD10- specific 
(5H11) or GFP-specific (9F9) antibodies. 5% (v/v) of the TCL that were used for the co-immunoprecipitations 
were subjected to Western blotting for expression control of HA-ARTD10 with ARTD10-specific antibodies 
(5H11) and HA-MacroD2 with HA-tag-specific antibodies (3F10). Actin served as loading control. 
B. 0.5 µg TAP-ARTD10 were applied to ADP-ribosylation assays supplemented or not with 500 µM of β-
NAD+. Afterwards the reactions were added to pulldown assays with His-tagged Macro1-3 or the His-tagged 
macrodomain of MacroD2 (MacroD2 sh). Interactions were monitored by SDS-PAGE and Western blotting with 
ARTD10-specific monoclonal antibodies (5H11) (upper panel). The Ponceau S Red staining served as control 
(lower panel). 50% (v/v) input of ADP-ribosylation assays were also applied to SDS-PAGE and Western 
blotting. 
 
The displayed experiments were performed three times with representative results being illustrated here.  
 
The observations of this experiment could be explained by either of the following two 
scenarios. The first one could be that the macrodomain of HA-MacroD2-iso1 is also capable 
of interacting with active HA-ARTD10 itself and thus competed with EGFP-Macro1-3 for 
binding, which would result in less HA-ARTD10 in the co-precipitations with EGFP-Macro1-
3. The other option would be that the macrodomain of MacroD2 removed the mono-ADP-
ribosylation sitting on HA-ARTD10 comparable to the in vitro results obtained by Rosenthal 
et al. (manuscript submitted). A decrease of mono-ADP-ribosylation would then result in a 
diminished interaction between HA-ARTD10 and EGFP-Macro1-3. In order to clarify these 
questions, pulldown experiments were conducted with the macrodomain of MacroD2 (Figure 
25B). After an ADP-ribosylation assay modified or unmodified ARTD10 was incubated 
together with His-tagged Macro1-3 or the His-tagged macrodomain of MacroD2. The His- 
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macrodomain of MacroD2 interacted very poorly with ARTD10 in comparison to His-
Macro1-3 (compare Figure 25B, lanes 4 and 6). Hence it can be concluded from this 
experiment that the effect of a decreased association between HA-ARTD10 and EGFP-
Macro1-3 in the presence of over-expressed HA-MacroD2 in cells (Figure 25A) is most likely 
not a result of binding competition. Rather the second scenario applies, implying a de-ADP-
ribosylation of HA-ARTD10 by HA-MacroD2 and thereby a reduction of association with 
EGFP-Macro1-3.  
 
Together these experiments highlighted the specificity of the functions of macrodomains in 
relation to ADP-ribosylation. Despite the structural conservation between these domains, 
diverse functions for different types of macrodomains can be noticed. The macrodomains of 
human macroH2A1.1, of ALC1 and of AF1521 of Archaeoglobus fulgidus are robust PAR 
binders (Ahel et al., 2009; Gottschalk et al., 2009; Karras et al., 2005; Timinszky et al., 2009). 
On the other hand MacroD1 and MacroD2 were reported to exhibit hydrolyzing properties 
because they are capable of converting OAADPr to ADPr and acetate (Chen et al., 2011). 
MacroD2 was additionally demonstrated to be able to hydrolyze the bond between mono-
ADPr and the substrate protein (Rosenthal et al., manuscript submitted). Also the catalytic 
center of the PAR-degrading enzyme PARG consists of a macrodomain-like structure (Slade 
et al., 2011). So there must be small but crucial differences in macrodomains, which are 
responsible for these enlisted, defined functions. Insight from crystallization of a bacterial 
PARG core fold suggests that in PARG a glutamate exists that can come into close proximity 
with the ribose-ribose bond of a PAR chain, perform a nucleophilic attack and thus support 
the cleavage of the bond (Slade et al., 2011). Also analysis of the crystal structures of the 
single macrodomains of Artd8 disclosed small differences in the contribution of amino acids 
for ADPr binding (Figure 20). Maybe the position of distinct individual amino acids like these 
within the catalytic center of the PARG enzyme is sufficient to determine the function of 
individual macrodomains. 
In contrast to PARG and MacroD2, no hydrolyzing activities could be documented for 
Macro2 and Macro3 of Artd8. First, hydrolyzing activities of Macro2 and Macro3 were tested 
on radioactively labeled automodified ARTD10 and not observed (Rosenthal et al., 
manuscript submitted). Secondly, the robust direct and mono-ADP-ribosylation-dependent 
binding to ARTD10 in all pulldown assays would have been hardly detectable if the ADPr 
was directly cleaved off. 
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Of note co-immunoprecipitation as wells as immunofluorescence imaging are not sufficient 
for measuring direct interactions between proteins. Instead they leave the possibility open that 
additional, not detected proteins within cells function as a bridge between the monitored 
proteins. Taking the in vitro experiments into account however (Figure 15 - Figure 19), which 
demonstrated a robust and direct binding, it can be assumed that ARTD10 is also directly 
recognized by macrodomains of Artd8 in cells. Furthermore this must be dependent on the 
catalytic activity of ARTD10 because neither co-localization nor co-immunoprecipitation was 
observed for the inactive mutant and when MacroD2 was co-expressed, a protein capable of 
hydrolyzing mono-ADP-ribosylation attached to ARTD10 that led to a decrease of the 
interaction. Consequently these experiments provide the first formal and direct evidence that 
Artd8 macrodomains recognize wild type ARTD10 and that at least exogenous ARTD10 
mono-ADP-ribosylates itself in cells. 
 
II.1.3 Endogenous ARTD10 is recognized by Artd8 macrodomains in cells  
To exclude the possibility of overexpression artifacts being responsible for the co-localization 
of ARTD10 and EGFP-Macro1-3 in cells, experiments with endogenous ARTD10 were 
performed. For that purpose U2OS cells that express relatively high levels of endogenous 
ARTD10 in contrast to other tested cell lines (data not shown), were treated with Interferon-α 
(IFNα) because it was shown that IFNα can stimulate expression of ARTD10 reporter gene 
constructs (Mahmoud et al., 2011) and also the expression of endogenous ARTD10 (A. Groß, 
Master Thesis). This results in enhanced ARTD10 protein biosynthesis in U2OS cells (Figure 
26A). ARTD10 is a rather late response gene of IFNα. Therefore cells were stimulated for 
24 h to trigger biosynthesis of sufficient protein levels. Additionally, these cells were 
transiently transfected with plasmids encoding EGFP or EGFP-tagged Macro1-3. Similar to 
the observations with overexpressed ARTD10, fluorescence signals for endogenous ARTD10 
accumulating in foci were obtained (Figure 26B). Furthermore cells that had been exposed to 
IFNα exhibited a significant stronger ARTD10 staining than unstimulated cells (Figure 26A 
and B), which was indicative of enhanced ARTD10 protein levels. Importantly the 
endogenous ARTD10 co-localized with EGFP-tagged Macro1-3 but not with the EGFP-tag 
alone following IFNα stimulation (Figure 26B and C). The association was further illustrated 
by the co-localization profile that was derived from the segment that is indicated by the red 
arrow (Figure 26B and C). However, it was also evident that only a subset of ARTD10 foci 
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contained EGFP-Macro1-3. In addition, no co-localization between ARTD10 and EGFP-
Macro1-3 was monitored in cells that were not treated with IFNα (Figure 26 B, lower panels).  
 
Figure 26: Endogenous ARTD10 co-localizes with Macro1-3 
A. U2OS cells were subjected to treatment with 1800 I.E. IFNα-2α (Roferon a, Roche), a derivative of IFNα and 
referred to as IFNα in the following, for 24 h or left untreated. Then cells were lysed and levels of ARTD10 in 
the lysates were detected by SDS-PAGE and Western blotting with ARTD10-specific antibodies (5H11). 
Incubation with actin-specific antibodies was used to monitor equal sample loading. 
B. U2OS cells were transiently transfected with plasmids encoding EGFP or EGFP-tagged Macro1-3 using the 
calcium phosphate transfection method. 24 h after transfection the indicated cells (upper panel) were stimulated 
with 1800 I.E. IFNα for 24 h. Subsequently cells were fixed with 3.8% para-formaldehyde and endogenous 
ARTD10 was stained using ARTD10-specific polyclonal antibodies (E09) and secondary α-rabbit antibodies 
conjugated with the fluorophor Alexa Fluor 555. Nuclei were stained with Draq 5™. Then confocal microscopy 
using a ZEISS LSM710 microscope was performed. A magnification of one of the merge images is displayed at 
the right. White arrows mark co-localization events. The red arrow indicates the area where the profile of panel 
C is derived from. Scale bar: 20 µM. 
C. Co-localization profile of ARTD10 and EGFP-Macro1-3 after IFNα treatment. It was conducted over a 
distance of 14 µM, which is shown by the red arrow in the magnification of panel B. 
 
The experiment was confirmed by two replications. 
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That could either be a result of unsufficient ARTD10 protein levels or of a lack of ARTD10 
activity in untreated cells. Currently there is no information about the activation of ARTD10’s 
enzymatic activities and it is not clear whether it is constitutively active or, more likely, 
regulated by so far unknown mechanisms. IFNα, which signals through the IFNα/β receptor 
that in turn phosphorylates JAK1 and non-receptor tyrosine kinase 2 (TYK2), induces 
activation of several signal transducer and activator of transcription (STATs) that drive target 
gene expression (González-Navajas et al., 2012). JAK1, TYK2 or target genes of the activated 
STATs as a secondary effect could modulate ARTD10 activity, maybe leading to increased 
auto-mono-ADP-ribosylation and in the observed enhanced co-localization with EGFP-
Macro1-3 in IFNα treated cells. There still might be only a subpopulation of endogenous 
active ARTD10 in U2OS cells, which could explain why association with EGFP-Macro1-3 
did not occur in all foci.  
 
Nonetheless, this data demonstrated that endogenous ARTD10, similar to exogenous 
ARTD10, co-localized with EGFP-Macro1-3. Beyond the in vitro interaction data and data 
derived from transient expression in cells, these experiments with endogenous ARTD10 
provide a third line of evidence that macrodomains of Artd8 interact with mono-ADP-
ribosylated ARTD10. 
 
II.1.4 ARTD1 does not contribute to the interaction between ARTD10 and 
macrodomains 
As noted before, macrodomains have been demonstrated to bind to PARylated proteins in 
cells (Timinszky et al., 2009). One concern was that mono-ADP-ribosylated proteins in cells 
might become substrates of polymer forming ARTDs and that this in turn might explain the 
interaction with macrodomains. Hence any contributions of ADPr polymer forming enzymes 
and especially of ARTD1 as the main PAR-generating enzyme to the above described effects 
should be excluded. For this reason the co-immunoprecipitations were repeated with lysates 
from HEK293 cells that were treated beforehand with the inhibitors Olaparib and IWR-1 endo 
(referred to as IWR-1). Olaparib inhibits ARTD1-4 and IWR-1 inhibits ARTD5-6 (Chen et 
al., 2009; Wahlberg et al., 2012). After inhibitor treatment with IWR-1 for 24 h and Olaparib 
for 2 h, cells were lysed and EGFP-proteins were immunoprecipitated with GFP-specific 
antibodies. The combined inhibition of ARTD1-6 did not influence the interaction between 
HA-ARTD10 and EGFP-Macro1-3 in cells (Figure 27A, upper panel lanes 1 and 2). As 
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already shown in the previous co-immunoprecipitation experiment, no interaction between 
HA-ARTD10 and EGFP alone or between HA-ARTD10-G888W and any of the EGFP-
constructs was detectable (Figure 27A, lanes 3-8).  
 
 
Figure 27: ARTD10 is co-precipitated with Macro1-3 independent from activity of bona fide ARTDs 
A. The transient co-transfection of HEK293 cells with plasmids encoding HA-ARTD10 or HA-ARTD10-
G888W together with EGFP or EGFP-tagged Macro1-3 was carried out and cells were treated with 2 µM IWR-1 
for 24 h and 10 µM Olaparib for 2 h as indicated. Directly after the treatment cells were lysed and 
immunoprecipiations were performed as described in Figure 24A (upper panel). 5% (v/v) TCL was subjected to 
Western blotting with ARTD10-specific (5H11), GFP-specific (9F9) or actin-specific antibodies as control 
(lower panel). Actin served as loading control for the TCL. 
B. HEK293 cells were treated with or without 2 µM IWR-1 for 24 h and 10 µM Olaparib for 2 h. Afterwards, the 
cells of the marked samples were subjected to 1 mM H2O2 in PBS for 10 min to induce oxidative stress. The 
reactions were stopped by addition of hot sample buffer. Subsequently the formation of PAR chains was 
monitored via Western blotting of TCL with PAR-specific antibodies. Detection of actin levels served as loading 
control.  
 
All experiments were performed at least three times with similar results. 
 
Furthermore the efficacy of Olaparib on ARTD1 as the main contributor to PAR formation in 
cells was tested. HEK293 cells were treated with Olaparib and IWR-1 under the same 
conditions as applied for the co-immunoprecipitation experiments. In order to activate 
ARTD1, which is mostly inactive under unstressed conditions, cells were exposed to H2O2 
that induces oxidative stress and DNA damage and consequently triggers PARylation by 
ARTD1 (Ahel et al., 2009; Blenn et al., 2006). ARTD1 was activated in HEK293 cells upon 
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H2O2 exposure as seen by the appearance of PAR signals (Figure 27B, lane 2). Without 
induction of oxidative stress a weak PAR forming activity was detectable in these cells as 
demonstrated by the diffuse PAR-staining (Figure 27B, lane 1). Nonetheless the treatment 
with Olaparib and IWR-1 prevented the PAR formation beyond this residual activity (Figure 
27B, lane 3), even if cells were exposed to oxidative stress (Figure 27B, lane 4). Together 
these experiments demonstrate that the observed interactions in co-immunoprecipitations did 
not depend on PARylation. 
 
 
Figure 28: Polymer forming ARTDs do not influence co-localization of overexpressed ARTD10 and 
Macro1-3 
The calcium phosphate transfection method served to transiently transfect Flp-In T-REx HeLa ARTD10 cells 
with plasmids encoding EGFP-Macro1-3. One day after transfection, ARTD10 biosynthesis was triggered by 
1 µg/ml doxycycline for 24 h or cells were left untreated. At the same time, the denoted samples were 
supplemented with 2 µM IWR-1 for 24 h and with 10 µM Olaparib for 2 h directly before cell fixation with 
3.8% para-formaldehyde. Subsequently, cells were stained for ARTD10 using monoclonal antibodies (5H11) 
and secondary α-rat antibodies labeled with the fluorescent dye AlexaFluor 555. Nuclei were stained with 
Draq5™. Localization of ARTD10 and EGFP-Macro1-3 was monitored by confocal microscopy with a Zeiss 
LSM710 microscope. On the right two magnifications of the merge pictures are shown. White arrows point at 
co-localization events. Scale bar: 20 µM. 
 
This experiment was conducted once in this cell line and repeated in U2OS cells, see Fig. 29. 
 
Next, the question whether PAR polymers contributed to co-localization in 
immunofluorescence experiments was addressed. Therefore, EGFP-tagged Macro1-3 was 
expressed in the Flp-In T-REx HeLa cells that stably express ARTD10 protein upon 
doxycycline treatment. Cells were treated with the indicated inhibitors simultaneously to 
doxycycline supplementation and immunofluorescence staining of ARTD10 was performed. 
As documented by previous experiments, staining of ARTD10 was only visible after 
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doxycycline induction and co-localization with EGFP-Macro1-3 occured (Figure 28, second 
row). The inhibitor treatment did not influence the co-localization (Figure 28, third row). 
Analog to these experiments, also the co-localization of endogenous ARTD10 and EGFP-
tagged Macro1-3 was measured in the presence of the inhibitors. Thus U2OS cells were 
transiently transfected with plasmids encoding EGFP or EGFP-tagged Macro1-3, ARTD10 
expression was enhanced by IFNα stimulation and cells were treated with Olaparib and IWR-
1. Again ARTD10 staining was significantly higher in cells that were stimulated with IFNα 
(Figure 29A, upper panel) and predominantly in that setting co-localization between ARTD10 
and EGFP-Macro1-3 could be observed in immunofluorescence imaging (Figure 29A). This 
co-localization did not occur in every ARTD10 dot-like structure but in some as discussed 
before. Similar to the previous experiment in the Flp-In T-Rex Hela cells, the interaction of 
ARTD10 and EGFP-Macro1-3 was independent of the inhibitor treatment (Figure 29A, upper 
panel). The co-localization was also clearly demonstrated by analyzing the fluorescence 
profile for a defined region of a cell (Figure 29A upper panel, and Figure 29B). Co-
localization with EGPF only did not occur. 
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Figure 29: Co-localization of endogenous ARTD10 and Macro1-3 does not require the activity of polymer-
forming ARTDs  
A. U2OS cells were transiently transfected with plasmids encoding EGFP or EGFP-tagged Macro1-3 by calcium 
phosphate transfection. 24 h after transfection, cells of the indicated samples were stimulated with 1800 I.E. 
IFNα and 2 µM IWR-1 for 24 h. 2 h prior to fixation, 10 µM Olaparib was added. Cells were then fixed with 
3.8% para-formaldehyde and immunofluorescence staining of ARTD10 was performed using polyclonal primary 
antibodies (E09) and Alexa Fluor 555-labeled secondary α-rabbit antibodies. Nuclei were visualized by Draq5™ 
staining. Samples were analyzed by confocal microscopy with a Zeiss LSM710 microscope. An enlargement of 
one depicted merge image is shown on the right. White arrows indicate co-localization events. The red arrow 
marks the location where the co-localization profile of panel B is derived. Scale bar: 20 µM. 
B. A co-localization profile of EGFP-Macro1-3 and ARTD10 after inhibitor treatment of U2OS cells is 
displayed. It is generated from a 14 µM long sector indicated in the enlargement of a merge image in panel A. 
Green line: EGFP-Macro1-3. Red line: ARTD10. Lilac line: nucleus. 
 
The experiment was conducted three times. 
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Lastly the histone variant macroH2A1.1(162-369) was addressed. As a known PAR binder it 
had been tested in in vitro pulldown experiments and did not bind to mono-ADP-ribosylated 
ARTD10 (Figure 18). An additional confirmation that it cannot interact in cells with active 
ARTD10 would further underline the hypothesis that the observed interaction between active 
ARTD10 and macrodomains of Artd8 is independent of any PARylation effect. For that 
reason U2OS cells were transiently transfected with plasmids encoding enhanced cyan 
fluorescent protein (ECFP) as control or ECFP-tagged macroH2A1.1(162-369). 
Immunofluorescence imaging analysis revealed that although both, ECFP only and ECFP-
macroH2A1.1(162-369) partially accumulated in foci in some cells, these foci did not co-
localize with endogenous ARTD10, irrespective of IFNα stimulation (Figure 30A and B). 
These foci were not caused by macroH2A1.1(162-369) because they were also observed with 
ECFP alone (Figure 30A, upper panels), thus being tag-specific. Western blot analysis 
confirmed the protein expression of ECFP and ECFP-macroH2A1.1 in U2OS cells (Figure 
30C).  
 
PARylation mediated by ARTD1-6 has been implicated in the regulation of a variety of 
important cellular processes, including DNA repair, apoptosis and WNT signaling (Ahel et 
al., 2009; Ahel et al., 2008; Callow et al., 2011; Gibson and Kraus, 2012). Thereby PAR 
chains often serve as scaffolds for recruitment of proteins participating in these processes 
(Gibson and Kraus, 2012; Kalisch et al., 2012). Due to the importance of these processes and 
signaling pathways a fine-tuned recognition of ADP-ribosylation can be anticipated. In this 
respect it appears likely that there are different readers for mono- and poly-ADP-ribosylation. 
However, although ADP-ribosylation has been studied for decades, it remains largely elusive 
how the target specificity of different ARTDs is generated. That is why it cannot be ruled out 
that mono-ADP-ribosylated proteins like ARTD10 become substrates for PAR-forming 
enzymes after their modification by mono-ADPr. This would result in PARylation of initially 
mono-ADP-ribosylated proteins, which are then recognized by reader modules of 
PARylation. Of note is also the enzymatic activity of PARG, which is able to remove PAR 
chains from modified proteins but leaves the last ADPr attached to the protein (Slade et al., 
2011). Thus originally PARylated proteins would appear to be mono-ADP-ribosylated after 
being targeted by PARG. 
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Figure 30: macroH2A1.1(162-369) does not co-localize with endogenous ARTD10 in cells 
A. U2OS cells were transiently transfected with plasmids encoding ECFP or ECFP-tagged macroH2A1.1(162-
369), stimulated with IFNα for 24 h and directly afterwards fixed with 3.8% para-formaldehyde. Staining of 
endogenous ARTD10 and nuclei was conducted as described in Figure 29. Confocal microscopy with a Zeiss 
LSM710 microscope was performed to determine protein localization in fixed cells. A magnification of the 
indicated merge image is shown. The red arrow shows the distance and localization where the profile illustrated 
in panel B was generated. Scale bar: 20 µM. 
B. Co-localization profile of ECFP-tagged macroH2A1.1(162-369) and endogenous ARTD10. 
C. U2OS cells were transiently transfected with plasmids coding for ECFP alone or ECFP-macroH2A1.1(162-
369). 48 h after transfection, cells were lysed in hot sample buffer and biosynthesis of the overexpressed genes 
was analyzed by SDS-PAGE and Western blotting with the ECFP-recognizing polyclonal GFP-specific 
antibodies (JM-3999-100). 
 
The displayed data is derived from one but is representative for two biologically independent experiments with 
similar results. 
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Together our data provides several lines of evidence that PARylation does not account for the 
interaction between ARTD10 and macrodomains of Artd8. On one hand, co-
immunoprecipitations with cell lysates of cells that were treated with inhibitors against the 
PAR-generating members of the ARTD family were performed (Figure 27). Also 
immunofluorescence imaging with transiently expressed or endogenous ARTD10 was carried 
out under ARTD1-6 inhibitory conditions (Figure 28, Figure 29). The interaction between 
active ARTD10 and Artd8 macrodomains was not influenced by Olaparib and IWR-1 in any 
of these experiments. On the other hand the well characterized PAR binder 
macroH2A1.1(162-369) was tested for binding to mono-ADP-ribosylated ARTD10 in vitro 
(Figure 18A) or for association in co-localization experiments (Figure 30). Although the 
binding to PARylated ARTD1 was confirmed in our experimental setups and demonstrated 
the functionality of macroH2A1.1(162-369) (Figure 18B), no interaction was obtained for 
ARTD10. Furthermore in contrast to macroH2A1.1(162-369), the single Artd8 macrodomains 
did not recognize PARylated ARTD1 (Figure 18B). Moreover, macroH2A1.1(162-369) did 
not co-localize with endogenous ARTD10 (Figure 30). A fourth line of evidence was defined 
by the distinct ARTD10 bands in Western blot analysis. If an originally mono-ADP-
ribosylated ARTD10 protein became subsequently a substrate for PARylating enzymes like 
ARTD1 in cells, diffuse bands would have been expected due to the heterogenous nature of 
PAR chains. Such diffuse bands could be observed for ARTD1 after automodification (Figure 
18B, lanes 2 and 12) but never occurred for ARTD10 in co-immunoprecipitation experiments 
(Figure 24A, Figure 25A, and Figure 27A). 
 
In summary inhibition of polymer forming ARTDs did not influence the interaction of 
ARTD10 with Macro1-3 under all experimental conditions studied. Beyond that, 
macroH2A1.1 was not recruited to foci of endogenous ARTD10. Thus our findings strongly 
suggest that interaction between active ARTD10 and macrodomains of Artd8 depend on 
intracellular mono-ADP-ribosylation by ARTD10 in cells. In conclusion this data and 
argumentation supports the hypothesis that despite of the general ability of most 
macrodomains to bind free ADPr, different and specialized macrodomains reading either 
mono- or poly-ADP-ribosylation exist.  
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II.1.5 Substrates of ARTD10 are bound by macrodomains after ADP-ribosylation 
So far the investigations concentrated on the recognition of ARTD10 itself after 
automodification by macrodomains. However, we were also interested in whether additional 
ARTD10 substrates are also able to interact with these macrodomains, which would provide a 
tool to screen for mono-ADP-ribosylated ARTD10 substrates in cells. In our previous 
published studies only core histones were identified as in vitro substrates of ARTD10 (Kleine 
et al., 2008). Though core histones are also demonstrated substrates of ARTD1 and 
accordingly are PARylated (Altmeyer et al., 2009; Kraus and Lis, 2003). Since PARylation is 
read by several macrodomains and although it was demonstrated in the last chapters that 
macrodomains of Artd8 do not recognize PARylation, we resolved to use other targets. As 
known from bacterial ADP-ribosyltransferases, G-proteins are often target of mono-ADP-
ribosylation (Di Girolamo et al., 2005; Kahn and Gilman, 1984a). Thus several small G-
proteins were tested and as a result, Ran in its GTP- but not GDP-bound form was a substrate 
of ARTD10 (H. Kleine, PhD thesis and Forst et al., manuscript submitted). Of note the 
loading with GTP causes a conformational change in Ran implying that the change in 
structure is a precondition for being targeted by ARTD10 (Pemberton and Paschal, 2005; 
Vetter et al., 1999). Furthermore, GSK3β, which is a component of several important cellular 
pathways including Wnt-β-catening signaling and hedgehog signaling (Clevers and Nusse, 
2012; Wu and Pan, 2010), was recently identified as a substrate of ARTD10 by a proto-array 
substrate screen and validated by in vitro ADP-ribosylation assays (Feijs et al., manuscript 
submitted). NF-κB essential modulator (NEMO) was also found to be an ARTD10 target by a 
member of our group (Verheugd et al., manuscript submitted). NEMO is involved in the 
control of the canonical NF-κB pathway as a scaffolding protein binding to K63-linked poly-
ubiquitin chains linked to members of the NF-κB signaling cascade (Miyamoto, 2011; 
Schröfelbauer et al., 2012). Therefore Ran-GTP, NEMO and GSK3β were tested for 
association with Artd8 macrodomains after modification by ARTD10. 
First an in vitro ADP-ribosylation assay with wild type ARTD10 and GST-tagged NEMO 
was conducted, which should lead to mono-ADP-ribosylation of GST-NEMO in the presence 
of the co-factor β-NAD+. As a further control to exclude influences of the co-factor β-NAD+, 
the ADP-ribosylation assay was also performed with β-NAD+ but in the absence of the 
ARTD10 enzyme. After a subsequent His-pulldown assay and SDS-PAGE, it was revealed by 
Western blot detection that modified GST-NEMO interacted with His-tagged Macro2, 
Macro3 and even more efficiently with Macro1-3, revealing comparable binding preferences 
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as ARTD10 itself (Figure 31A). Surprisingly in this experiment also a signal indicative of 
modified ARTD10 binding to His-Macro1 (Figure 31A, lane 4) was obtained although in all 
previous experiments no interaction was obvious (Figure 15, Figure 16, Figure 19, Figure 24, 
and Figure 31B). Still the signal intensity was weaker as the ones for the other macrodomains. 
One conceivable explanation might be that the affinity of Macro1 to mono-ADP-ribosylated 
ARTD10 is considerably lower than the affinity of the remaining macrodomains of Artd8 but 
not completely abolished. This would be consistent with data from the crystal structure of 
Macro1 where an important hydrogen bond was missing but others were still present (Figure 
20). Comparing the ARTD10 signal intensity for the interaction of ARTD10 with His-
Macro1-3 to the intensity of the ARTD10 input signal (Figure 31A, lanes 2 and 13), it can be 
concluded that more than 50% of ARTD10 was automodified and recognized by His-Macro1-
3. 
 
Figure 31: NEMO and GSK3β are mono-ADP-ribosylated by ARTD10 and bound by macrodomains in 
vitro 
A. Enzymatic ADP-ribosylation assays were performed with or without 0.5 µg TAP-ARTD10 in the presence or 
absence of 500 µM β-NAD+. 2 µg of GST-tagged NEMO were added to the ADP-ribosylation assay. Next the 
reaction including both proteins was subjected to a pulldown assay with His-tagged macrodomains of Artd8 
coupled to TALON™ metal affinity resin. Bound proteins were determined by SDS-PAGE and Western blot 
analysis with ARTD10-specific (E09) and NEMO-specific antibodies respectively (upper panel). The blot 
membrane was stained with Ponceau S Red for control (lower panel). As an input control, 50% (v/v) of ADP-
ribosylation assays carried out with the indicated proteins with our without β-NAD+ were simultaneously 
analyzed by SDS-PAGE and Western blotting with specific antibodies. 
B. The experimental set-up was as in panel A with the difference that 1 µg of GST-tagged GSK3β was subjected 
to the APD-ribosylation assay instead of GST-tagged NEMO and GSK3β-specific antibodies were used for 
detection in Western blotting. Additionally the binding deficient mutant His-Macro2-G1055E was included in 
the pulldown assay. 
The results being representative for three independent experiments are displayed. 
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Thus the automodification reaction was apparently very efficient this time. So this might give 
reason for the signal of His-Macro1 binding to ARTD10. No signal indicative of an 
interaction between GST-NEMO and His-Macro1 was obtained (Figure 31A, lanes 3-5). 
Beyond that, a similar experimental set-up was used for assessment of another ARTD10 
substrate, GST-GSK3β. This substrate was also recognized by His-tagged Macro2, Macro3 
and Macro1-3 but not by the binding-deficient mutant of Macro2 after mono-ADP-
ribosylation (Figure 31B). The faint signal for unmodified GST-GSK3β in lane 9 can most 
likely be explained by unspecific binding to TALON™ metal affinity resin because the signal 
was significantly weaker as the signal for modified GST-GSK3β interacting with His-
Macro1-3 (Figure 31B, lane 10). Next it was tested whether free ADPr could compete with 
mono-ADP-ribosylated GST-GSK3β for binding to His-Macro1-3 as it was performed for 
ARTD10 (compare Figure 17C). Hence increasing concentrations of free ADPr were used in 
the pulldown assays with His-tagged Macro1-3 and modified or unmodified GST-GSK3β and 
ARTD10. The interaction of both, modified ARTD10 and GST-GSK3β with His-Macro1-3 
was reduced in the presence of 100 µM or higher concentrations of free ADPr (Figure 32). 
Thus these experiments indicate that mono-ADP-ribosylation of two ARTD10 substrates can 
also be read by Macro2, Macro3 and Macro1-3 in vitro. 
 
Figure 32: Association of Macro1-3 with mono-ADP-ribosylated GSK3β is reduced in presence of free 
ADPr 
First an ADP-ribosylation assay was carried out as described in Figure 31B. The reaction was incubated in a 
pulldown assay with His-tagged Macro1-3 immobilized on TALON™ metal affinity resin. Furthermore free 
ADP-ribose was added to the pulldown in increasing concentrations. The evaluation of the pulldown assay was 
conducted as in Figure 31B. 
 The same result was obtained by two further independent experiments. 
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As a third substrate Ran-GTP was investigated. Therefore Ran loaded with GppNHp, which is 
a non-hydolyzable analog of GTP (Vetter et al., 1999), was used. Pulldown assays with 
modified or unmodified Ran-GppNHp mediated by an ADP-ribosylation reaction with 
ARTD10 and His-Macro1-3 or His-Macro3 were performed, comparably to the previously 
described pulldown assays. Like NEMO and GSK3β, Ran-GppNHp was also recognized by 
His-Macro3 and His-Macro1-3 (Figure 33A and B). Here it must be mentioned that the 
protein migrating at 43 kDa (Figure 33A, lane 1 and 2) seemed to be an impurity of the Ran 
protein purification that is recognized by the Ran-specific antibody because it only occurs in 
the input lanes. If it was a Ran-specific band it would be expected to occur also in the 
pulldown of His-Macro1-3 and modified Ran (Figure 33A, lane 4). For His-Macro2 no 
consistent results could be obtained, which is the reason why it is not shown here.  
In addition the interaction with Ran was also tested in cells. HEK293 cells were transiently 
co-transfected with plasmids encoding HA-tagged ARTD10 or ARTD10-G888W together 
with the EGFP-tagged macrodomain constructs. In GFP-specific immunoprecipitations 
endogenous Ran was found associated with EGFP-Macro1-3, similar to HA-ARTD10, and 
also with EGFP-Macro3 (Figure 33C). Importantly, this was only true when wild type HA-
ARTD10 but not the inactive mutant was co-expressed.  
In summary three substrates in addition to ARTD10 interacted with Macro3 and Macro1-3 
upon mono-ADP-ribosylation by ARTD10 in vitro. Whereas GSK3β and NEMO were also 
bound by Macro2 in vitro, Ran-GppNHp was preferentially recognized by Macro3. Of note 
Ran-GppNHp also interacted in cells with Macro3 and Macro1-3 after co-expression of wild 
type ARTD10 but not of the catalytically inactive mutant. In conclusion, macrodomains of 
Artd8 are not restricted to reading mono-ADP-ribosylation on ARTD10 itself but are also 
capable to do so for at least a subset of ARTD10 substrates. To elaborate on this, further 
substrates need to be tested in the future. 
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Figure 33: Artd8 macrodomains interact with mono-ADP-ribosylated Ran, a novel ARTD10 substrate 
A and B. 1 µg Ran-GppNHp was incubated together with 0.5 µg ARTD10 in the presence or absence of 500 µM 
β-NAD+ in an ADP-ribosylation assay. Binding to His-tagged Macro1-3 (A) or His-tagged Macro3 (B) coupled 
to TALON metal affinity resin was analyzed via SDS-PAGE and Western blot probed with ARTD10-specific 
(E09) or Ran-specific antibodies. The Ponceau S Red staining served as control for protein amounts (A, lower 
panel). The purified Ran-GppNHp protein was a kind gift of Alfred Wittinghofer (MPI, Dortmund). 
C. HEK293 cells were transiently co-transfected with plasmids encoding HA-tagged ARTD10 or ARTD10-
G888W together with EGFP-tagged macrodomain constructs. Then the cells were lysed and co-
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immunoprecipiations with tag-specific antibodies were performed (α-GFP). SDS-PAGE and Western blot 
analysis of bound proteins with ARTD10- and GFP-specific antibodies were applied for detection of transiently 
expressed proteins and Ran specific antibodies were used for endogenous Ran. TCL, 5% (v/v) of lysates used for 
immunoprecipitations, were evaluated as control for the expression of the corresponding proteins via Western 
blotting with ARTD10-, Ran- and GFP-specific antibodies. Actin detection was used as control for equal 
loading. 
 
In this context the question of the binding modalities arose. So far macrodomains have only 
been connected to free ADPr- and PAR-binding, with the ADPr sitting deep within the 
macrodomain fold. Because PAR chains can consist of up to 200-400 ADPr units and because 
macrodomains recognize the terminal ADPr of a PAR chain (D'Amours et al., 1999; Gibson 
and Kraus, 2012; Timinszky et al., 2009), it seems unlikely that PAR-binding macrodomains 
like macroH2A1.1 stand in contact with residues of the PARylated substrate protein backbone 
although this was not explicitly shown. WWE (Wang et al., 2012) and PBZ domains (Gibson 
and Kraus, 2012; Isogai et al.) are also reported to interact with PAR chains exhibiting 
especially affinities for the O-glycosidic bond linking two ADPr units and PBZ domains 
additionally for the adenine ring of the terminal ADPr. It is not clear how the basic and 
hydrophobic peptide binding to PAR is mediated (Kalisch et al., 2012). Consequently it 
remains largely elusive how the specificity of these PAR-binding modules is achieved but 
extensive contact formation with the protein backbone seems unlikely for at least three of the 
four modules. In contrast, for several readers of other PTMs contributions of the protein 
backbone are required for connecting to the PTMs, making these interactions more selective 
and more stable. As an example bromodomains, known readers of lysine acetylation, reveal a 
rather low affinity for an acetylated lysine alone. In fact studies imply an importance of the 
modification pattern around the acetylated site for several bromodomains. Additionally, 
residues surrounding the acetylated site are also supposed to make contacts to bromodomains. 
Thus this type of domain does not only recognize the acetylation but is dependent on contacts 
with further residues of the protein backbone (Filippakopoulos and Knapp, 2012; 
Filippakopoulos et al., 2012; Zeng and Zhou, 2002). Moreover the phospho-tyrosine binding 
SH2 domain possesses a very conserved phospho-tyrosine binding cleft but additionally 
recognizes residues C-terminal of the phosphorylation site, which determines the specificity 
of SH2 domains of different proteins (Boggon and Eck, 2004; Pawson, 2004). 
Of note modifications like acetylation or phosphorylation and most likely also mono-ADP-
ribosylation reside in closer proximity to the protein backbone than terminal ADPrs of PAR 
chains. So concerning the binding specificity of Artd8 macrodomains to mono-ADP-
ribosylated ARTD10 and also to its three tested and modified substrates, there are two 
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imaginable scenarios: The first one is the exclusive bonding to the mono-ADP-ribose attached 
to a protein as suggested for other macrodomains interacting with PAR. This option could 
well be clarified in further experiments. Other validated or still putative mARTs of the ARTD 
family could be tested in auto- or substrate modification assays with subsequent pulldown 
experiments analogous to those carried out here. One candidate could be ARTD15 which has 
recently been described to automodify and mono-ADP-ribosylate karyopherin-β1 (Di Paola et 
al., 2012). Notably also mono-ADP-ribosylating activities of ARTD8 itself have been 
validated by our group (unpublished findings of H. Kleine and A. Braczynski) and it would be 
interesting to test whether Artd8 macrodomains recognize modified Artd8 in trans or even in 
cis. On the other hand ARTD1 could be subjected to auto-PARylation and afterwards be 
treated with PARG. Since PARG is known to be unable to remove the last ADPr attached to 
the protein (Slade et al., 2011) this would result in mono-ADP-ribosylated ARTD1. Usage of 
the ARTD1-E988K mutant would also serve that purpose because its catalytic activity has 
been demonstrated to be restricted to mono-ADP-ribosylation (Rolli et al., 1997). 
Additionally, also mono-ADP-ribosylated targets of ecto-ARTs could be investigated for 
binding to Macro1-3. Ecto-ARTs are well described to target arginines instead of the acidic 
residues, which are suggested for mARTs of the ARTD family (Glowacki et al., 2002; Kleine 
et al., 2008). So the linkage between ADPr and protein would be chemically different from 
the one implied for ARTDs. In summary, if macrodomains of Artd8 recognized also the 
substrates of other mARTs from the ARTD family or ecto-ARTs in the proposed experiments 
as well as PARG-treated ARTD1 that would point at a backbone-independent binding.  
The other option would favor the contribution of the protein backbone, either amino acid 
sequence or structure, to binding specificity of Artd8 macrodomains, which then in turn could 
lead to a selectivity for ARTD10 substrates. Also here experiments with other mARTs could 
assist in answering this question. However specificity for ARTD10 substrates would postulate 
that also ARTD10 requires a distinct target motif for mono-ADP-ribosylation. At the moment 
this question is difficult to answer because of the insufficiency of general tools to identify 
modified sites on substrates. So far, sequence alignments of target substrates and peptide 
arrays of differentially modified core histone tails as known ARTD10 targets did not reveal 
any obvious similarities (K. Feijs, unpublished data from PhD thesis). The only identified 
automodification site, mediated by comparisons with ARTD1 and mutagenesis studies, is the 
glutamate at position E882 of ARTD10. It is one but not the only automodification site of 
ARTD10 (Kleine et al., 2008). Nevertheless, a peptide containing this site is only poorly 
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modified (unpublished data of our group). Together that led to the assumption that secondary 
or tertiary structure rather than pure amino acid sequence are relevant to define an ARTD10 
target. Imaginable, also macrodomains of Artd8 could see this protein structure. Contributions 
of the protein backbone could also explain, why different substrates like Ran-GppNHp and 
GSK3β are differentially recognized after mono-ADP-ribosylation. Whereas Ran-GppNHp 
predominantly associated with Macro3, GSK3β was recognized by Macro2 and Macro3. It 
needs to be investigated in the future, which of the two scenarios is true. Also a combination 
of the two binding modes might be possible. 
Finally the question of the biological relevance of the interaction of mono-ADP-ribosylated 
ARTD10 and its substrates and these macrodomains has to be addressed. PBZ domains in 
APLF were demonstrated to be crucial for the recruitment of APLF to PARylated DNA 
damage sites where APLF in turn facilitates the association of the histone variant 
macroH2A1.1 to these locations. MacroH2A1.1 then also binds to PAR via its macrodomain 
(Mehrotra et al., 2011; Timinszky et al., 2009). Thus this PBZ PAR-binding module is a 
targeting domain. Similarly, the E3 ubiquitin ligase CHFR is targeted to its substrate ARTD1 
by its PBZ domain and also WWE domains of ubiquitin ligases serve the purpose of making 
contact between the ligase and its substrate, dependent on ADPr polymers (Callow et al., 
2011; Kashima et al., 2012; Levaot et al., 2011; Wang et al., 2012; Zhang et al., 2011). 
Similar tasks could also account for Artd8 macrodomains. Of note this work focused on the 
macrodomains as single modules and the identification of a tool to monitor intracellular 
mono-ADP-ribosylation of ARTD10. However, it must be considered that these 
macrodomains are part of a protein that itself is not only a putative mono-ADP-
ribosyltransferase of the ARTD family (Kleine et al., 2008; Otto et al., 2005) but an enzyme 
with validated mART activity as shown by our group (unpublished findings). Considering the 
initial observation for starting this project that also full length ARTD10 and Artd8 co-localize 
in cells, the question has to be asked why a mART of the ARTD family is targeted to a 
substrate of another family member but only after it was mono-ADP-ribosylated. Currently, it 
can only be speculated about the answer. There is limited published knowledge about the 
function of ARTD8 in cells. It has been described originally as a coactivator of the 
transcription factor STAT6. For this transcription enhancement of STAT6 target genes, the C-
terminal part of ARTD8 including macrodomains, WWE domain and the active catalytic 
domain are required (Cho et al., 2009). However, not STAT6 is ADP-ribosylated by ARTD8 
but p100, which constitutes another STAT6 coactivator (Cho et al., 2009; Yanagawa et al., 
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2007). Of note our group has performed substrate screens for ARTD10 where, among others, 
GSK3 was identified as a target (Feijs et al., manuscript submitted). However, this screen was 
also repeated for Artd8 and although distinct target proteins were found for ARTD10 and 
Artd8, there was also a substantial overlap of substrates (unpublished findings of our group). 
Here the possibility of false positive results could not be excluded yet. Nevertheless at least 
all tested ARTD10 substrates could be validated by radioactive in vitro ADP-ribosylation 
assays (Feijs et al., manuscript submitted). So as one hypothesis, ARTD10 and Artd8 could 
share some target proteins in cells. Thus mono-ADP-ribosylation conducted by both proteins 
on a target could either exhibit cooperative effects or on the other hand even opposing 
consequences on a subset of their target proteins in a time and signal regulated manner. In this 
scenario, the macrodomains would then serve as recruiters for Artd8 to the already by 
ARTD10 modified targets. It could also be imagined that Artd8 does not target the same 
protein as ARTD10 but proteins associated with ARTD10 targets. Comprehensive 
investigations of these hypotheses are required in the future. As a first approach it could be 
monitored in in vitro ADP-ribosylation assays whether shared target proteins of both mARTs 
are more efficiently modified by ARTD8 after they had been mono-ADP-ribosylated by 
ARTD10.  
Obviously, the affinity of Artd8 macrodomains is sufficient to recruit Artd8 molecules to 
intracellular mono-ADP-ribosylated ARTD10. Still for the usage of macrodomains as an 
antibody-like tool in order to monitor intracellular mono-ADP-ribosylation of other substrates 
than ARTD10 itself and Ran-GTP, stronger binding will be required for detecting 
physiological substrates. The following has to be considered. Currently it is not clear, to what 
degree intracellular proteins like NEMO and GSK3β are modified and if all the proteins or 
only a subset are targeted. The latter can be assumed given the fact that GSK3 exists in 
various pools, which are differentially activated by distinct signaling pathways (Ding et al., 
2000; Harwood, 2001; Wu and Pan, 2010). In contrast Ran is an abundant protein in the cell 
and the Ran-GTP concentration are very high in the nucleus and at chromosomes during 
mitosis because a Ran-GTP gradient is actively created depending on the localization of its 
guanine nucleotide exchange factor RCC1 (Clarke and Zhang, 2008). This might have led to a 
locally efficient mono-ADP-ribosylation after ARTD10 overexpression, which might have 
been sufficient to be recognized by Macro3 and Macro1-3. For other substrates it might be 
worth considering optimization of the binding affinities first before using macrodomains as a 
tool to visualize mono-ADP-ribosylation in cells. As a technique, the recently described soft 
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randomization mutagenesis yielding a 50% mutation rate of each amino acid including 
residues that contribute to binding could be applied. As a proof of principle this method was 
combined with the phage display screening and a SH2 phospho-tyrosine superbinder was 
generated by Kaneko et al. (Kaneko et al., 2012). This could be performed analogously on 
Artd8 macrodomains with subsequent screening against interaction with modified but not 
unmodified ARTD10 protein. 
Furthermore, for the first time an in vitro ARTD10 substrate, Ran-GppNHp/Ran-GTP, could 
be demonstrated to be mono-ADP-ribosylated in cells as well. The small G protein Ran is a 
multifaceted protein. On the one hand it was proven to be a crucial protein for nuclear-
cytoplasmic shuttling. A gradient of the GTP-bound form of Ran being high in the nucleus 
and low in the cytoplasm is of particular importance for this process. One of Ran-GTP’s tasks 
is to build a ternary complex with exportins and cargo proteins to facilitate their nuclear 
export (Clarke and Zhang, 2008; Pemberton and Paschal, 2005). One common exportin 
requiring Ran-GTP is CRM1 that had also been shown to be responsible for the export of 
ARTD10 from the nucleus (Kleine et al., 2012). Thus during this process ARTD10 and Ran-
GTP meet and come into close proximity where mono-ADP-ribosylation of Ran-GTP by 
ARTD10 would be feasible. Also a subsequent recognition by macrodomains of ARTD8 
could be possible because as a transcriptional co-activator and interactor of STAT6, ARTD8 
most likely also occurs in the nucleus (Cho et al., 2009). This could be easily tested by a 
knockdowm of CRM1 together with Macro1-3 and ARTD10 over-expression and subsequent 
co-immunoprecipitations. 
The organization of spindle poles during mitosis by triggering the release of spindle assembly 
factors from importins is also Ran-dependent. This facilitates one of importins’ pro-mitotic 
functions (Clarke and Zhang, 2008). One of these factors is TPX2, which among other 
functions stimulates Aurora kinase A, a key regulator of mitosis (Clarke and Zhang, 2008; 
Kiyomitsu and Cheeseman, 2012). Strikingly Aurora kinase A was also identified as an 
ARTD10 substrate in the Proto-Array screen (unpublished data from our lab). Thus also in 
this scenario a connection between Ran-GTP and ARTD10 is conceivable. However, it is not 
clear which consequences mono-ADP-ribosylation of Ran-GTP has. Taking mono-ADP-
ribosylation by bacterial toxins into account, this modification often exerts an inhibitory effect 
on its substrate. As an example mono-ADP-ribosylation of eEF2 by the diphtheria toxin 
inhibits its functions in protein biosynthesis. Modification of the Gs subunit of the 
heterotrimeric stimulatory G-protein by the cholera toxin constrains its intrinsic GTPase 
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activity (Honjo et al., 1968; Honjo et al., 1971; Kahn and Gilman, 1984a, b). As a side note, 
Ran-GTP only possesses a very low intrinsic GTPase activity and RanGEF is needed for 
hydrolyzation of GTP (Clarke and Zhang, 2008). Admittedly these toxin-mediated effects are 
intended to interfere with the host’s metabolism and might not mirror physiological cell 
conditions but also mono-ADP-ribosylation of receptors on T-cells by the ecto-ART ART1 
leads to inhibition of receptor signaling (Liu et al., 1999). However, it remains to be unraveled 
whether and if at which point this GTP hydrolyzation process is influenced by mono-ADP-
ribosylation. For example it could be speculated that mono-ADP-ribosylation inhibits the 
interaction with RanGEF and as a result Ran would stay in its GTP-bound form. This could in 
turn diminish the Ran-GTP gradient that is important for nuclear import-export processes but 
may also have consequences on mitotic progression. Although most studies about the 
involvement of Ran in mitosis were carried out in X. laevis egg extracts, first experiments in 
human cells with a Ran-GTP mutant that exists always in the GTP-bound form indicated 
higher frequencies of mitotic defects like multipolar spindle formation (Clarke and Zhang, 
2008; Moore et al., 2002). So if the mono-ADP-ribosylation of Ran prevented GTP-
hydrolysis a delay in mitotic progression might be expected. This suggests that ARTD10 
activity must be tightly regulated. The recognition of Ran by Macro1-3 and Macro3 after 
overexpression of ARTD10 in Figure 33C indicated that Ran was mono-ADP-ribosylated but 
overexpression does usually not represent a physiological status of a cell. For this reason it is 
essential to study mono-ADP-ribosylation of endogenous Ran with physiological levels of 
ARTD10 in the future but therefore a readout for endogenous mono-ADP-ribosylation is 
required. To explore this first step, overexpression of proteins was indispensable and a step 
towards that direction is provided by this work. 
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II.2 ARTD10 is substrate of the acetyltransferase GCN5 
In the first part of this work, a novel reader domain for mono-ADP-ribosylation by ARTD10 
was found and analyzed. In the second part acetylation of ARTD10 was addressed as a 
potential mechanism to regulate ARTD10. ARTD10 was found to play a role in NF-κB 
signaling and in regulating GSK3β activity by our group (Verheugd et al., manuscript 
submitted, Feijs et al., manuscript submitted). We postulate that these activities of ARTD10 
are regulated. However beyond the phosphorylation on threonine T101 by Cyclin E/CDK2 
(Chou et al., 2006), no further evidence has been published describing post-translational 
modification and thus potential regulation of ARTD10 itself.  
 
 
Figure 34: Phosphorylation site prediction for ARTD10 
The scheme depicts potential phosphorylation sites within ARTD10. It was generated with the help of the 
phosphorylation prediction program NetPhos 2.0 (Blom et al., 1999). The positions of the amino acids of 
ARTD10 are marked on the x-axis whereas the phosphorylation potential is indicated on the y axis. Blue lines: 
serines; green lines: threonines; red lines: tyrosines. A standard threshold was chosen. Amino acid sites below 
the threshold are regarded by the program algorithm as unlikely to be phosphorylated. 
 
In a first step to study regulation of ARTD10, PTMs attached to ARTD10 have to be 
determined and analyzed. Phosphorylation constitutes one classical regulator of protein 
activity (Anjum and Blenis, 2008; Cross et al., 1995). A database scanning of ARTD10 for 
potential phosphorylation acceptor amino acids revealed 57 serines, 49 threonines and 13 
tyrosines (Hulo et al., 2006). Thus initially an in silico analysis was performed in order to 
predict how many of these sites might be targeted by kinases. Therefore, several online 
programs were consulted and an exemplary result of the program NetPhos 2 is depicted 
(Figure 34) (Blom et al., 1999). This analysis indicated 37 predicted phosphorylation sites and 
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so ARTD10 has a high potential to be phosphorylated. However, the sequences of these 
putative phosphorylation sites did not match consensus sequences of defined kinases, as 
analyzed by kinase prediction programs like NetPhosK (data not shown). This significantly 
complicates study on phosphorylation. That is why it was decided to focus on another PTM as 
a first approach to investigate ARTD10’s modifications.  
 
 
Figure 35: Lysines in ARTD10 
The scheme of ARTD10 indicates where the 9 lysines (K) are located. Numbers mark the amino acid positions. 
 
Beyond phosphorylation also acetylation is an often-found PTM that modulates enzyme 
activity but also stability and subcellular localization (Hassa et al., 2005; Inuzuka et al., 2012; 
Lin et al., 2012; Patel et al., 2004). ARTD10 possesses only 9 lysines within its 1025 amino 
acids (Figure 35) (Hulo et al., 2006). Applying the prediction of acetylation on internal lysine 
(PAIL) program, which operates with an algorithm that is based on experimentally defined 
acetylation sites, indicated that some of these lysines might be acetylated (Li et al., 2006). The 
highest available threshold was 0.5. Lysine K274 exhibited a particularly high potential for 
being modified by acetylation (Table 2). 
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Table 2: Acetylation site prediction for ARTD10 
The online available PAIL program was used for prediction of potential acetylation sites in ARTD10 (Li et al., 
2006). Sequences from ARTD10 are given, corresponding lysines are marked in red and the amino acid position 
in the protein is indicated. A threshold of 0.5 is regarded as a high stringency threshold by Li et al. Higher scores 
stand for higher likeliness of a position to be an acetylation target. 
Peptide Position Score Threshold
QGPRATKHALLRT 274 2.15 0.5 
  GPVETSKGLLGQE 392 1.62 0.5 
  VSPGCVKLAGQEG 436 1.39 0.5 
 DGGTDGKAQLVVH 706 0.96 0.5 
  LAGQTLKGPWNNL 814 0.69 0.5 
 NATVYGKGVYFAR 916 0.97 0.5 
 PNADGHKAVFVAR 941 1.68 0.5 
 
Hence as a first approach four different abundant acetyltransferases were tested for their 
ability to modify ARTD10 in vitro. 0.3 µg of baculo-purified His-tagged acetyltransferases 
GCN5, P/CAF, CBP and p300 (kindly provided by M. Hottiger) were incubated together with 
0.25 µg of TAP-purified ARTD10 and 0.25 mM acetyl-CoA. An acetylation capacity of His-
tagged GCN5, P/CAF and p300 towards ARTD10 in vitro was documented by Western blot 
analysis with monoclonal acetyl-lysine-specific antibodies (Figure 36A). No signal was 
detectable for His-CBP. Additionally, a signal indicative for His-p300 auto-acetylation was 
observed (Figure 36A). Because the acetyltransferases GCN5 and P/CAF have also been 
reported to directly acetylate c-MYC, an interaction partner of ARTD10 (Patel et al., 2004; 
Yu et al., 2005), these two enzymes were used in the following experiment. Next it was tested 
whether the in vitro data were also reproducible in cells. Therefore U2OS cells were 
transiently co-transfected with plasmids encoding ARTD10 and the indicated tagged 
acetyltransferases (Figure 36B). The cells were treated with the histone deacetylase inhibitors 
trichostatin A (TSA) and nicotinamide (NAM) in order to prevent putative deacetylation prior 
to lysis (Avalos et al., 2005; Bitterman et al., 2002; Yoshida et al., 1995). Cells were lysed in 
RIPA-buffer, which is a stringent lysis buffer containing 1% desoxycholate and 0.1% SDS in 
order to inhibit deacetylases and completely solubilize the nucleus because GCN5 and P/CAF 
activity has been described in the nucleus in most publications (Carrozza et al., 2003; Krebs et 
al., 2011).  
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Figure 36: ARTD10 is acetylated by GCN5 
A. In an in vitro acetylation assay, 0.25 µg of TAP-ARTD10 were incubated together with 0.3 µg of the 
indicated His-tagged HATs and the HAT co-factor acetyl-CoA was added at a concentration of 0.25 mM. After 
this acetylation assay, 60% of the reaction volume was analyzed by SDS-PAGE and a subsequent Western 
blotting. Possible acetylation was analyzed by immunoblotting with monoclonal acetyl-lysine-specific antibodies 
(K103) (top panel). The remaining 40% of the reaction volume was separated in a SDS-PAGE and coomassie 
brilliant blue staining was performed for control (bottom panel). 
B. U2OS cells were transiently co-transfected with the plasmids expressing the indicated proteins and treated 
with 3 µM trichostatin A and 5 mM nicotinamide (NAM) for 5 h prior to cell lysis in Ripa buffer. Afterwards 
immunoprecipitations with ARTD10-directed antibodies (5H11) were performed. The acetylation status of 
ARTD10 was analyzed via SDS-PAGE and Western blotting using acetyl-lysine specific antibodies (K103). The 
biosynthesis of the exogenous proteins was controlled by submitting 5% of the TCL to Western blotting with the 
indicated protein- or tag-specific antibodies. Detection of actin served as loading control for the TCL. 
C. HCT116 cells were transiently co-transfected with plasmids encoding ARTD10 and plasmids for HA-GCN5 
or empty vectors. Cells of the indicated samples were treated with TSA and NAM and the experiment was 
performed as described in panel B with the exception that ARTD10 was immunoprecipitated with polyclonal 
ARTD10-specific antibodies (E09).  
 
The experiments of panel A and B were performed three times with comparable outcome. Data from panel C 
was validated by one further experiment. 
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ARTD10 was immunoprecipitated and its acetylation status was measured via Western blot 
analysis with monoclonal acetyl-lysine-specific antibodies. An acetylation-specific signal was 
observed for ARTD10 immunoprecipitated from cells with exogenous HA-GCN5 and only a 
very weak acetylation-specific signal for ARTD10 immunoprecipitated from cells co-
expressing Flag-P/CAF (Figure 36B). Although ARTD10 protein levels were slightly higher 
in total cell lysates derived from cells co-transfected with an empty control vector than in 
lysates of cells that had been co-transfected with HA-GCN5 or Flag-P/CAF encoding 
plasmids (Figure 36B, TCL), the precipitated ARTD10 protein levels from lysates of HA-
GCN5- or Flag-P/CAF overexpressing cells were even (Figure 36B, IP, second panel). Thus 
GCN5 has the potential to acetylate ARTD10 in vitro and in cells. The capacity of P/CAF to 
modify ARTD10 in cells would require further testing because the signal was very weak. In 
several cases, the substrate specificity of acetyltransferases is described as dependent on the 
differentiation state of cells or controlled by specific signaling (Okumura et al., 2006; Pickard 
et al., 2010). Therefore additional cell types and conditions will have to be analyzed to further 
evaluate an intracellular acetylation of ARTD10 by P/CAF.  
 
Furthermore, an experiment was performed to test the acetylation status of ARTD10 in 
another cell line and to validate the GCN5-specificity of the acetylation signal for ARTD10. 
HCT116 cells were transiently co-transfected with ARTD10-encoding plasmids and HA-
GCN5 encoding plasmids or empty vectors. Also in immunoprecipitations from these cells 
acetylation of ARTD10 could be detected (Figure 36C). ARTD10 was acetylated in cells 
without inhibition of deacetylases if HA-GCN5 was co-expressed as well but not if HA-
GCN5 was not co-expressed, even if cells had been supplemented with deacetylase inhibitors 
(Figure 36C, lanes 1 and 2). It was again and also in general frequently observed that 
ARTD10 protein levels and also levels of several other proteins tested in our group were 
lower upon co-expression of His-GCN5 compared to controls (Figure 36B, Figure 36C, and 
data not shown). The reasons remain to be unraveled. Together these data indicated that the 
acetylation was mediated by His-GCN5 and not by another endogenous acetyltransferase 
because otherwise an acetylation-specific signal for ARTD10 would also have been expected 
from cells transfected with empty vectors and treated with TSA and NAM. On the other hand, 
that implied that endogenous GCN5 did not acetylate ARTD10 in such a quantitative manner 
that it could be visualized by Western blot analysis. The amount of available endogenous 
GCN5 could have been an issue. Additionally, it might be imaginable that ARTD10 is only 
acetylated by endogenous GCN5 at specific stages of the cell cycle or after stimuli triggering 
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certain pathways, which might have been overcome by simply overexpressing GCN5. As an 
example for expanding these in-cell investigations with endogenous GCN5 the experiment 
should also be repeated in other cell lines, which are known to have high levels of GCN5 
protein or in which GCN5 has been demonstrated to be regulated. 
Together these findings suggested also an intracellular GCN5-specific acetylation of ARTD10 
in two different cell lines, which has to be validated with endogenous proteins in the future. 
 
As next step the amino acid(s) in ARTD10 that are targeted by GCN5 were mapped. In vitro 
acetylation assays with purified His-GCN5 on different overlapping GST-tagged fragments of 
ARTD10 were performed in which lower amounts of His-GCN5 were used to increase 
specificity, being at the threshold for detection on polyacrylamide gels stained with coomassie 
brilliant blue. As revealed by acetyl-lysine-specific signals in Western blot analysis, the GST-
fragment containing amino acids 206-459 was modified by His-GCN5 (Figure 37). The other 
proteins on the Western blot that were detected by these acetyl-lysine-specific antibodies were 
most likely breakdown products (Figure 37, lower panel). Since the ARTD10 GST-fragments 
used were partially overlapping, it was concluded that the acetylated amino acid(s) must be 
located between amino acids 256 and 408.  
 
 
Figure 37: GCN5 acetylates an ARTD10 fragment  
In vitro acetylation assays were performed with 0.2 µg of the His-tagged acetyltransferase GCN5 on 0.5 µg of 
the indicated GST-tagged fragments of ARTD10. 60% (v/v) of the reaction volume was analyzed by SDS-PAGE 
and Western blotting with monoclonal acetyl-lysine specific antibodies (K103, top panel). 40% (v/v) of the 
reaction volume was conducted to SDS-PAGE and the gel was subsequently stained with coomassie brilliant 
blue for control (lower panel). Asterisks (*) mark the GST-tagged ARTD10 fragments. 
 
Two further experiments confirmed the result. 
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There are two lysines located within the region of amino acids 256 to 408. Of note, one of 
these is the highly predicted putative acetylation site K274 (Table 2). To identify the site of 
modification, in vitro acetyltransferase assays with His-tagged GCN5 and tandem affinity 
purified full length ARTD10 in the presence (acetylated sample) or absence (non-acetylated 
sample) of the co-factor acetyl-CoA were conducted. The proteins were separated via SDS-
PAGE and the polyacrylamide gel was stained (Figure 38A). Parts of the stained ARTD10-
bands were cut out, proteins digested with trypsin, and the resulting peptides analyzed by 
mass spectrometry (Figure 38B). Mass spectrometry itself was conducted and analyzed by 
Corinna Henkel (Institute of Pathology, RWTH Aachen University). Comparison of spectra 
generated from peptides of the acetylated (green) or non-acetylated (red) samples revealed 
one potential hit (Figure 38B). The green peaks represented a peptide ion of a mass of 
951.565 Da. This mass corresponded to the expected mass of an acetylated ATKacHALLR 
peptide (aa 272-279 of ARTD10). The neighboring green only peaks corresponded to the 
same peptide but having naturally occurring 13C isopes of carbon atoms instead of 12C only 
and thus exhibiting mass differences of 1 Da. The peaks representative of peptide ions of a 
mass of 955.554 Da were found for both samples, thus not indicative of an acetylated peptide. 
The sequence of this peptide is RTLPAELR (aa 744-751 of ARTD10). 
Since the peaks were only present in the spectrum of acetylated and not in the one of non-
acetylated samples, this was indicative for an acetylation of this peptide. This peptide contains 
only one lysine, hinting at an acetylation of lysine K274. That would mean that although the 
analysis was performed on full length ARTD10, the site mapped by mass spectrometry 
matched one of the two lysines in the fragment identified above (Figure 37) and the top hit of 
the PAIL prediction program (Table 2). Thus three types of experiments would point into the 
same direction.  
The possibility of a non-GCN5-specific N-terminal acetylation of this peptide, maybe 
occurring during processing, could not completely be excluded by the experimental data but 
database research revealed lysine acetylation as more likely (data not shown). However, the 
sequence coverage of ARTD10 in this mass spectrometry analysis was 32 – 40% for the 
acetylated and non-acetylated samples (data not shown). Thus up to 68% of ARTD10 
peptides derived by trypsin digestion could not be detected by mass spectrometry. If too few 
arginines or lysines are present in a protein sequence, tryptic digestion mainly generates larger 
peptides that cannot be detected easily by mass spectrometry either. That is the case for parts 
of ARTD10. As an approach to reach a higher coverage in further mass spectrometry analysis, 
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other proteases or combinations of proteases could be used that cleave at other amino acids 
than trypsin and generate other peptides that may be shorter and more suitable for mass 
spectrometry analysis. 
 
          
 
 
Figure 38: Mass spectrometry analysis of an acetylation of ARTD10 by GCN5 
A. An in vitro acetylation assay with 0.6 µg of GCN5 and 1 µg of tandem affinity purified ARTD10 in the 
presence of absence of 0.25 mM acetyl-CoA was conducted. Subsequently, proteins were separated by SDS-
PAGE under mass spectrometry conditions and stained with gel code blue stain (Pierce). Approximately one 
third of the ARTD10 bands were cut out (marked by the boxes), the gel pieces were washed and an in-gel trypsin 
digestion was performed overnight. From that point on, samples were further processed by Corinna Henkel 
(Institute of Pathology, RWTH Aachen University).  
B. A spectrum of the mass spectrometry analysis of the two in panel A described samples is depicted. Values on 
the x-axis give the ratio of mass per charge of the ions. Since in this case the charge of the ions was 1, the values 
correspond to the peptide masses in Dalton. The peaks mark peptides that were detected by the mass 
spectrometer. Green lines are derived from two measurements of ARTD10 that was incubated with GCN5 in the 
presence of acetyl-CoA, red/orange lines originate from two measurements of the ARTD10 sample without 
acetyl-CoA addition. Amino acid sequences corresponding to peptide ions of peaks are given.  
This experiment was performed once. 
 
A 
B 
ATKacHALLR 
RTLPAELR 
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The peptide containing lysine K392 also belonged to these peptides that were not detected. 
Thus it still could not be determined, if only lysine K274 or also K392 are targeted by GCN5. 
To further evauluate this, lysine K274 was mutated to arginine, a non-acetylatable but still 
positively charged amino acid. GST-ARTD10(206-459)-K274R protein was expressed in 
bacteria and included in the in vitro acetylation assays with His-tagged GCN5. Acetylation 
assays with His-GCN5 and wild type GST-ARTD10(206-459) served as a positive control 
whereas the incubation of His-GCN5 together with BSA or acetylation assays with His-GCN5 
and wild type GST-ARTD10(206-459) without addition of acetyl-CoA were used as negative 
controls (Figure 39A). It was indicated by Western blot analysis with monoclonal acetyl-
lysine-specific antibodies that only wild type ARTD10 was acetylated by His-GCN5 and the 
K274R mutant was not. In order to further verify this result, the experiment was repeated but 
the immunodetection was conducted with polyclonal acetyl-lysine specific antibodies (Figure 
39B). Also here an acetyl-lysine-specific signal could be observed for GST-ARTD10(206-
459) but not for the GST-ARTD10(206-459)-K274R mutant.  
 
Figure 39: Lysine K274 is acetylated by GCN5 
A. Acetylation assays were conducted with 0.2 µg of baculo-derived His-tagged GCN5 and 0.5 µg of bacterially 
expressed GST-tagged ARTD10(206-459) or the mutant ARTD10(206-459)-K274R fragments in the presence 
or absence of 0.25 mM of the co-factor acetyl-CoA. Applying BSA or GST-ARTD10(206-459) without acetyl-
CoA to acetylation assays served as negative control. 60% (v/v) of the reaction was subjected to SDS-PAGE and 
Western blotting with monoclonal acetyl-lysine-specific antibodies (K103). 40% (v/v) of the reaction volume 
was used for SDS-PAGE with subsequent coomassie brilliant blue staining to monitor applied protein levels. 
B. Acetylation assays were performed as described in panel A with the exception that polyclonal acetyl-lysine-
specific antibodies were used for Western blot analysis. 
 
The results were confirmed by two further experiments. 
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Additionally, equally intense acetyl-lysine-specific signals for His-GCN5 were generated by 
the polyclonal antibodies indicating even application of His-GCN5 to the assay and auto-
acetylation of His-GCN5. These signals were not observed in the previous experiments 
(compare Figure 37 and Figure 39A) and might be explained by the fact that two different 
antibodies were used. Monoclonal antibodies recognize a single epitope, whereas polyclonal 
antibodies usually recognize multiple epitopes on a single antigen, here acetylated-lysine 
peptides. So it is conceivable that the epitope on acetylated His-GCN5 was too diverse from 
the acetylated peptide, which was used for generating the monoclonal antibody K103 and thus 
autoacetylation of His-GCN5 was only recognized by the polyclonal antibodies. Still the 
monoclonal antibody was suitable for detecting acetylated K274 on ARTD10, which was 
confirmed by the polyclonal antibodies. This data suggested strongly that K274 on ARTD10 
is a target site for GCN5. Acetylation of K392 by GCN5 seems unlikely because neither of 
the antibodies detected acetylation on the GST-ARTD10(206-459)-K274R mutant, which 
contained K392.  
In order to make a statement about potential acetylation of the remaining 7 lysines by GCN5 
further experiments will have to be performed in the future because acetylation assays with 
His-GCN5 on the different ARTD10 GST-fragments (Figure 37) were evaluated by 
immunodetection with the monoclonal acetyl-lysine antibody K103. For testing this, this 
experiment needs to be repeated with polyclonal antibodies. Additionally, this experiment 
could be performed with radioactively labeled acetyl-CoA, which would circumvent any 
antibody recognition issues. 
Acetylation is a wide-spread PTM of proteins contributing to functions like orchestration of 
gene expression by acetylating histones, thereby modulating chromatin structure (Glozak and 
Seto, 2007; Kouzarides, 2000; Struhl, 1998). Also non-histone proteins are subjective of 
acetylation (Bouchard et al., 2001; Kouzarides, 2000). GCN5 is known as a member of the 
multi-protein STAGA complex that is mainly active in the nucleus. However, the apparent 
preference of GCN5 for histones that is obvious when studying the list of publications, might 
also be caused by the fact that acetylation was only investigated in the context of histones for 
a long time (Kouzarides, 2000). The acetylation of the essential transcription factor c-MYC at 
two lysines is an example for a non-histone protein being targeted by GCN5. This 
modification is reported to increase c-MYC’s half-life time (Patel et al., 2004). 
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One question that has to be answered is where and how ARTD10 and GCN5 meet. One 
protein that might establish a connection between ARTD10 and GCN5 is the proto-oncogene 
c-MYC. Heterodimerization of c-MYC with its partner MAX facilitates binding of this 
complex to specific DNA regions called E-boxes, capable of both, promoting activation or 
repression of gene transcription (Lüscher, 2001). The support of transcriptional activation by 
MYC is achieved by recruitment of co-activator complexes like chromatin remodelers and 
also histone acetyltransferases (Amati et al., 2001; Lüscher, 2001; Lüscher and Vervoorts, 
2012). Of note, one of these histone acetyltransferases interacting with c-MYC and being 
targeted to specific genes is GCN5. This is mediated via the transformation/transcription 
domain-associated protein (TRRAP), a component of the eukaryotic STAGA complex 
(McMahon et al., 2000; Nagy and Tora, 2007; Park et al., 2001). In summary, c-MYC recruits 
the STAGA complex to specific genes resulting in histone acetylation and facilitation of 
transcription and is also subject of acetylation by GCN5 itself (Patel et al., 2004). 
Consequently a close connection between these two proteins is implied. Importantly, 
ARTD10 shuttles between the nucleus and the cytoplasm and was demonstrated to interact 
with c-MYC (Kleine et al., 2012; Yu et al., 2005). Accordingly as one possibility, GCN5 and 
ARTD10 might come into close proximity by both associating with c-MYC. However, only a 
few further direct interaction partners of ARTD10 have been identified beyond c-MYC so far. 
These are the poly-ubiquitin receptor p62 (Kleine et al., 2012) and also NEMO (Verheugd et 
al, manuscript submitted). More than these may exist and some may be capable of mediating 
the connection to GCN5 instead of c-MYC. This is in accordance with the general idea of 
GCN5 and STAGA complexes to make contact to substrates through distinct complex 
subunits (Baker and Grant, 2007). So far it revealed to be difficult to define consensus 
sequences recognized by HATs itself (Roth et al., 2001) like it is well known for example in 
the field of kinases. For HATs like GCN5 it was reported that 3-5 residues upstream and 
downstream of the lysine are important for binding (Berndsen and Denu, 2008). However, the 
sequence GKxxP was found as only a weak motif for GCN5 (Roth et al., 2001) and is distinct 
from the sequence identified in ARTD10. This also supports the idea that other GCN5 
complex components might be responsible for targeting it to ARTD10, which does not 
necessarily have to happen in the nucleus according to Conacci-Sorell et al. because they 
reported the presence of GCN5 also in the cytoplasm (Conacci-Sorrell et al., 2010). Possible 
interactions could be tested by in vitro pulldown assays with ARTD10 and members of the 
STAGA complex. Also, ARTD10 could be immunoprecipitated from HCT116 or U2OS cell 
lysates after treatment of these cells with the deacetylase inhibitors and subsequently mass 
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spectrometry could be performed in order to identify potential co-immunoprecipitated 
interaction partners that might be involved in the acetylation process.  
Additionally, the identification of the corresponding histone deacetylase to remove the 
acetylation should be addressed in the future. As a first attempt, cells could be transfected 
with plasmids encoding ARTD10 and GCN5 but not only be treated with the combination of 
TSA and NAM but with either one or the other and subsequently immunoprecipitations and 
Western blot analysis with acetyl-lysine-specific antibodies could be performed. Since TSA 
specifically inhibits HDACs (Furumai et al., 2001), and NAM targets sirtuins, class III 
enzymes of HDACs (Avalos et al., 2005; Bitterman et al., 2002), differences in the ARTD10 
acetylation status could shed light on the class of the responsible antagonist of GCN5. 
Also the effect of this acetylation on ARTD10 will need further investigation in the future. 
The part of ARTD10 where the acetylation is located is distant to the catalytic domain of 
ARTD10 in the primary structure. This might imply that the catalytic activity is not 
influenced. Nevertheless it must be kept in mind that no crystal structure of the full length 
ARTD10 exists. Thus it is not known whether the N-terminal part harboring the acetylation 
site can come into proximity of the C-terminus with the catalytic domain in the tertiary 
structure. Consequently, it would be worth testing the influence of the acetylation on the 
catalytic activity in further experiments. Due to time limits this was not in the scope of this 
work. Also enhancement of the protein stability of ARTD10 is imaginable as it was described 
for c-MYC after acetylation by GCN5 (Patel et al., 2004). 
Furthermore, the acetylation site was found seven amino acids upstream of the glycine rich 
region. Strikingly, glycine rich regions are often reported in the context of RRMs in plants 
and cyanobacteria in glycine-rich RNA-binding proteins (GRPs). The genes encoding this 
domain combination, i.e. a glycine-rich domain and an RRM, are usually induced at low 
temperatures (Gendra et al., 2004; Maruyama et al., 1999; Vermel et al., 2002). Also in 
humans the two cold-inducible RNA binding proteins, RNA binding motif protein 3 (RBM3) 
and cold-inducible RNA binding protein (CIRP) have been reported. They also combine 
RNA-binding motifs with glycine-rich domains and are typically involved in RNA 
metabolism upon mild cold-shocks and other cellular stress (Derry et al., 1995; Lleonart, 
2010). Moreover, RRMs are implicated in the control of alternative splicing, general 
translation control under normal cell conditions and bind both, nucleic acids and proteins 
(Nilsson et al., 2007; Trzcińska-Daneluti et al., 2007; Tsuda et al., 2011). Neither deeper 
RESULTS AND DISCUSSION 
100 
analysis of the function of the RRM nor any contribution of the glycine-rich region have been 
studied or described for ARTD10 so far. Recently ARTD10 was discovered to induce 
apoptosis and both, the catalytic activity and the RRM were essentially required suggesting 
functionality of the RRM in ARTD10 (Herzog et al., manuscript submitted). Additionally, 
ARTD10 binds RNA via its RRM (B. Lippok and B.Lüscher, unpublished observation). It 
remains to be unraveled whether the RRM targets ARTD10 to its substrates by binding to 
associated RNAs and if the glycine-rich region makes contributions. Considering the above 
entiteled publications, cooperation between the glycine-rich region and the RRM function in 
ARTD10 is possible. Thus an acetylation located between these two domains, directly 
neighboring the glycine-rich region, might affect RNA or substrate binding by ARTD10. 
However before testing this speculative hypothesis, the function of the RRM in ARTD10 has 
to be determined.  
Also considering the described acetylation status of other members of the ARTD family might 
be insightful. ARTD1 is documented to co-activate NF-κB target genes, independently of its 
PARylation capacity, by interacting with components of the mediator complex and with the 
NF-κB subunits p50 and p65. ARTD1’s acetylation by p300/CBP plays a crucial role in their 
process (Hassa et al., 2001; Hassa et al., 2005). These acetylations can be prevented by 
previous sumoylation at lysine K486 that results in reduced co-activator function and 
indicates a cross-talk between these PTMs (Messner et al., 2009). Such cross-talk could also 
be imagined for the acetylation site of ARTD10 because directly adjacent is a threonine, 
which is a potential phosphorylation site. In a first mass spectrometry attempt to identify 
phosphorylation sites on ARTD10, this threonine was found to be phosphorylated (K. Jurcic 
and A. Forst, unpublished findings). No responsible kinase could be identified so far for this 
site, which is the reason why the site could not be validated by in vitro kinase assays. 
ARTD10 is also phosphorylated by inhibitor of NF-κB kinase epsilon (IKK) at at least two 
so far unmapped sites between aa 206 and 459 (Verheugd, Ph.D. thesis) These modifications 
could be involved in the postulated cross-talk and regulation of ARTD10. This has to be taken 
into consideration for further studies of the GCN5 mediated acetylation of ARTD10. 
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III Conclusions and perspectives 
 
The mono-ADP-ribosylation of ARTD10 is read by Artd8 macrodomains 
 
In this work the finding of novel functions for macrodomains, an old domain type, is 
documented. ARTD7-17 are novel putative or validated intracellular mono-ADP-
ribosyltransferases of the ARTD family (Kleine et al., 2008) and this modification lacks 
reader domains. In this work, several lines of evidence could be established that support the 
existence of such domains. They were found in a protein that is also related to mono-ADP-
ribosylation. Macro2 and Macro3 of Artd8 are shown here to interact with ARTD10 and also 
with its tested mono-ADP-ribosylated substrates. This characterization included in vitro 
experiments demonstrating the direct and specific interaction of these domains with 
automodified ARTD10 as well as with the substrate proteins Ran-GTP, NEMO and GSK3β. 
Mono-ADP-ribosylation was essential for this interaction. In cells, Macro2, Macro3 and 
especially Macro1-3 co-localized with active ARTD10 and they also interacted as 
demonstrated by co-immunoprecipiations. The demonstration that transient expression of 
MacroD2, a novel hydrolyzer of the ADPr-ARTD10 bond (Rosenthal et al., manuscript 
submitted), interfered with the interaction between ARTD10 and Macro1-3 confirmed that 
also in cells mono-ADP-ribosylation was an essential prerequisite for association. As a major 
concern, contributions of PAR-polymer forming enzymes to the observed interactions, 
especially of ARTD1 as the main synthesizer of PAR in cells, could be excluded by several 
experiments. Consequently this work demonstrates for the first time that macrodomains of 
Artd8 can read mono-ADP-ribosylation mediated by the founding member of novel mono-
ADP-ribosyltransferases, ARTD10, which can be expaneded into developing these domains 
to serve as an antibody-like tool specific for ARTD10-dependent mono-ADP-ribosylation in 
future work. Furthermore this work demonstrates that ARTD10 is actually active in cells and 
automodifies as well as modifies substrates like Ran-GTP. Strikingly, Macro1 of Artd8 
exhibited significantly reduced affinity for free ADPr and did not interact with mono-ADP-
ribosylated ARTD10 in all experiments except for one. Thus macrodomains of Artd8 do not 
appear to be completely redundant concerning their function. 
The identification of a new function for a subset of macrodomains illustrates the importance 
of this domain type in the field of ADP-ribosylation. Although having a structurally similar 
and conserved catalytic core at first sight (Chen et al., 2011; Karras et al., 2005), they more 
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and more reveal to be highly specialized. On one hand there are macrodomains as readers of 
PARylation (Timinszky et al., 2009) and as demonstrated by this work, others are able to read 
mono-ADP-ribosylation. On the other hand other types of macrodomains have been reported 
that exhibit catalytic cleavage activity, either towards PAR (Slade et al., 2011), OAADPr 
(Chen et al., 2011) or mono-ADP-ribosylation attached to proteins (Rosenthal et al., 
manuscript submitted). Of note, cleavage activity of MacroD2 for example has been described 
towards both, OAADPr (Chen et al., 2011) and mono-ADP-ribose on proteins (Rosenthal et 
al., manuscript submitted), implying that hydrolyzing activity of certain macrodomains may 
not be limited to a single type of substrate. Conversely, for the investigated reader-
macrodomains in this work, either mono- or poly-ADP-ribose binding was noted. A 
schematic summary of described functions for macrodomains is provided by Figure 40. 
 
Figure 40: Summary of macrodomain functions 
A schematic representation of different functions of macrodomain types is illustrated. Representatives for each 
domain type are indicated. (1) PAR binding modules. (2)  Binding modules for mono-ADP-ribosylation by 
ARTD10. (3) Macrodomains removing ADPr attached to substrates. (4) PARG, reported to possess a 
macrodomain-like catalytic center cleaving ribose-ribose bonds of PAR. (5) Macrodomains cleaving OAADPr to 
ADPr and acetate. (6) As a common feature, all macrodomains bind free ADPr. 
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Although the biological relevance of macrodomains of Artd8 being recruited to modified 
ARTD10 substrates is still unclear, the discovery of a possible tool to monitor mono-ADP-
ribosylation enables future investigations of intracellular mono-ADP-ribosylation by the 
ARTD family Therefore improvements of Macro2 and 3 by mutagenesis may be 
advantageous for increasing sensitivity for substrates. Finally we are now one step closer to 
the long-term objective of analyzing intracellular mono-ADP-ribosylation by ARTD10 as a so 
far poorly described PTM. A role of ARTD10 in signaling has been proposed by our group 
because ARTD10 modifies GSK3β and thereby impairs its kinase activity (Rosenthal et al., 
manuscript submitted, Feijs et al., manuscript submitted) or mono-ADP-ribosylates NEMO, a 
component of the NF-κB signaling pathway (Verheugd et al., manuscript submitted). Beyond 
that, a set of further kinases, like Aurora kinase A and Polo-like kinase 1, was identified by in 
vitro substrate screens (Feijs et al., manuscript submitted) and Macro2 and 3 of Artd8 may 
serve well for validating these in vitro results in cells and assist in investigating the effect of 
mono-ADP-ribosylation on these kinases. 
 
ARTD10 is substrate of the acetyltransferase GCN5 
Besides being an enzyme transferring PTMs onto its substrates, ARTD10 itself is subject of 
PTMs as demonstrated by the second part of this work. As a first step towards studying the 
activation and/or regulation of ARTD10, it was discovered that ARTD10 is acetylated in vitro 
and in cells, and lysine K274 could be mapped as an acetylation acceptor site. The responsible 
acetyltransferase is GCN5. In future studies it will be interesting to see which impact this 
acetylation has on ARTD10 concerning its catalytic activity, target specificity, protein 
stability and function in general. Regarding the localization of this acetylation site, a putative 
influence on the function of the RRM, eventually in combination with the glycine-rich region 
could be conceivable and interesting. Beyond that, the identification of the responsible 
deacetylase and the time point when the acetylation is mediated will be important to be 
unraveled in future studies. Additionally, there is still need to examine further PTMs on 
ARTD10 that regulate its activtiy. Being able to stimulate ARTD10 activity in cells in 
combination with a method to analyze enzymatic mono-ADP-ribosylation activity by usage of 
the here identified reader domains would provide considerable advancement for investigation 
of the above mentioned role of ARTD10 in intracellular signaling. 
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IV Experimental procedures 
 
Materials and Methods are described according to standard protocols used in the Institute of 
Biochemistry and Molecular Biology, RWTH Aachen University, and modified regarding 
individual differences in experimental procedures. 
IV.1 Consumables and Reagents 
IV.1.1 Consumables 
Consumables were purchased from:  
Amersham Biosciences, Ansell, Becton Dickinson, Biometra, Bio-Rad, Brand, Braun, 
Corning, Costar, Eppendorf, Falcon, Fisher Scientific, Fuji, Greiner, Kimberlex-Clark, Merck, 
Millipore, Nalgene, Nerbe Plus, Nunc, Roth, Sarstedt, Sartorius, Schleicher&Schuell, 
Stratagene, TPP, VWR 
IV.1.2 Reagents 
Reagents, with a purity of at least analytical grade, were obtained from: 
Abcam, AbD Serotec, Applichem, BD Biosciences, Biozym, Calbiochem, Cellsignaling, 
Clontech, Difco, Eurogentec, Fermentas, Fluka, GE Healthcare, Hoechst, Gibco, Invitrogen, 
InvivoGen, Jackson Immuno Research, Macherey&Nagel, MBL, Merck, MP Biomedicals, 
New England Biolabs, Novagen, Perkin Elmer, Pierce, Promega, Qiagen, Rockland, Roche, 
Roth, Sigma Aldrich, Stratagene, Tulip Biolabs, Zymo Research 
 
IV.2 Antibodies 
 
Antigen  Description 
α-acetyl-lysine K103 Monoclonal Immunglobulin (IgG)2a antibodies generated 
against a synthetic peptide containing acetylated lysine (clone 
AC-K-103, Cellsignaling). 
α-acetyl-lysine Polyclonal rabbit antibody serum immunized against synthetic 
peptides with acetylated lysines (9441, Cellsignaling)  
α-Actin  Monoclonal IgG1 antibodies derived from mice, recognizing an 
epitope that is conserved across species (clone C4, MP 
Biomedicals). 
α-PARP1 (ARTD1) Polyclonal antibody serum generated against baculo-derived 
full length recombinant ARTD1 (1835238, Roche).  
α-ARTD10 5H11 Rat monoclonal IgG antibodies raised against amino acids 300-
350 of recombinant human GST-ARTD10 (clone 5H11, 
Elisabeth Kremmer). 
α-ARTD10 E09 Polyclonal rabbit antibody serum recognizing epitopes in 
aa206-459 of recombinant human GST-ARTD10 (clone E09, 
custom made by Eurogentec). 
α-Flag  This is an IgG1 mouse monoclonal antibody generated against a 
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synthetic Flag peptide (DYKDDDDK) (clone M2, 
Sigmaaldrich). 
α-GAPDH Mouse monoclonal IgG1 antibodies generated against human 
cardiac muscle GADPH (clone 4G5, AbD Serotec). 
α-GFP Monoclonal mouse IgG1 antibodies generated against the full 
length amino acid sequence of GFP (246 aa) from the jellyfish 
Aequorea Victoria (clone 9F9, Rockland). 
α-GFP (JM-3999-100) Polyclonal IgG antiserum from rabbits generated against GFP 
protein from the jellyfish Aequorea Victoria. It recognizes GFP 
as well as derivatives like ECFP (JM-3999-100, MBL). 
α-GSK3β Polyclonal rabbit antibodies against amino acids 345-420 of 
human GSK3β (H-76, Santa Cruz). 
α-GST Monoclonal mouse antibodies generated against recombinant 
GST (clone 2C8, Elisabeth Kremmer). 
α-HA Monoclonal IgG1 antibodies derived from a rat that was 
immunized with a HA peptide (YPYDVPDYA) from influenza 
hemagglutinin (HA) protein, (clone 3F10, Roche). 
α-IKKγ (NEMO) Polyclonal antiserum from rabbit generated against a synthetical 
peptide containing the c-terminus of NEMO (2685, 
Cellsignaling). 
α-mouse IgG (H+L) 
conjugated to Alexa 
Fluor® 488 
Secondary antibodies raised in goat recognizing IgG mouse 
antibodies. The antibodyies are coupled to the fluorescent dye 
Alexa Fluor® 488 (A-11001, Invitrogen). 
α-mouse IgG + IgM 
(H+L) conjugated to 
horseradish peroxidase 
(HRP) 
Secondary antibodies raised in goat recognizing heavy and light 
chains of IgG and IgM antibodies from mice (115-035-068, 
Jackson Immuno Research). 
α-PAR Mouse monoclonal IgG3 antibodies generated against purified 
poly-ADP-ribose (clone 10H, Tulip Biolabs) 
α-Ran  Mouse monoclonal IgG2b antibodies raised against amino acids 
207-216 from human denatured recombinant protein (clone 
ARAN1, Abcam). 
α-rabbit IgG (H+L) 
conjugated to Alexa 
Fluor® 555  
Secondary antibodies raised in goat recognizing IgG rabbit 
antibodies. The antibodyies are coupled to the fluorescent dye 
Alexa Fluor® 555 (A-21428, Invitrogen). 
α-rabbit IgG (H+L) 
conjugated to HRP  
Secondary antibody raised in goat recognizing heavy and light 
chains of IgG antibodies from rabbits (111-035-144, Jackson 
Immuno Research). 
α-rat IgG (H+L) 
conjugated to Alexa 
Fluor® 555  
Secondary antibodies raised in goat recognizing IgG rat 
antibodies. The antibodies are coupled to the fluorescent dye 
Alexa Fluor® 555 (A-21434, Invitrogen). 
α-rat IgG + IgM (H+L) 
conjugated to HRP 
Secondary antibodies raised in goat recognizing heavy and light 
chains of IgG and IgM antibodies from rats (112-035-068, 
Jackson Immuno Research). 
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IV.3 Oligonucleotides 
Oligonucleotides were purchased from MWG Biotech or Sigma Aldrich, Germany. 
Sequences are indicated in 5’-3’ direction. 
Name Sequence 
2_G1055E_for 
 
GGATCTTAAACTCAACAAAAACCCCTTTCTCAGGC 
 
2_G1055E_rev 
 
GCCTGAGAAAGGGGTTCTTGTTGAGTTTAAGATCC 
 
attB1_mP14_Macro2 
 
GGGGACAAGTTTGTACAAAAAAGCAGGCTCCCCCCAG
AAACAGGGCAGTCTGCTG 
 
attB2_mP14_Macro2 
 
GGGGACCACTTTGTACAAGAAAGCTGGGTCTTATCCAT
TATTTCTCTTGTCAAATTC 
 
attB1_mP14_Macro3 
 
GGGGACAAGTTTGTACAAAAAAGCAGGCTCCAGCCCT
ACTTTAGGAATGCATGAA 
 
attB2-PARP14 
 
GGGGACCACTTTGTACAAGAAAGCTGGGTCTTAGGTGT
AAGGACACTGTT 
 
PARP10_K274R_for 
 
GGCCTAGGGCTACCAGGCATGCTCTCCT 
 
 
PARP10_K274R_rev 
 
AGGAGAGCATGCCTGGTAGCCCTAGGCC 
 
 
IV.4 Plasmids 
IV.4.1 Gateway-System Entry vectors 
Name of vector Description 
pDONR/Zeo This is a vector designed for the Gateway cloning system. It 
carries attP1 and attP2 sites, which flank the negative selective 
ccdB cDNA. Further features are M13 priming sites for forward 
and reverse sequencing as well as a zeocin resistance gene under 
control of an EM7 promotor allowing the selection in Escherichia 
coli (E. coli) DH5. This vector is constructed for the 
recombination of attB-PCR products into the sequence that is 
flanked by the attP1 and attP2 sites. Thereby, the negative 
selection marker cDNA ccdB is replaced and bacteria transformed 
with this vector can grow on agar plates containing zeocin  
(Invitrogen). 
pDONR/Zeo-Artd8-
Macro1 
This is an entry vector that was generated by a Gateway BP-
reaction (BP-reaction) with pDONR/Zeo and an attB-PCR product 
encoding aa 802-989 of murine Artd8 (H. Kleine). 
pDONR/Zeo-Artd8-
Macro2 
 
This is an entry vector that was created by a BP-reaction with 
pDONR/Zeo and an attB-PCR product encoding aa 1012-1204 of 
murine Artd8 using the primers attB1_mP14_Macro2 and 
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attB2_mP14_Macro2 (A. Forst). 
pDONR/Zeo-Artd8-
Macro2-G1055E 
This is an entry vector that was generated by site directed 
mutagenesis of the vector pDONR/Zeo-Artd8-Macro2 using the 
primers 2_G1055E_for and 2_G1055E_rev (A. Forst). 
pDONR/Zeo-Artd8- 
Macro3 
This is an entry vector that was obtained by a BP-reaction with 
pDONR/Zeo and an attB-PCR product encoding aa 1225-1399 of 
murine Artd8 (A. Forst). 
pDONR/Zeo-Artd8-
Macro1-3 
This is an entry vector that was designed by a BP-reaction with 
pDONR/Zeo and an attB-PCR product encoding aa 802-1399 of 
murine Artd8 (H. Kleine). 
pDONR/Zeo-
macroH2A1.1(162-369) 
This is an entry vector that was generated by a BP-reaction with 
pDONR/Zeo and an attB-PCR product encoding aa 162-369 of 
isoform 1 of the murine histone variant macroH2A1.1 (H. Kleine). 
pDONR/Zeo-
macroH2A1.1(162-369)- 
G224E/F348A 
This is an entry vector that was obtained by a BP-reaction with 
pDONR/Zeo and an attB-PCR product encoding aa 162-369 of 
isoform 1 of the murine histone variant macroH2A1.1. 
Additionally, glycine 224 was mutated to glutamate and 
phenylalanine 348 to alanine by site directed mutagenesis (H. 
Kleine). 
pDONR/Zeo-Artd8-WWE This is an entry vector that was created by a BP-reaction with 
pDONR/Zeo and an attB-PCR product encoding aa 1539-1617 of 
murine Artd8 (H. Kleine). 
pDONR/Zeo-ARTD10 This is an entry vector that was generated by a BP-reaction with 
pDONR/Zeo and an attB-PCR product encoding aa 1-1025 of 
human ARTD10 (H. Kleine). 
 
IV.4.2 Prokaryotic expression vectors 
 
Name of vector Description
pDEST17 Bacterial expression vector with attR1 and attR2 sites, which 
flank the Gateway cassette encoding for a chloramphenicol 
resistance cDNA and a ccdB cDNA (Invitrogen). Upon a LR 
reaction with a Gateway Entry vector carrying the gene of 
interest, this cassette is replaced by the cDNA of interest. 
Additionally, the vector encodes a hexahistidine-tag (His-tag), 
which is in frame with the cDNA of interest (N-terminus) after 
the LR reaction and enables His-tagged protein purifications. 
The cDNA expression is under the control of a T7 promoter.  
pDEST17-Artd8 Macro1 Bacterial expression vector encoding a His-Macro1 fusion 
protein derived from a Gateway LR-reaction (LR-reaction) with 
the entry vector pDONR/Zeo-Artd8-Macro1 and pDEST17 (A. 
Forst) 
pDEST17- Artd8 Macro2 Bacterial expression vector encoding a His-Macro2 fusion 
protein derived from a LR-reaction with the entry vector 
pDONR/Zeo-Artd8-Macro2 and pDEST17 (A. Forst) 
pDEST17-Artd8 Macro2-
G1055E 
Bacterial expression vector encoding a His-Macro2-G1055E 
fusion protein derived from a LR-reaction with the entry vector 
pDONR/Zeo-Artd8-Macro2-G1055E and pDEST17 (A. Forst) 
pDEST17-Artd8 Macro3 Bacterial expression vector encoding a His-Macro3 fusion 
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protein derived from a LR-reaction with the entry vector 
pDONR/Zeo-Artd8-Macro3 and pDEST17 (A. Forst) 
pDEST17-Artd8 Macro1-
3 
Bacterial expression vector encoding a His-Macro1-3 fusion 
protein derived from a LR-reaction with the entry vector 
pDONR/Zeo-Artd8-Macro1-3 and pDEST17 (A.Forst) 
GW-pGEX4T2 This is a bacterial vector for N-terminal GST-fusion protein 
expression, which is controlled by a Ptac promotor. Furthermore 
the vector carries M13 priming sites for forward and reverse 
sequencing, an ampicillin resistance cDNA and a lacI repressor 
gene. This enables induction of GST-fusion protein expression 
after transformation in E. coli BL21 bacteria and isopropyl-β-D-
1-thiogalacopyranoside (IPTG) supplementation (Amersham). 
A gateway cassette with attR1 and attR2 sites, which flank a 
chloramphenicol resistance and a ccdB cDNA was introduced 
into the vector, allowing Gateway cloning (R. Lilischkis). 
GW-pGEX4T2-Artd8 
Macro1 
Bacterial expression vector encoding a GST-Macro1 fusion 
protein generated by a LR-reaction using the entry vector 
pDONR/Zeo-Artd8-Macro1 and GW-pGEX4T2 (H. Kleine) 
GW-pGEX4T2-Artd8 
Macro2 
Bacterial expression vector encoding a GST-Macro2 fusion 
protein generated by a LR-reaction using the entry vector 
pDONR/Zeo-Artd8-Macro2 and GW-pGEX4T2 (A. Forst) 
GW-pGEX4T2-Artd8 
Macro3 
Bacterial expression vector encoding a GST-Macro3 fusion 
protein generated by a LR-reaction using the entry vector 
pDONR/Zeo-Artd8-Macro3 and GW-pGEX4T2  (A. Forst) 
GW-pGEX4T2-Artd8 
Macro1-3 
Bacterial expression vector encoding a GST-Macro1-3 fusion 
protein generated by a LR-reaction using the entry vector 
pDONR/Zeo-Artd8-Macro1-3 and GW-pGEX4T2 (H. Kleine) 
GW-pGEX4T2-
macroH2A1.1(162-369) 
Bacterial expression vector encoding a GST-
macroH2A1.1(aa162-369) fusion protein generated by a LR-
reaction using the entry vector pDONR/Zeo-macroH2A1.1(162-
369) and GW-pGEX4T2 (H.Kleine) 
GW-pGEX4T2-
macroH2A1.1(162-369) -
G224E/F348A 
Bacterial expression vector encoding a GST-
macroH2A1.1(162-369) G224E/F348A fusion protein 
generated by a LR-reaction using the entry vector pDONR/Zeo-
macroH2A1.1(162-369)-G224E/F348A and GW-pGEX4T2 
(H.Kleine) 
GW-pGEX-Artd8-WWE Bacterial expression vector encoding a GST-WWE fusion 
protein generated by a LR-reaction using the entry vector 
pDONR/Zeo-Artd8-WWE and GW-pGEX4T2 (H.Kleine) 
pNIC28-Bsa4 This is a bacterial pET vector for expression of  aHis-tag fusion 
protein under a T7 promoter controlled by a lac operator. The 
His-tag is integrated into an N-terminal, 22 aa fusion peptide 
including a TEV-cleavage site. The vector is designed for LIC-
cloning, whereby the negative selection SacB gene is removed 
(Novagen). 
pNIC28-Bsa4- ARTD8 -
Macro1 
Bacterial vector encoding aa 784-984 of ARTD8 as N-
terminally His--fusion protein (kindly provided by H.Schüler) 
pNIC28-Bsa4- ARTD8 -
Macro2 
Bacterial vector encoding aa 994-1196 of ARTD8 as N-
terminally His--fusion protein (kindly provided by H.Schüler) 
pNIC28-Bsa4- ARTD8 - Bacterial vector encoding aa 1208-1388 of ARTD8 as N-
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Macro3 terminally His--fusion protein (kindly provided by H.Schüler) 
pNIC28-Bsa4- ARTD8 -
Macro1-3 
Bacterial vector encoding aa 794-1388 of ARTD8 as N-
terminally His--fusion protein (kindly provided by H.Schüler) 
pNIC28-Bsa4- ARTD8 -
Macro2+3 
Bacterial vector encoding aa 994-1388 of ARTD8 as N-
terminally His--fusion proteins (kindly provided by H.Schüler) 
pETM-33-His-GST-
MacroD2 sh 
Bacterial expression vector encoding the macrodomain of 
human MacroD2, equipped with N-terminal His- and GST-tags 
(kindly provided by M.Hottiger) 
 
IV.4.3 Eukaryotic expression vectors 
 
Name of vector Description 
GW-pEGFP  This is a eukaryotic expression vector designed for generating 
fusion proteins carrying an N-terminal EGFP-tag. The cDNA of 
interest expression is controlled by a constitutive CMV promoter 
(Clontech). Furthermore, a Gateway cassette with attR1 and 
attR2 sites, which flank a chloramphenicol resistance and a ccdB 
cDNA, was introduced into the vector, allowing Gateway 
cloning by LR reactions (H. Kleine). 
GW-pEGFP-Artd8-
Macro1 
This is a eukaryotic expression vector encoding an EGFP-
Macro1 fusion protein generated by a LR-reaction using the 
entry vector pDONR/Zeo-Artd8-Macro1 and the destination 
vector GW-pEGFP (A. Forst). 
GW-pEGFP-Artd8-
Macro2 
This is a eukaryotic expression vector encoding an EGFP-
Macro2 fusion protein generated by a LR-reaction using the 
entry vector pDONR/Zeo-Artd8-Macro2 and the destination 
vector GW-pEGFP (A. Forst). 
GW-pEGFP-Artd8-
Macro2-G1055E 
This is a eukaryotic expression vector encoding an EGFP-
Macro2-G1055E fusion protein generated by a LR-reaction 
using the entry vector pDONR/Zeo-Artd8-Macro2-G1055E and 
the destination vector GW-pEGFP (A. Forst). 
GW-pEGFP-Artd8-
Macro3 
This is a eukaryotic expression vector encoding an EGFP-
Macro3 fusion protein generated by a LR-reaction using the 
entry vector pDONR/Zeo-Artd8-Macro3 and the destination 
vector GW-pEGFP (A. Forst). 
GW-pEGFP-Artd8-
Macro1-3 
This is a eukaryotic expression vector encoding an EGFP-
Macro1-3 fusion protein generated by a LR-reaction using the 
entry vector pDONR/Zeo-Artd8-Macro1-3 and the destination 
vector GW-pEGFP (A. Forst). 
GW-pECFP This is a eukaryotic expression vector designed for generating 
fluorescently labeled fusion proteins carrying an N-terminal 
ECFP-tag. The cDNA of interest expression is controlled by a 
constitutive CMV promoter (Clontech). Also, a Gateway cassette 
with attR1 and attR2 sites encompassing a chloramphenicol 
resistance and ccdB cDNA was introduced into the vector, 
allowing Gateway cloning by LR- Reactions (H. Kleine). 
GW-pECFP-
macroH2A1.1(162-369) 
This is a eukaryotic expression vector encoding aa 162-369 of 
macroH2A1.1 as ECPF-fusion protein generated by LR-
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 reaction using the entry vector pDONR/Zeo-mH2A1.1(162-
369) and the destination vector GW-pECFP (H. Kleine) . 
GW-pECFP-
macroH2A1.1(162-369)-
G224E/F348A  
This is a eukaryotic expression vector encoding a ECFP-
mH2A1.1(162-369)-G224E/F348A fusion protein generated by 
LR-reaction using the entry vector pDONR/Zeo-mH2A1.1(162-
369)-G224E/F348A and the destination vector GW-pECFP (H. 
Kleine). 
pEVRFO-HA This is a eukaryotic expression vector enabling expression of N-
terminally HA-tagged proteins under a CMV promoter/ 
enhancer. Additionally the vector has splicing and 
polyadenylation signals of the β-globin gene (rabbit) and a SV40 
origin of replication. 
pEVRFO-HA-ARTD10 This is a eukaryotic expression vector encoding the full-length 
human ARTD10 (aa 1-1025) cDNA with an N-terminal HA-tag. 
It was generated by ligating ARTD10 from pSport-p150 into the 
multiple cloning site of pEVRFO-HA (S. Schreek). 
pEVRFO-HA-ARTD10-
G888W 
This vector was generated from pEVRFO-HA-ARTD10 by site 
directed mutagenesis (E. Poreba). 
pEVRFO-HA-MacroD2 
iso1 
This is a eukaryotic expression vector that was created by 
ligating the cDNA of isoform 1 of human MacroD2 from 
pEGFP-MacroD2 iso1 (kindly provided by M.Hottiger), digested 
with BamHI and XbaI followed by Klenow fill-in, into 
pEVRFO-HA, digested with SmaI (N. Herzog). 
pcDNA5/FRT/TO This is a eukaryotic expression vector, driven by a CMV/ TetO2 
promoter, which was designed for usage with the Flp-In T-REx 
system (Invitrogen). Thus the sequence of the Tet operator was 
introduced twice into this vector. Upon co-transfection with 
plasmids encoding the Flp recombinase it stably integrates into a 
FRT site, which is inserted into the genome of Flp-In T-REx 
cells. The vector contains the eukaryotic selection marker 
hygromycine resistance cDNA. Expression of the cDNA of 
interest in Flp-In T-REx cells or other cells expressing a Tet 
repressor has to be induced by doxycycline supplementation. 
However in all other cell lines the cDNA of interest is 
constitutively expressed by the CMV promoter (Invitrogen). 
Further features of the vector are a BGH polyadenylation signal 
and a BGH reverse priming site.  
GW-pcDNA5/FRT/TO  The pcDNA5/FRT/TO was equipped with the Gateway cloning 
cassette frame A enabling gateway cloning. The parental vector 
pcDNA5/FTO/TO (Invitrogen) was digested with HindIII and a 
Klenow fill in was performed. The Gateway cassette was 
digested with EcoRV and ligated into the parental vector (A. 
Forst). 
pcDNA5/FRT/TO/ARTD
10 
This vector was generated by cloning the cDNA encoding full 
length human ARTD10, digested with KpnI and XbaI followed 
by a Klenow fill in, into the vector pcDNA5/FRT/TO, which 
was treated with KpnI and EcoRV beforehand (N. Herzog). 
GW-pcDNA5/FRT/TO/ 
ARTD10-K274R 
This is a eukaryotic expression vector encoding a ARTD10-
K274R protein derived from a LR-reaction by usage of the entry 
vector pDONR/ Zeo-ARTD10-K274 and the destination vector 
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GW-pcDNA5/FRT/TO (A.Forst).  
pEQ176P2 This is a mammalian expression vector that was derived from the 
parental vector pEQ176, carrying the bacterial β–galactosidase 
cDNA. In pEQ176P2 the majority of this cDNA was deleted by 
enzymatic digestion with PvuII and subsequent relegation 
(Firzlaff et al., 1991). This vector was used to fill up transient 
transfections to apply equal amounts of DNA for each 
transfected samples, if the corresponding backbone vector of the 
transfected plasmids was not availabe. 
pCX-Flag-P/CAF This is a mammalian expression vector carrying the human 
P/CAF cDNA for protein expression with a C-terminal Flag-tag 
as described in (Yang et al., 1996) . 
IV.5 Work with DNA 
IV.5.1 Enzymatic digestion of plasmid DNA 
Restriction enzymes (Fermentas, NEB) 
 
 
10x Magic buffer   200 mM Tris pH 7.5 
700 mM NaCl  
200 mM KCl 
100 mM MgCl2 
0.5 mM spermine 
0.125 mM spermidine 
 
In general, 0.5-1 g plasmid DNA was digested in 1 x Magic Buffer with 5 units of restriction 
enzymes (Fermentas, NEB). Time and temperature for restriction was adapted to the 
manufactorer’s instructions and depending on the restriction enzyme. Digested DNA was 
analyzed by agarose gel electrophoration.  
 
IV.5.2 Klenow fill in 
The Klenow fragment exo- (Fermentas) is part of the DNA polymerase I complex of E. coli. 
It still contains the 5’-3’ polymerase function but is devoid of any exonuclease activity. It is 
used for filling up 5’ overhangs of double stranded DNA being generated by enzymatic 
digestion of plasmid-DNA with restriction enzymes. Thereby the 5’ overhang serves as 
template. 
In this work, plasmid-DNA was digested by restriction enzymes according to the 
manufacturer’s instructions. Afterwards, 0.2 l (2 units) of Klenow fragment exo- 
(Fermentas) and dNTPs at a final concentration of 0.05 mM were added to the reaction and 
incubated at 37 °C for 10 min. The enzymatic activity was inactivated by heating it at 75 °C 
for further 10 min. 
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IV.5.3 Agarose gel electrophoration 
Tris-Base EDTA (TBE) buffer 89 mM Tris-Base 
89 mM boric acid 
2 mM ethylenediaminetetraacetic acid (EDTA) 
 
10x DNA loading buffer 50 mM Tris pH 8.0 
50 mM EDTA 
50% (v/v) glycerol 
0.25% (w/v) bromophenol blue 
0.25% (w/v) xylene cyanol 
 
DNA ladder 1kb (Fermentas)  
Agarose Low EEO (Applichem)  
The agarose gel electrophoration was performed in order to separate genomic DNA 
fragments, undigested or digested plasmid-DNA according to its size. The size of DNA was 
determined by comparison to a defined DNA marker ladder (Fermentas). Basically, the 
electrophoration was carried out as described in (Sambrook and Russell, 2006). Routinely, a 
gel of 1% (w/v) agarose in TBE containing 0.1 mg/ml ethidium bromide was used. The DNA 
intercalating reagent ethidium bromide was applied to visualize the separated gel fragments 
under UV light at a wavelength of 302 nm.  
 
IV.5.4 Polymerase chain reaction 
The polymerase chain reaction (PCR) is a method suitable for enzymatical amplification of 
double stranded DNA sequences in repetitive cycles. This technique mimics the intracellular 
DNA replication. Two sorts of oligonucleotides, which are complementary to the forward or 
the reverse DNA strand respectively, are needed. First, heating denatures double stranded 
template DNA. Then a cool down step follows until a temperature is reached that allows the 
oligonucleotides to anneal to their complementary DNA strands of the single stranded DNA. 
Usually, this happens at approximately 60 °C but has to be determined for each type of 
oligonucleotide. The next step is the chain elongation, carried out by a commercially available 
DNA polymerase originally derived and modified from thermophilic bacteria. These three 
steps are repeated several times resulting in an exponential increase of DNA copy numbers.  
In this work the PCR was generally performed using the Phusion® High-Fidelity DNA 
Polymerase Kit (Thermo Scientific) according to the manufactorers instructions. Reaction 
products were controlled by DNA-sequencing (Seqlab).  
 
IV.5.5 Gateway cloning 
Gateway recombination cloning (Invitrogen) enables the cloning of a cDNA into an entry 
vector and subsequently into a variety of destination vectors. The system is based on the 
recombination system of phage I that integrates via a recombinase into a specific location in 
the E. coli chromosome. Thereby, a recombination between the attP site in the phage genome 
and the attB site in the bacterial genome occurs.  
For Gateway cloning, a PCR with specific primers for the cDNA of interest was carried out 
using the Phusion® High-Fidelity DNA Polymerase Kit (Thermo Scientific). These primers 
were flanked by the bacterial attB sites. Subsequently, the PCR product was cloned into an 
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entry vector carrying attP sites (e.g. pDONR/Zeo) via a BP-Reaction. This reaction created 
attL1 and attL2 sites that in turn allowed the recombination between the cassette with the attL 
sites and the cDNA of interest and a destination vector carrying attR sites via a LR reaction.  
The BP-Reaction and LR-Reaction were performed according to the manufacturer’s 
instruction except that only 50% of the indicated recombinase and buffer amounts were used 
per reaction. 
 
IV.5.6 Site directed mutagenesis  
Site directed mutagenesis allows the mutation of one or more amino acids in a protein 
sequence.  
This was obtained using specific mutagenesis primers for mutating base pairs in a PCR 
reaction performed on the cDNA encoding the protein of interest. The online “Quik change 
primer design” program (Stratagene) was applied for the design of mutagenesis primers. 
Routinely, a mutagenesis PCR with 50 ng of template DNA and the components of the 
Phusion® High-Fidelity DNA Polymerase Kit (Thermo Scientific) was performed 
corresponding to the manufactorers instructions. Afterwards, the insertion of the mutation was 
controlled by DNA-sequencing (Seqlab). 
  
IV.6 Work with prokaryotic cells 
IV.6.1 Bacteria strains 
E. coli DH5 (Invitrogen) 
deoR endA1 hsdR17 (rk-, mk+) supE44 thi-1 recA1 gyrA96 relA1 (argFV169-LacZYA) U169 
80lacZ  M15 F- - 
E. coli XL10-Gold	(Stratagene) 
Tetr D(mcrA)183 D (mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 gyrA96 relA1 lac 
Hte [F’ proAB lacqZDM15 Tn10 (Tetr) Amy Camr] 
 
E. coli BL21(DE3) pLysS (Stratagene) 
B F- dcm ompT hsdS (rB– mB–) gal (DE3) [pLysS Camr] 
 
E. coli rosetta gamiTM (Novagen) 
Δ( ara–leu)7697 ΔlacX74 ΔphoA PvuII phoR araD139 ahpC galE galK rpsL  
F'[lac+ lacI q pro] gor522::Tn10 trxB pRARE2 (Camr, Kanr, Strr, Tetr)4 
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IV.6.2 Culture medium for prokaryotic cells 
Luria Broth (LB) medium 1% (w/v) tryptone (AppliChem) 
0.5% (w/v) yeast extract (AppliChem) 
1% (w/v) NaCl 
pH 7.0 
 
Low salt LB medium  1% (w/v) tryptone 
0.5% (w/v) yeast extract 
0.5% (w/v) NaCl 
 
Agar plates (Amp/Kan): LB medium 
1.5% (w/v) Bacto Agar (Difco) 
100 g/ml ampicillin or 
30 g/ml kanamycin 
 
Agar Plates (Zeo): Low salt LB medium 
1.5% (w/v) Bacto Agar (Difco) 
50 g/ml zeocin (Invitrogen) 
 
IV.6.3 Protocols for work with prokaryotic cells 
IV.6.3.1. Transformation of bacteria 
For transformation of bacteria, the method of heat shocking was chosen. Therefore, 100 l of 
chemically competent bacteria were thawn on ice. The plasmid-DNA that should be 
introduced was added to the bacteria at a concentration of approximately 100 ng-1000 ng for 
one transformation. The mixture was incubated on ice for 15 – 30 min. Consequently, bacteria 
were heat shocked in a 42 °C water bath for 45 sec. The tube was chilled on ice for 2 min. For 
regeneration of bacteria, they were shaken together with 700 l of LB medium (or low salt 
LB medium if plasmids encoding a zeocin resistance were introduced) at 300 rpm at 37 °C for 
up to 30 min. Finally, bacteria were pelleted at 1000 x g for 3 min and plated on agar plates 
containing the corresponding antibiotics and incubated at 37 °C over night.  
 
IV.6.3.2. Mini-preparation of plasmid-DNA from bacteria 
A mini-preparation enables small-scale purification of plasmid-DNA that has been introduced 
into and replicated by bacteria before.  
Generally, plasmid-DNA was purified from a 3 ml transformed bacteria culture derived from 
a single clone that had been grown at 37 °C over night. For the purification process the kits 
“GeneJETTM Plasmid” (Fermentas) or “ZippyTM Plasmid Miniprep” (Zymo Research) were 
used according to the manufacturer’s instructions. However, ddH2O instead of the elution 
buffer was used for elution of plasmid-DNA. 
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IV.6.3.3. Maxi-preparation of plasmid-DNA from bacteria 
TE buffer 10 mM Tris HCl, pH 7.5 
1 mM EDTA 
 
A single colony of with plasmid-DNA transformed bacteria was used to inoculate an over-
night culture consisting of 300 ml LB medium and appropriate antibiotics. Bacteria were 
pelleted and the purification was conducted with the “NucleoBond Xtra Maxi” kit (Macherey 
and Nagel) according to the manufacturer’s protocol. The elution of plasmid-DNA was 
performed with TE buffer. 
 
IV.6.3.4. Purification of glutathione-S-transferase (GST)-tagged fusion proteins 
LB-growth medium 0.5% yeast extract 
1% peptone 
10 mM NaCl 
0.4 % glucose 
50 g/ml ampicillin or 
30 g/ml kanamycin 
 
IPTG 0.4 mM 
 
Lysozyme 100 g/ml 
 
TNE buffer 20 mM Tris pH 8.0 
150 mM NaCl 
1 mM EDTA pH 8.0 
5 mM Dithiothreitol (DTT) 
14 g/ml aprotinin 
1 mM Pefa-Bloc SC (Roche) 
 
PBS 140 mM NaCl 
2.6 mM KCl 
2 mM Na2HPO4 
1.45 mM KH2PO4 
 
GST-washing buffer 100 mM Tris pH 8.0 
120 mM NaCl 
 
GST-elution buffer 20 mM glutathione in 2 mM HEPES pH 8.0 
100 mM Tris pH 8.0 
120 mM NaCl 
Glutathione sepharose (Sigma Aldrich) 
 
Proteins of interest that are N-terminally fused to a GST-protein can be bacterially produced 
and subsequently be purified out of bacterial lysates by coupling to glutathione sepharose.  
Routinely, 1 g of plasmid encoding the GST-fusion protein was transformed into E. coli 
BL21 or E. coli Rosetta-gami™ bacteria, which were plated onto agar-plates containing 
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ampicillin or kanamycin. Growth of colonies was allowed at 37 °C for 12 h. Several colonies 
were picked and used to grow a pre-culture of 50 ml at 37 °C over-night. 25 ml of the pre-
culture were used to inoculate the main culture of 500 ml, which was incubated until an OD600 
of 0.5-0.7 was achieved. At this point, the biosynthesis of the fusion protein was induced by 
addition of 0.4 mM IPTG at 37 °C for 1 h and afterwards at 20 °C over-night to avoid 
formation of inclusion bodies. On the following day, the bacteria were pelleted at 4400 x g 
(Beckman Coulter, Avanti J-26 XP) and the pellet was usually resuspended in 30 ml TNE 
buffer. All following steps were performed at 4 °C. Lysis of the bacterial cell wall was 
achieved by treatment with 100 g/ml lysozyme for 30 min. Next, the lysate was sonified 
(Branson, Cell Disruptor B15) with 3 x 25 pulses at 60% output, left on ice for 5 min and 
centrifuged at 10000 x g (Eppendorf, 5810 R) for 30 min. The supernatant was incubated with 
1 ml of TNE-equilibrated glutathione sepharose under permanent agitation for 1 h. 
Subsequently, the sepharose was washed three times with PBS. Pelleting of the sepharose was 
routinely performed at 200 x g. Afterwards glutathione sepharose was resuspended in 1 ml 
PBS, transferred to a chromatography column (Biorad, Poly-Prep Chromatorgraphy column) 
and rinsed with 1 ml GST-washing buffer. Finally the bound GST-fusion proteins were eluted 
in three fractions by 500 l GST-elution buffer each. The concentration of fusion proteins was 
determined by comparison to bovine serum albumin (BSA) calibration curves in SDS-PAGE 
followed by rapid coomassie brilliant blue staining. 
 
IV.6.3.5. Purification of hexahistidine (His)-tagged fusion proteins 
LB-growth medium 0.5% yeast extract 
1% peptone 
10 mM NaCl 
0.4% glucose 
50 µg/ml ampicillin or 
30 µg/ml kanamycin 
 
IMAC Lysis/ Washing (L/W) 
buffer 
20 mM HEPES pH 7.5 
10% glycerol 
200 mM NaCl 
0.1% (v/v) NP-40 
10-20 mM imidazole 
14 µg/ml aprotinin 
 
IMAC elution buffer 20 mM HEPES pH 7.5 
10% glycerol 
200 mM NaCl 
0.1% NP-40 
10 mM EDTA 
10 mM DTT 
14 g/ml aprotinin 
 
IPTG 0.4 mM 
 
Lysozyme 100 g/ml 
 
TALON™ metal affinity resin (BD Biosciences) 
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The principle of purification of His-fusion proteins is corresponding to the one of GST-fusion 
protein purification with the exception that proteins carry a hexahistidine (His)-tag instead of 
a GST-tag. Therefore, Talon™ metal affinity resin is used to immobilize the His-tagged 
proteins instead of glutathione-sepharose. All bacterial His-protein expression plasmids used 
in this work were under the control of a T7 promotor. Therefore, E. coli BL21 or E. coli 
Rosetta-gami™ bacteria were used for the preparation of bacterial lysates since they have a 
gene encoding the T7 RNA polymerase introduced into the araB locus of the araBAD operon. 
So, the transcription and translation of the T7 RNA polymerase could be induced by addition 
of IPTG (Invitrogen). 
 
The first steps, including transformation of bacteria, growing pre-cultures and main cultures 
and the induction of the His-fusion protein biosynthesis were carried out as described in 
chapter IV.6.3.4. After induction of His-fusion protein biosynthesis overnight, bacteria were 
spinned at 4400 x g (Beckman Coulter, Avanti J-26 XP). All subsequent steps were carried 
out at 4 °C. The pellet was lysed by resolving it in 30 ml IMAC L/W buffer containing 
100 µg/ml lysozyme. Following lysis of bacterial cell walls was completed by sonficiation 
with 3 x 25 pulses at 60% output (Branson, Cell Disruptor B15). An incubation step on ice for 
5 min followed. Cell debris was removed by centrifugation at 10000 x g for 30 min 
(Eppendorf, 5810 R). In the meantime, 500 µl of TALON™ metal affinity resin was 
equilibrated with 5 ml of IMAC L/W buffer and adjacently added to the supernatant of the 
lysate. The mixture was incubated under permanent agitation for 1 h. Next, the metal affinity 
resin was pelleted at 200 x g and washed twice with 5 ml IMAC L/W buffer. In order to elute 
the fusion protein from the resin, beads were transferred to an eppendorf tube and incubated 
with IMAC elution buffer for 10 min under agitation. This was performed three times, 
resulting in three elution fractions of His-fusion proteins. The concentration was determined 
by SDS-PAGE und subsequent rapid coomassie brilliant blue staining.  
 
IV.7 Work with eurkaryotic cells  
 
IV.7.1 Eukaryotic cell lines 
HEK293 (ATCC CRL-1573) 
This is an adherent, epithelial, human embryonic kidney cell line, containing sequences of 
adenovirus 5 DNA (Integration site: chromosome 19q13.2). It is hypotriploid and 30% of the 
cells harbour 64 chromosomes. 
Growth medium: Dulbecco’s modified Eagle’s medium (DMEM) with GlutaMAX-I and 
4.5 g/l glucose, 10% (v/v) fetal calf serume (FCS), 10000 units/ml penicillin, and 
10000 g/ml streptomycin. 
 
U2OS (ATCC HTB-96) 
This is an adherent human osteosarcoma cell line, isolated from a 15-year old Caucasian 
female. It has a hypertriploid chromosome number. 
Growth medium: DMEM with GlutaMAX-I and 4.5 g/l glucose, 10% (v/v) FCS, 
10000 units/ml penicillin, and 10000 g/ml streptomycin. 
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HCT116 (ATCC CCL-247) 
HCT116 is an adherent human epithelial colorectal carcinoma cell line. 62% of the cells 
reveal an almost diploid chromosome number with 45 chromosomes on average. 
Growth medium: McCoy’s 5a medium with GlutaMAX-I, 10% (v/v) FCS, 10000 units/ml 
penicillin, and 10000 g/ml streptomycin. 
HeLa (ATCC CCL-2) 
HeLa cells are adherent human cervical epithelial cells that were derived from a 31-year-old 
female suffering from cervical adenocarcinoma. The adenocarcinoma was caused by infection 
with the human papillomavirus 18. The cells reveal a 100% aneuploidy.  
Growth medium: DMEM with GlutaMAX-I and 4.5 g/l glucose, 10% (v/v) FCS, 
10000 units/ml penicillin, and 10000 g/ml streptomycin. 
Flp-In T-REx HEK293 (Invitrogen) 
This is a HEK293 cell line, which is designed for stably integrating a cDNA encoding the 
cDNA of interest into a particular genomic location. This is achieved by the integration of a 
Flp Recombination Target (FRT) site into that genomic location (Invitrogen). A plasmid 
carrying an expression cassette encoding the cDNA of interest under a CMV promoter and a 
coupled hygromycine resistance gene flanked by FRT sites can be co-transfected with an 
expression plasmid encoding a Flp-Recombinase. The Flp-Recombinase mediates the stable 
integration of the expression cassette into the genomic location with the FRT site. 
Additionally, a Tet-Repressor system from pcDNA6/TR has been introduced into these cells 
enabling the tetracycline dependent induction of the expression of the stably integrated cDNA 
of interest. 
Growth medium: DMEM with GlutaMAX-I and 4.5 g/l glucose, 10% (v/v) FCS, 
10000 units/ml penicillin, and 10000 g/ml streptomycin. For maintenance of the stably 
integrated FRT sites and the Tet-repressor, cells were supplemented with 100 g/ml zeocin 
and 10 g/ml blasticidin. 
Flp-In T-REx HEK293 C-TAP-ARTD10/ Flp-In T-REx HEK293 C-TAP-ARTD10-G888W 
These stably transfected cell lines were obtained using the Flp-In-T-REx system (Invitrogen) 
by co-transfection of the plasmids pcDNA5/FRT/TO/C-TAP-ARTD10 or 
pcDNA5/FRT/TO/C-TAP-ARTD10-G888W and pOG44, encoding the Flp-Recombinase (H. 
Kleine). Selection of stable cells was achieved via the supplementation of the antibiotics 
hygromycine B and blasticidin S to the cell culture medium (Kleine et al., 2008). 
Growth medium: DMEM with GlutaMAX-I and 4.5 g/l glucose, 10% (v/v) FCS and 
10000 units/ml penicillin, 10000 g/ml streptomycin. For maintenance of the stably 
integrated constructs encoding C-TAP-ARTD10/C-TAP-ARTD10-G888W and the Tet-
repressor, cells were supplemented with 50 g/ml hygromycine B and 10 g/ml blasticidin S.  
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Flp-In T-REx HeLa 
This is a HeLa derived cell line with genomically integrated FRT sites, utilizing the 
Invitrogen Flp-In T-Rex system, comparably to the Flp-In T-REx HEK293cells. 
Growth medium: DMEM with GlutaMAX-I and 4.5 g/l glucose, 10% (v/v), 10000 units/ml 
penicillin, and 10000 g/ml streptomycin. For maintenance of the stably integrated FRT sites 
and the Tet-repressor, cells were supplemented with 100 g/ml zeocin and 10 g/ml 
blasticidin. 
Flp-In T-REx HeLa ARTD10/ Flp-In T-REx HeLa ARTD10-G888W 
These stably transfected cell lines were derived by co-transfection of pOG44 and 
pcDNA5/FRT/TO/ARTD10 or pcDNA5/FRT/TO/ARTD10-G888W respectively (N. 
Herzog). Selection of stable cells was achieved via the supplementation of the antibiotics 
hygromycine B and blasticidin S to the cell culture medium 
Growth medium: DMEM with GlutaMAX-I and 4.5 g/l glucose, 10% (v/v), 10000 units/ml 
penicillin, and 10000 g/ml streptomycin. For maintenance of the stably integrated constructs 
encoding ARTD10/ARTD10-G888W and the Tet-repressor, cells were supplemented with 
200 g/ml hygromycine B and 10 g/ml blasticidin S  
 
IV.7.2 Material for work with eukaryotic cells 
 
Material Concentration 
 
PBS 
 
140 mM NaCl 
2.6 mM KCl 
2 mM Na2HPO4 
1.45 mM KH2PO4 
 
DMEM with GlutaMAX-I and 4.5 g/l 
glucose (Gibco) 
 
 
McCoy’s 5a with GlutaMAX-I (Gibco) 
 
 
FCS (Gibco) 
 
 
Dimethyl sulfoxide (DMSO), cell culture 
grade (AppliChem) 
 
 
Doxycycline (Sigma) 1 mg/ml 
 
Penicillin/ streptomycin (Seromed) 10000 units/ml / 10000 g/ml 
 
Blasticidine S (Invitrogen) 10 mg/ml 
 
Hygromycine B (InvivoGen)  100 mg/ml 
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Zeocin (InvivoGen) 100 mg/ml 
 
IWR-1 endo (Sigmaaldrich) 
 
20 mM 
Olaparib (Selleckchem) 
 
100 mM 
Trypsin/EDTA in PBS (Seromed) 0.5/0.2% (w/v) 
 
Tissue culture dishes (Sarstedt): Diameter (∅ሻ 6 cm/10 cm 
 
Tissue culture plates (TPP): 6-well, 12-well 
 
Cryo tubes (Nalgene): 1 ml 
 
 
IV.7.3 Culture conditions of eukaryotic cell lines 
All cells were cultured under a humidified atmosphere and with supplementation of 5% CO2 
at 37 °C. 
The medium and supplements used for culturing of the single cell lines are indicated above in 
the description of each cell line. Generally, cells were maintained in ∅	 10 cm dishes and 
seeded onto dishes or plates of different sizes for performance of the experiments. 
 
IV.7.4 Passaging of adherent cell lines 
In order to subculture adherent cell lines, cells were carefully washed with PBS without 
loosening them from the cell culture dishes. Afterwards, they were incubated with 1 ml of 
Trypsin/EDTA per ∅	 10 cm dishes until detachment from the dish was observable. 
Subsequently, cells were recovered in fresh medium and an aliquot was transferred onto a 
new tissue culture dish containing fresh medium. 
 
IV.7.5 Cryo-conservation of cells 
Cryo-conservation medium 90% (v/v) FCS + 10% (v/v) DMSO 
 
 
Cryo-conservation enables the long-term storage of cell lines. Therefore, cells were grown in 
the logarithmic phase until 80% of confluency was reached. Then cells were rinsed with PBS, 
pelleted, resuspended in 1 ml cryo-conservation medium and transferred into a cryo-
conservation tube. In order to facilitate a slow cool-down and freezing process, the cryo-
conservation tubes were wrapped in several tissues, placed into a styrofoam container and 
kept at -80°C for 2-3 days. Subsequently, the tissues were removed and cells were stored 
at -150 °C.  
For thawing of cryo-conservated cells, they were rapidly thawed at 37 °C and 10 ml of fresh 
cell culture medium was added. To remove residual DMSO, cells were pelleted at 200 x g and 
resuspended in fresh medium. 
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IV.7.6 Transfection of DNA into eukaryotic cells: Calcium phosphate method 
1x Hepes buffered saline (HBS) buffer  138 mM NaCl 
17 mM Hepes 
5 mM KCl 
0.71 mM Na2HPO4.2H2O 
pH 6.95 
 
CaCl2  125 mM 
 
HEPES buffer 142 mM NaCl 
10 mM HEPES 
6.7 mM KCl 
pH 7.3  
 
Generally, the transient transfection of U2OS, HEK293, HeLa and Flp-In-TREx HeLa cells 
was mediated by usage of the calcium phosphate method (Chen and Okayama, 1988). 
Principally the DNA forms a complex together with CaCl2. This complex is endocytosed by 
the cells. Usually, the DNA does not integrate into the genome of the cells, except if special 
techniques like the Flp-In T-REx system of Invitrogen are used. 
For transient transfection of cells, 8 x 105 – 1 x 106 cells were seeded onto a ∅	10cm dish, 
3 x 105-8 x 105 cells were seeded onto a ∅	6cm dish or 5 x 104 were seeded onto 12-well 
plates. On the following day, plasmid-DNA for the transient transfection was diluted in 
1 x HBS buffer containing 125 mM CaCl2 (for amounts of plasmid-DNA and 1x HBS buffer 
see below). Routinely 10 – 50% of the total amount of transfected plasmid-DNA was reserved 
for each cDNA(s) of interest and the respective backbone vector or pEQ176P2 was used for 
filling up to achieve equal amounts of transfected plasmid-DNA for the individual samples.  
∅ tissue culture dish 1 x HBS + CaCl2 g of transfected plasmid-
DNA 
10 cm 1000 l 20 
6 cm 400 l 7 
12-well 62 l 3.12 
 
The mixture was vortexed for 2 sec, centrifuged and incubated at room temperature for 
15 min. Then it was added drop wise onto the cells. After transfection of HEK293 cells, they 
were incubated at normal growth conditions for 6 -7 h. Subsequently, they were washed once 
with HEPES buffer and cultured in fresh medium for another 48 h. Flp-In-TREx HeLa, HeLa 
and U2OS cells were washed with HEPES buffer 24 h after transfection and cultivated in 
fresh medium for further 24 h until the corresponding experiments were performed.  
 
IV.7.7 Transfection of DNA into eukaryotic cells: FuGENE HD transfection 
(Roche, Promega) 
FuGENE HD is a non-liposomal transfection reagent that forms complexes with the DNA and 
that can be uptaken by the cells. HCT 116 and infrequently HeLa cells were transfected by 
FuGENE HD in accordance with the manufactorers instructions. Thereby, a 
FuGENE HD/DNA ratio of 6/2 was applied. 
EXPERIMENTAL PROCEDURES 
122 
IV.7.8 Preparation of cell lysates and co-immunoprecipitation 
TAP-lysis buffer 50 mM Tris, pH 7.5 
150 mM NaCl 
1 mM EDTA 
10% (v/v) glycerol 
1 mM DTT 
1% (v/v) NP-40 
100 μM Na3VO4 
10 mM-glycerophosphate 
1 x HALT protease inhibitor cocktail (Pierce) 
 
Protein-G-Sepharose “4 fast flow” (Amersham Biosciences) 
An immunoprecipitation allows the separation of proteins from total cell lysates by the 
application of protein-specific antibodies, which are immobilized by coupling to protein-A or 
protein-G-sepharose. Protein-A and protein-G, originally derived from Staphylococcus 
aureus, are suitable for non-covalent binding of antibodies. If the immunoprecipiation is 
performed under non-stringent buffer conditions, the precipitation of intact protein complexes 
is possible. This process is denoted as co-immunoprecipitation. 
In this work, HEK293 cells were seeded at a density of 1.5 x 106 cells per dish onto ∅	10 cm 
dishes. The next day cells were transiently transfected. Cells were treated with inhibitors 
when indicated, pelleted, and washed with PBS 48 h after transfection. The cell pellet was 
lysed in approximately 350 l of TAP-lysis buffer per 6 x 106 cells. After incubation on ice 
for 5 min, the cell lysate was centrifuged at 16000 x g and 4 °C for 20 min. This step was 
necessary to remove cell debris. In the meantime, 26 l (slurry) of Protein-G-Sepharose was 
equilibrated with TAP-lysis buffer. 5% (v/v) of the lysate was kept for an input control, 
whereas the remaining lysate was incubated together with the Protein-G-Sepharose and 0.6 g 
of -GPF antibodies (9F9, Rockland) on a rotator at 4 °C for 2 h. Following, bound proteins 
were analyzed via SDS-PAGE and Western blotting. 
 
IV.7.9 Preparation of cell lysates for analysis of acetylation 
RIPA buffer 10 mM Tris, pH 7.4 
150 mM NaCl 
1% (v/v) NP-40 
1% (v/v) desoxycholate (DOC) 
0.1% SDS  
1 x HALT protease inhibitor cocktail (Pierce) 
3 M Trichostatin A (TSA) 
5 mM Nicotinamide (NAM) 
 
Protein-G-Sepharose “4 fast flow” (Amersham Biosciences) 
U2OS or HCT116 cells were seeded on ∅	6cm tissue culture dishes at a density of 8 x 105 
cells per dish. The following day cells were co-transfected with plasmids encoding ARTD10 
and the indicated acetyltransferases using the FugeneHD method. Cells were treated 24 h or 
48 h after transfection with 3 M/5 mM of the histone deacetylase inhibitors TSA/NAM for 
5 h. Adjacently approximately 6 x 106 cells were lysed in 300 l of RIPA buffer, incubated on 
ice for 5 min and sonified using the BioRuptor UCD200 sonificator (Diagenode) for 15 min at 
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highest output. All lysis steps were performed at 4 °C. Then cell debris was removed by 
centrifugation at 16000 x g for 20 min. After keeping 5% (v/v) of the lysate for input controls, 
the remaining lysate was subjected to an immunoprecipiation with 26 l (slurry) of 
equilibrated Protein-G-Sepharose and 5 l of ARTD10-specific monoclonal antibodies 
(5H11) or 0.5 g of ARTD10-specific polyclonal antibodies (E09). For further analysis, SDS-
PAGE and Western Blotting was performed. 
 
IV.8 Work with proteins 
IV.8.1 Immunofluorescence imaging of cells with overexpressed 
ARTD10/ARTD10-G888W 
Fixing solution 3.8% para-formaldehyde in PBS 
 
Permeabilisation solution 0.1% Triton-X-100 in PBS 
 
Blocking solution 0.1% Triton-X-100 + 1 % BSA in PBS 
 
Antibody diluting solution 0.2% BSA in PBS 
 
Secondary antibody (Alexa Fluor, 
Invitrogen) 
2 mg/ml 
 
 
Glass coverslips 
 
 
Hoechst 33258 (Invitrogen) 10 mg/ml 
 
Draq5TM (Cellsignaling) 5 mM 
 
Mowiol 4-88  
 
IWR-1 endo (Invitrogen) 2 µM  
 
Olaparib (Selleckchem) 
 
10 µM 
 
In immunofluorescence studies the localization of proteins within cells can be detected.  
Therefore, cells are fixed, permeabilised and stained with protein-specific primary antibodies 
and fluorescent-dye labeled secondary antibodies, directed against species-specific Fc parts of 
the primary antibody. The staining can be visualized by laser-scanning microscopy when a 
laser excites the fluorescent dyes at a specific wavelength, which leads to light emission of 
another wavelength. A camera can detect this. By usage of secondary antibodies coupled to 
different fluorescent-dyes it is possible to monitor the cellular distribution of different 
proteins within a single cell with laser-scanning confocal microscopy.  
For immunofluorescence studies with overexpressed ARTD10, 5 x 104 Flp-In T-REx HeLa 
cells that stably express ARTD10 or ARTD10-G888W upon doxycycline addition were 
seeded onto glass coverslips in 12-well plates on day 1. One day after seeding, cells were 
transfected with the indicated plasmids using the Fugene HD or calcium phosphate 
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transfection method. If applicable, cells were treated with 2 M IWR-1 for 24 h on day 3. At 
the same day, ARTD10 expression was induced by addition of 1 g/l doxycycline for 24 h if 
not indicated otherwise. On day 4, cells, which have been treated with IWR-1, were 
additionally treated with 10 M of Olaparib. Adjacently, cells were washed twice with PBS 
and fixed with 500 l of fixing solution at room temperature for 30 min. The fixing solution 
was extensively washed away with PBS and exchanged against 500 l of permeabilisation 
solution. After incubating for 5 min at room temperature, 500 l blocking solution was 
applied for 30 min. Another PBS washing step was performed before 50 ml of a solution of 
primary antibodies, diluted 1:50 – 1:1000 (v/v) in antibody dilution solution, was spottet on 
parafilm and the coverslips incubated on it headfirst in a dark humid chamber at 37 °C for 1 h. 
Afterwards, coverslips were washed thoroughly with PBS. Secondary antibodies, conjugated 
to the desired Alexa-Fluor fluorophores (Invitrogen), were diluted 1:1000 (v/v) in antibody 
dilution solution and incubated as described for the primary antibody at room temperature for 
30 min. In order to remove the secondary antibody solution, coverslips were rinsed with PBS 
and subsequently with ddH2O. For staining of the nuclei, coverslips were incubated with 
Hoechst 33258 (Invitrogen) or Draq5TM (Cellsignaling), which were liquidated in water at a 
concentration of 10 mg/ml (Hoechst 33258) or 5 mM (Draq5TM) respectively at room 
temperature for 5 min. Following, coverslips were washed with ddH2O and fixed in Mowiol 
4-88 and kept at 4 °C. The evaluation was performed with either the Zeiss Axiovert 100M 
Confocal Laser Scanning Microscope (LSM510) or the confocal Zeiss LSM 710 Laser 
Scanning Microscope. All adjustments and settings were kept equal for all images belonging 
to a single experiment. 
In the case of the LSM510 microscope (Zeiss), a C-Apochromat 63x/1.2 water immersion 
objective together with a twofold digital zoom were applied and images were acquired by the 
LSM510 software from Zeiss. Settings are stated below. 
Fluorochrome Emission 
maximum 
Excitation 
wavelength 
Laser Detection 
EGFP 509 nm 
(Patterson et 
al., 1997) 
(Patterson et 
al., 
2001)(Patterson 
et al., 
2001)(Patterson 
et al., 2001)  
488 nm Argon  
(30 mW output) 
488 nm single 
channel PMT with 
505-530 nm 
bandpass filter 
Alexa Fluor 555 565 nm 543 nm Helium-Neon  
(1 mW output) 
543 nm main beam 
splitter with a 
552-627 nm 
spectral META-
detector 
 
The LSM710 microscope (Zeiss) was equipped with a Plan-Apochromat 63x/1.40 oil DIC M7 
corrigated objective. A 1.5 fold digital zoom was applied and the ZEN 2009 software (Zeiss) 
was used for acquisition. Settings are indicated below. 
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Fluorochrome Emission 
maximum 
Excitation 
wavelength 
Laser Detection 
EGFP 509 nm 
 
488 nm Argon  
(2% output) 
Main beam splitter 
with a 493-550 nm 
bandpass filter 
Alexa Fluor 555 565 nm 561 nm Helium-Neon  
(2% output) 
Main beam splitter 
with a 562-660 nm 
bandpass filter 
Draq5™ 650 nm 633 nm Helium-Neon 
(2% output) 
Main beam splitter 
with a 661-759 nm 
bandpass filter 
ECFP 477 nm 
(Patterson et 
al., 2001) 
405 nm UV  
(25% output) 
Main beam splitter 
with a 454-553 nm 
bandpass filter 
Hoechst 33258 app. 455 nm 343 nm UV 
(2% output) 
Main beam splitter 
with a 425-483 nm 
bandpass filter 
 
IV.8.2 Immunofluorescence imaging of cells with endogenous ARTD10 
Fixing solution 3.8% para-formaldehyde in PBS 
 
Permeabilisation solution 0.2% Triton-X-100 in PBS 
 
Blocking solution 20% horse serum in PBS 
 
Antibody diluting solution 20% horse serum in PBS 
 
Secondary antibody  
(Alexa Fluor, Invitrogen) 
2 mg/ml 
 
Glass coverslips 
 
 
Hoechst 33258(Invitrogen) 10 mg/ml 
 
Draq5TM (Cellsignaling) 5 mM 
 
Mowiol 4-88 
 
 
IWR-1 endo (Sigmaaldrich) 
 
2 µM 
Olaparib (Selleckchem) 
 
10 µM 
U2OS cells were seeded onto glass coverslips in a 12-well plate at a density of 40000 cells per 
well. At the following day, cells were transiently transfected with the indicated macrodomain 
constructs using the calcium phosphate method described above. 24 h after transfection, cells 
were stimulated with 1800 I.E. of IFN-2Roferon a, a derivative of IFNα purchased from 
Roche and referred to as IFNα) for 24 h. If applicable, cells were also treated with 2 M 
IWR-1 for 24 h at the same time, followed by treatment with 10 M of Olaparib for 2 h 
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before fixation. For fixation, cells on coverslips were washed twice with PBS and incubated 
with 500 l of fixation solution. Fixation solution was washed away with PBS and exchanged 
against permeabilisation solution for 5 min. The subsequent blocking of unspecific antibody 
binding sites was performed with 500 l of blocking solution at 37 °C for 30 min. The 
polyclonal, purified antibody against ARTD10 (E09) was diluted 1:200 (v/v) in antibody 
dilution solution and incubated on the coverslips at 37 °C for 45 min. The secondary antibody 
staining as well as the nuclear staining, the embedding of coverslips in Mowiol 4-88 and 
microscopy analysis were conducted under the same conditions as described for 
immunofluorescence of overexpressed ARTD10.  
 
IV.8.3 Denaturing discontinuous SDS-PAGE 
Stacking gel 30%/ 0.8% acrylamide/ bisacrylamide 
  
Laemmli running buffer 25 mM Tris base 
250 mM glycine 
0.1% (w/v) SDS 
 
5 x Sample buffer 250 mM Tris, pH 6.8 
500 mM DTT 
10% (w/v) SDS 
0.5% (w/v) bromphenolblue 
50% (v/v) glycerol 
 
Protein standard Page Ruler prestained protein ladder 
10-170kDa (Fermentas) or protein marker VI 
(10-245) (Applichem) 
 
A SDS-PAGE is a method to separate proteins according to their size. SDS, which is a 
negatively charged tenside, binds to proteins whereas the amount of bound SDS corresponds 
to its size. Consequently, the netto charge of the proteins is negative. This allows the 
separation of proteins from a mixture exclusively by their molecular mass. 
The SDS-PAGE was preceded in accordance with the method described by Laemmli 
(Laemmli, 1970) using 10% or 12% polyacrylamide separating gels, 5% stacking gels and the 
Laemmli running buffer as indicated above. A protein standard was also applied in order to 
evaluate the molecular weight of the proteins subjected to SDS-PAGE. 
 
IV.8.4 Western Blot 
Semidry-transfer buffer  
(for nitrocellulose-membranes) 
25 mM Tris-Base 
192 mM Glycin 
20% (v/v) Methanol 
 
Ponceau S Red 0.5% (w/v) Ponceau S Red 
1% acetic acid in H2O 
PBS-T PBS 
0.05% (v/v) Tween-20 
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TBS-T 50 mM Tris, pH 7.6 
150 mM NaCl 
0.05% (v/v) Tween-20 
 
Western blotting is a method to transfer negatively charged proteins separated according to 
their size from a SDS-polyacrylamide-gel to nitrocellulose membranes. The transfer is 
mediated by a blotting chamber with applied electricity. During this process the SDS gets 
detached from proteins allowing renaturation to a certain extent. Consequently, this method 
enables the detection of the proteins on the membranes by specific antibodies.  
In this work the polyacrylamide-gel was equiliberated with semidry-transfer buffer and a 
nitrocellulose membrane was laid on top of it, directed to the positive pole of the blotting 
chamber. These were enclosed by a sandwich of three layers of Whatman paper soaked with 
semidry-transfer buffer. The transfer was carried out with the supplement of 2 mA electric 
current per cm² of nitrocellulose membrane for 75 min. 
After the blotting procedure, gels were stained with Ponceau S Red for control for 2 min. For 
removement of the Ponceau Red S the membrane was rinsed twice with phosphate-buffered- 
saline-tween 20 (PBS-T) or Tris-buffered-saline-tween 20 (TBS-T).  
 
IV.8.5  Immunodetection 
PBS-T PBS 
0.05% (v/v) Tween-20 
 
TBS-T 50 mM Tris, pH 7.6 
150 mM NaCl 
0.05% (v/v) Tween-20 
 
Blocking solution 5% low fat dry milk powder in PBS-T or 
TBS-T 
 
ECL Ready-to-use solutions (Pierce) 
 
Antibodies According to the manufacturer’s Instructions 
 
After Western blotting proteins are fixed in at least partial renatured conditions on the blotting 
membranes. This allows the detection of proteins with specific antibodies. At first this 
procedure comprises an incubation step with blocking solution in order to block unspecific 
binding sites for antibodies on the membrane. Afterwards, succeeding incubations with 
primary and secondary antibodies take place. Whereas the primary antibody targets the 
designated protein on the membrane, the secondary antibodies are directed against the 
species-specific Fc part of the primary antibodies. These secondary antibodies are coupled to 
HRP, which can convert chemiluminescence substrates under light emission. Lastly, the light 
emission can be detected by a LAS-3000 camera (Fuji). 
In this work the membranes were incubated in blocking solution at room temperature for 
30-60 min. Afterwards the membrane was rinsed with PBS-T or TBS-T, depending on the 
primary antibody, for 5 min. If not indicated otherwise, primary antibodies were diluted in 
PBS-T or TBS-T at concentrations as suggested by the manufacturer and incubated at 4 °C 
over night or at room temperature for 2 h. Subsequently, the membrane was rinsed twice with 
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PBS-T or TBS-T, which was followed by an incubation step with the species-specific 
secondary antibody, diluted 1:5000 (v/v) in PBS-T or TBS-T, at room temperature for 45 min. 
Finally, bound antibodies were analyzed by the LAS-3000 camera (Fuji). 
 
IV.8.6 Rapid coomassie staining 
Coomassie brilliant blue G250 solution 0.06 mg/ml in 10% acetic acid in H2O 
 
Coomassie brilliant blue is an anionic dye that binds quantitavely to proteins and enables 
visualization of protein bands in polyacrylamide gels as described by Diezel et al. (Diezel et 
al., 1972) 
In this work, first a SDS-PAGE was performed as described above. Then, the polyacrylamide 
gel was stained with the Coomassie brilliant blue G250 solution at room temperature for 
30 min without prior fixation. Destaining of the gel to remove the dye binding to non-protein 
parts was achieved by washing the gel with water over-night.   
 
IV.8.7 GST-pulldown assays  
GST-pulldown buffer 100 mM Tris-HCl pH 7.6 
250 mM NaCl 
50 mM KCl 
5 mM MgCl2 
0.5% (v/v) NP-40 
1 mM DTT 
0.5 mM EDTA 
10% (v/v) glycerol 
 
Glutathione sepharose (Sigma Aldrich) 
 
The principle of a GST-pulldown assay is the immobilization of a GST-tagged protein on 
glutathione-sepharose. This enables the pulldown of the corresponding GST-tagged proteins 
out of solution and additionally the co-pulldown of proteins interacting with GST-tagged 
proteins. 
25 µl of a slurry glutathione-sepharose suspension were washed once with GST-pulldown 
buffer. Subsequently 5 µg of GST-tagged proteins were added to 350 µl of GST-pulldown 
buffer and incubated with glutathione sepharose at 4 °C for 2 h. Beads were washed twice 
with 400 µl GST-pulldown buffer. Afterwards, ARTD1, ARTD10 or ARTD10-G888W which 
had been subjected to a ADP-ribosylation assay (described in IV.9.1) before, were added to 
the beads together with 350 µl fresh GST-pulldown buffer and incubated at 4 °C for further 
2 h. Finally glutathione sepharose was washed three times with GST-pulldown buffer and 
bound proteins were analyzed by a SDS-PAGE and Western blotting. 
 
 
 
IV.8.8 Hexahistidine (His)-pulldown assays 
IMAC (L/ W) buffer 20 mM HEPES pH 7.5 
10% glycerol 
200 mM NaCl 
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0. % (v/v) NP-40 
10-20 mM imidazole 
 
TALON™ Metal Affinity Resin (BD Biosciences) 
 
The aim of His-pulldown assays corresponds to the principle of GST-pulldown assays with 
the exception that proteins carry a hexahistidine-tag instead of a GST-tag. Therefore, Talon™ 
metal affinity resin is used in the assay instead of glutathione-sepharose. 
Routinely 5 µg of hexahistidine-tagged protein were coupled to 25 µl of equiliberated 
Talon™ metal affinity resin in the presence of 350 µl IMAC L/ W buffer under permanent 
agitation at 4 °C for 2 h. Next, the beads were washed twice with and resuspended in fresh 
350 µl IMAC L/ W buffer. ADP-ribosylation reactions (described in IV.9.1) were added and 
incubated at 4 °C for 2 h. Subsequently, the pulldown assay was evaluated by SDS-Page and 
Western blotting. The imidazole concentrations for the IMAC L/ W buffer was empirically 
determined for each pulldown experiment and is indicated below. 
 
Protein added to His-pulldown Imidazole concentration  
ARTD10 10 mM (or concentration adjusted to the 
additional proteins listed below) 
GSK3β 15 mM 
NEMO 15 mM  
RanGppNHp 20 mM 
 
IV.8.1 Tandem affinity purification  
TAP-lysis buffer 50 mM Tris, pH 7.5 
150 mM NaCl 
1 mM EDTA 
10% (v/v) glycerol 
1 mM DTT 
1% (v/v) NP-40 
14 μg/ml aprotinin 
4 μM leupeptin 
0.5 mM phenylmethylsulphonyl fluoride 
(PMSF) 
100 μM sodium vanadate 
 
TEV-buffer 50 mM Tris pH 7.5 
150 mM NaCl 
0,5 mM EDTA 
1 mM DTT 
 
Calmoduline (CaM)-binding buffer  10 mM Tris pH 7.5 
150 mM NaCl 
0,2% (v/v) NP-40 
1 mM magnesium-acetate 
2 mM CaCl2 
1 mM imidazol 
10 mM -mercaptoethanol 
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CaM-washing buffer 50 mM ammonium-bicarbonate pH 8,0 
75 mM NaCl 
1 mM magnesium-acetate 
1 mM imidazol 
2 mM CaCl2 
CaM-elution buffer 50 mM ammonium-bicarbonate pH8.0 
25 mM EGTA 
 
IgG-Beads: IgG Sepharose 6 Fast Flow (Amersham Biosciences) 
 
CaM-Beads: Calmoduline Sepharose 4B (Amersham Biosciences) 
Tandem affinity purification (TAP purification) enables particular clean and specific protein 
purification under non-denaturing conditions. Therefore, a TAP-tag is added to the C- or N-
terminus of a protein by molecular cloning. The tag contains protein A from 
Staphylococcus aureus, followed by a tobacco etch virus (TEV) protease cleavage sequence 
and the calmodulin binding protein (CBP). So a two-step purification process is possible. First 
the fusion protein is bound to beads loaded with IgG, cleaved off by the TEV protease and 
can secondly be purified by Calmoduline Sepharose 4Bsince the remaining CBP-tag binds to 
it in a Ca2+ dependent manner. 
Flp-In T-REx HEK293 C-TAP-ARTD10 cells or Flp-In T-REx HEK293 C-TAP-ARTD10-
G888W cells were grown in spinner cultures until a density of 5 x 106/ ml cells in 1 l culture 
medium was reached. 12 h prior to purification, ARTD10 expression and biosynthesis was 
induced by addition of 1 g/ml doxycycline. The complete following purification process was 
performed at 4 °C. After harvesting, the cells were washed with ice-cold PBS and lysed in 
20 ml TAP-lysis buffer/5 x 108 cells per liter of cell suspension. The cell lysate was incubated 
with 200 l equilibrated IgG-Sepharose 6 Fast Flow (Amersham Biosciences) for 1 h. 
Afterwards, beads were washed twice with TAP-lysis buffer and once with TEV-cleavage 
buffer. For TEV-cleavage, the beads were resuspended in 300 µl TEV-cleavage buffer and 
3 µl of active TEV-protease (Invitrogen) was added. The mixture was shaken for 18 h. The 
supernatant was transferred onto 200 l equilibrated CalmodulinSepharose 4B (Amersham 
Biosciences). The remaining IgG Sepharose was rinsed once with Calmodulin-binding buffer 
and the wash was combined with the supernatant. For efficient binding of the proteins, 5 mM 
CaCl2 was added. After a 90 min incubation time, beads were washed three times with 
calmodulin-washing buffer. The bound protein was eluted under permanent agitation with 
calmodulin-elution buffer for 30 min. 
IV.9 Enzymatic assays 
IV.9.1 ADP-ribosylation assay 
ADP-ribosylation assay buffer 50 mM Tris pH 8.0 
0.2 mM DTT 
4 mM MgCl2 
 
-NAD+  (Sigma) 50 M or 500 M 
 
All ADP-ribosylation assays were performed in ADP-ribosylation assay buffer with a total 
reaction volume of 30 µl at 30 °C under permanent agitation (1100 rpm) for 30 min. If not 
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indicated otherwise, 0.5 µg of the respective ARTD enzyme and 1-5 µg of substrate were 
used. Assays were carried out using 0 µM, 50 µM or 500 µM of β-NAD+.  
Subsequently, the ADP-ribosylation assay reaction was subjected to GST-/ or His-pulldown 
assays or directly analyzed by SDS-PAGE and Western blotting with specific antibodies. 
 
IV.9.2 Acetylation-assay 
5x Buffer A2 250 mM Tris Cl, pH 8.0 
50% (v/v) glycerol 
0.5 M NaCl 
20 mM MgCl2 
1 mM ZnCl2 
0.25 mM acetyl-CoA 
 
Inhibitors 3 M TSA 
5 mM NAM 
1 x HALT Inhibitor Cocktail (Pierce) 
 
In this assay, a purified acetyltransferases catalyzes in-vitro acetylation of substrate proteins. 
The co-factor acetyl-CoA has to be supplemented.  
Routinely, the assay was performed in a reaction volume of 20 µl containing 1x Buffer A2, 
0.25 mM acetyl-CoA (Sigma), deacetylase inhibitors and protease inhibitors. Indicated 
amounts of substrate protein and purified acetyltransferase were applied. The reaction was 
performed under agitation at 1400 rpm in a ThermoShaker (BioRad) at 30 °C for 30 min. 
Reaction products were analyzed by SDS-PAGE and Western blotting using specific 
antibodies. 
 
IV.9.3 Acetylation assay and sample preparation for mass spectrometry 
100 % Methanol, mass spectrometry grade 
 
 
Iodoacetamide 100 mM 
 
Fixation solution 50% (v/v) methanol 
10% (v/v) acetic acid 
40% (v/v) Millipore water 
Gel code blue stain (Pierce)  
Millipore water 
 
 
Trypsin gold, mass spectrometry grade 
(Promega) 
 
 
Solution 1 
 
10  mM ammonium bicarbonate 
Solution 2 1:1 mixture of solution 1 and acetonitrile 
 
Importantly, all solutions and reagents for the acetylation assay as well as for the SDS-PAGE 
were sterile filtered through a 0.22 µM filter (Millipore). All equipment for the subsequent 
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SDS-PAGE was cleaned with 100 % methanol, mass spectrometry grade. Acetylation assays 
were performed with 0.6 µg His-tagged GCN5 and 1 µg TAP-ARTD10 as described in IV.9.2 
in the presence and one in the absence of 0.25 mM acetyl-CoA. 4 x sample buffer was added 
to the reaction products of the acetylation assay. After boiling at 100 °C for 10 min, it was 
cooled down and incubated together with iodoacetamide at a final concentration of 100 mM at 
55 °C for 10 min. After a SDS-PAGE with a 12 % polyacrylamide separating gel and 5 % 
stacking gel, the gel was treated with fixation solution for 20 min and stained with gel code 
blue stain in accordance with the manufacturer’s instructions in a sterile petri dish for 1 h. 
Subsequently the gel was rinsed three times with Millipore water for 10 min respectively. 
Approximately one third of the bands that should be analyzed were cut out with a sterile 
scalpel, transferred into an eppendorf tube and incubated with solution 1 for 10 min. Then the 
supernatant was removed and solution 2 was added for another 10 min. Three alternate wash 
steps with solution 1 and 2 followed. Subsequently the washed pieces of gel were vaccum 
dried for 20 min. For trypsin digestion, the mass spectrometry grade trypsin enzyme was 
dissolved in 600 µl of solution 1. The dissolved trypsin enzyme was further diluted 1:40 in 
solution 1 and 2 µl were added to the vacuum dried gel pieces. Trypsin digestion was 
conducted at 37 °C over night. Then the samples were handed to Corinna Henkel (Institute of 
Pathology, RWTH Aachen University, Germany) for mass spectrometry analysis. 
IV.10  Crystallization of macrodomains 
The crystallization experiments displayed in this work were performed and analyzed by 
Herwig Schüler and Tobisas Karlberg (Structural Genomics Consortium and Department of 
Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden). For the 
experimental procedures see Forst et al, manuscript submitted. 
IV.11 Isothermal titration calorimetry 
The isothermal titration calorimetry of this work was conducted by Bianca Nijmeijer and 
Andreas Ladurner (Institute of Physiological Chemistry, University of München, Germany) 
Details of the experimental procedure are given in Forst et al., manuscript submitted.  
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VI Appendix 
VI.1 Abbreviations 
°C Degree Celsius 
µ Micro 
3BP2 SH3 domain-binding protein 2 
aa Amino acid 
ac Acetylation 
acetyl-CoA Acetyl-CoenzmyeA 
ADP Adenosine diphosphate 
ADPr ADP-ribose 
AIF Apoptosis inducing factor 
ALC1 Amplified in liver cancer protein 1 
AMD Automodification domain 
AMF Autocrine motility factor 
AMP Adenosine monophosphate 
AMPK Adenosine monophosphate-activated kinase 
ANK  Ankyrin repeat 
APLF Aprataxin and PNK-like factor 
ARH ADPr hydrolase 
ART ADP-ribosyltransferase 
ARTD ADP-ribosyltransferase diphteria toxin-like 
ASH absent small and homeotic disc 
ATAC Ada2a-containing complex 
ATCC American Type Culture Collection 
ATP Adenosine triphosphate  
BER Base excision repair 
bp Base pair 
BRCA1 Breast cancer 1 early onset 
BRCT BRCA1 carboxyterminal domain 
BSA Bovine serum albumine 
CaM Calmodulin 
cAMP cyclic adenosine monophosphate 
CBD Centrosome binding domain 
CDK Cycline-dependent kinase 
CHFR Checkpoint with forkhead and RING finger domains 
protein 
CIRP Cold-inducible RNA binding protein 
CK Casein kinase 
CoaSt6 Coactivator of STAT6 
CREB CBP binding protein 
CRM1 Chromosome-region maintenance protein-1 homolog 
Da Dalton 
ddH2O Di-destilled H2O 
DDHD2 DDHD domain-containing protein 2 
DEK DNA-dependent protein kinase 
DMEM Dulbecco’s modified Eagle’s medium 
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DMSO Dimethyl sulfoxide 
DNA Desoxyribonucleic acid 
dNTP Deoxyribonucleotide triphosphate 
DOC  Desoxycholate 
DSB Double strand break 
DSBR Double strand break repair 
DTT Dithiothreitol 
E. coli Escherichia coli 
e.g. For example 
ECFP Enhanced cyan fluorescent protein 
EDTA Ethylenediaminetetraacetic acid 
eEF2 Elongation factor 2 
EGFP Enhanced green fluorescent protein 
et al. et alii 
FCS Fetal calf serum 
FRT Flip Recombination Target 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GCN5 General control of amino acid synthesis protein 5 
GDAP2 Ganglioside-induced differentiation-associated protein 2 
GDP Guanidine diphosphate 
GNAT GCN5 N-acetyltransferase 
GSK Glycogen synthetase kinase 
GST Glutathione S transferase 
GTP Guanidine triphosphate 
H Histone 
h Hour 
HA Haemagglutinin 
HAT Histone acetyltransferase 
HBS Hepes buffered saline 
HDAC Histone deacetylase 
HEK Human embryo kidney 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
His Hexahistidine 
HPS Histidine-proline-serine rich region 
HR Homolgous recombination 
HRP Horseradish peroxidase 
H-Y-E Histidine-tyrosine-glutamate 
i.e. id est 
I.E. International units 
IFN  Interferon 
IgG Immunglobulin G 
IgM Immunglobulin M 
IKKε Inhibitor of NF-κB kinase epsilon 
IL Interleukin 
IPTG Isopropyl-β-D-1-thiogalacopyranoside 
ITC Isothermal titration calorimetry 
JAK2 Janus kinase 2 
JMJD2A JMJ domain containing demethylase 2A 
k Kilo 
Kd Dissociation konstant 
KAT Lysine acetyltransferase 
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l Liter 
LB Luria Broth 
m Milli 
M Molar 
m Meter 
M Mega 
Macro Macrodomain 
mART Mono-ADP-ribosyltransferase 
MBT Malignant brain tumor 
Mcl myeloid leukemia cell differentiation protein 
me Methylation 
min Minute 
MLL Mixed lineage leukemia 
mp Membrane proteins 
mRNA Messenger RNA 
MVP-BD Major vault particle-binding domain 
MYST Morf, Ybf2, Sas2, Tip60 
n Nano 
NAD+ Nicotinamide dinucleotide (oxidized form)  
NADH Nicotinamide dinucleotide (reduced form) 
NAM Nicotinamide 
NEMO NF-κB essential modulator 
NES Nuclear export signal 
NF-B Nuclear factor-B 
NHEJ Non-homolgous end joining 
NLS Nuclear localization signal 
NPC Nuclear pore complex 
O- ortho- 
OAADPr O-acetyl-ADP-ribose 
PAIL Prediction of acetylation on internal lysine 
P/CAF P300/CBP-associated factor 
P2X7 Purinergic receptor P2X ligand-gated ion channel 7 
PAGE Polyacrylamide gel electrophoresis 
PAR Poly-ADP-ribose 
PAR Poly-ADP-ribose 
PARG Poly-ADP-ribose glycohydrolase 
PARP Poly-ADP-ribose-polymerase 
PARylation Poly-ADP-ribosylation 
PBS Phosphate buffered saline 
PBZ PAR binding zinc finger 
PCNA Proliferating cell nuclear antigen 
PCR Polymerase chain reaction 
PGI Phosphoglucose isomerase 
ph Phosphorylation 
PHD Plant homeo domain 
Pim serine/threonine-protein kinase 
PMSF Phenylmethylsulphonyl fluoride 
PRD PARP regulatory domain 
PRMT Protein arginine N-methyltransferase 
PTM Posttranslational modification 
RanBP Ran-binding protein 
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RanGAP1 RanGTPase activating protein 
RanGEF Ran guanine exchange factor / RCC1 
RBM3 RNA binding protein 3 
RING Really interesting new gene 
RNA Ribonucleic acid 
RNF RING finger protein  
RRM RNA recognition motif 
R-S-E Arginine-serine-glutamate 
R-S-EXE Arginine-serine-glutamate-X-glutamate 
SAGA Spt-Ada-Gcn5-acetyltransferase 
SAM Sterile alpha motif 
SDS Sodium dodecyl sulfate  
SIRT Sirtuin 
sp  Secreted proteins 
SQSTM1 Sequestosome 1 
SSB Single strand break 
SSBR Single strand break repair 
STAGA SPT3-TAF9-GCN5-acetyltransferase 
STAT Signal transducer and activator of transcription 
T. curvata Thermomonospora curvata 
TAP Tandem affinitiy purification 
TBE Tris-Base EDTA 
TCL Total cell lysate 
Tet Tetracycline 
TEV Tobacco etch virus 
Tip60 Tat interactive protein 60 
TNE Tris–NaCl-EDTA 
TPX2 Targeting protein for xklp2 
TRF1 Telomeric repeat binding factor 1 
tRNA Transfer RNA 
TRRAP Transformation/transcription domain-associated protein 
TSA Trichostatin A 
TYK2 Tyrosine kinase 2 
U2OS Human osteo sarcoma 
UBP Ubiquitin protease 
UIM Ubiquitin interaction motif 
UV Ultra violett  
VEEV Venezuelan equine encephalitis virus 
VIT Vault-protein inter-alpha-trypsin 
vWA Willebrand type A 
W Watt 
WGR Tryptophane-glycine-arginine domain 
WWE Tryptophane-tryptophane-glutamate 
X. laevis Xenopus laevis 
XPA DNA repair protein complementing XP-A cells 
XRCC1 DNA repair protein XRCC1 
ZF/THP Zinc finger/ TiPARP homolgous domain 
ZnF1/ ZnF2 Zinc finger 1/ Zinc finger 2 
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oder die Erkenntnis, dass manche Städte mehr als ein Ibis Hotel haben. 
Labor 1, es war toll, mit Euch tagtäglich den Laboralltag zu teilen: Kai Hänel, Andrea Ullius, 
Dr. Ulli Linzen, Marc Dohmen, Carolina Pfaff, Alex Stephan und Elena Meuser, danke. Elena 
Buerova gilt ein besonderer Dank für Ihre große Hilfbereitschaft. 
Auch allen anderen heutigen und ehemaligen Mitarbeitern der Lüschers (und denen, die ich 
vergessen habe) möchte ich für die hervorragende Arbeitsathmosphäre und vieles mehr 
danken: Dr. Henning Kleine für die Betreuung in den ersten Jahren; Dr. Jörg Vervoorts, Dr. 
Juliane Lüscher-Firzlaff, Dr. Jörg Hartkamp, Dr. Ferdinand Kappes und Dr. Christian 
Preisinger für den wissenschaftlichen Input, sowie Dr. Franzi Flick, Dr. Christian Cornelissen, 
Nadine Schall, Jorgo Agalaridis, Annika Gross, Lora Heffele, Dominik Schwab, Max 
Kaufmann, Jürgen Stahl, Angelina Kriescher, Marcel Robbertz, Patricia Hans, Nathalie 
Tomanek, Angelika Szameit, Daniela Otten, Sven Vosshall, Dr. Jens Schirrmacher, Dr. 
Nadine Hein, Dr. Stephan Dreschers, Dr. Steffi Speckgens, Gabriele Lützeler, Elke Meier, 
Anne Bracszinsky und Stefan Brüning für ihre Zusammenarbeit, und auch Unternehmungen 
außerhalb der Arbeit. Christian Preisinger und Franzi Flick, danke fürs Korrekturlesen! 
Meinen Eltern gilt ein spezieller Dank für die ständige Unterstützung in allen Lebenslagen!             
Kai, danke für alles! 
APPENDIX 
163 
VI.7 Eidesstattliche Erklärung 
 
Ich versichere hiermit an Eides statt, dass ich die vorliegende Dissertation selbstständig und 
ohne unzulässige fremde Hilfe erbracht habe. Ich habe keine anderen als die angegebenen 
Quellen und Hilfsmittel benutzt, sowie wörtliche und sinngemäße Zitate kenntlich gemacht. 
Die Arbeit hat in gleicher oder ähnlicher Form noch keiner Prüfungsbehörde vorgelegen. 
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